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ABSTRACT 
The objective of this study was to conduct an intervention study to test how low-fat 
yogurt consumption affects postprandial metabolism, chronic inflammation, and intestinal barrier 
function. Apparently healthy premenopausal women with body mass index (BMI) of 18.5 to 27 
(lean) or 30 to 40 kg/m2 (obese) participated in a 9-week controlled intervention study. 
Participants in each BMI range were randomly assigned to either a low-fat yogurt-supplemented 
group (Y, yogurt lean; YO, yogurt obese) or a soy pudding-supplemented control group (C, 
control lean; CO, control obese), with n = 30/group. Participants consumed 12 oz. of yogurt or 
the control food daily for 9 weeks while maintaining usual caloric intake. At wk 0, 3, 6 and 9, 
participants provided fasting blood samples for determination of inflammation and endotoxemia, 
and for weight and blood pressure measurement. At wk 0 and 9, participants consumed 8 oz. of 
yogurt or the control food, followed by a high-fat, high-carbohydrate challenge meal. Blood 
samples were taken at baseline, 1, 2, 3, and 4 h after the meal to assess postprandial metabolism. 
At baseline, obese participants had increased plasma glucose, triglyceride, insulin, interleukin-6 
(IL-6), high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), 
lipopolysaccharide-binding protein (LBP), LBP/soluble CD14 (sCD14) ratio, but less 
immunoglobulin M endotoxin-core antibody (IgM EndoCAb) than lean participants. The 
  
challenge meal induced postprandial increases in IL-6, glucose, and LBP/sCD14 ratio in CO. 
However these postprandial responses were suppressed in YO. Yogurt consumption also reduced 
postprandial hypoglycemia in Y, possibly by preventing insulin over-secretion. Both challenge 
meals had similar responses, except 15% decreased IL-6 area under the curve in the second test. 
After 9 weeks, YO had decreased fasting plasma IL-6, hsCRP, TNF-α, TNF-α/soluble tumor 
necrosis factor receptor II (sTNF-RII) ratio, but increased IgM EndoCAb. These improvements 
occurred despite ~ 0.9 kg weight gain in YO and CO. YO diastolic blood pressure decreased at 
wk 3, but was not maintained at wk 6 and 9. In conclusion, consuming low-fat yogurt improved 
postprandial metabolism and reduced biomarkers of chronic inflammation in healthy obese 
premenopausal women, in part because of improved intestinal barrier function. 
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Chapter 1: Introduction 
  
2 
 
1.1 Overview 
Obesity is an abnormal or excessive accumulation of fat that poses a risk to health. A 
person with a body mass index (BMI) between 25 and 30 is classified as overweight and a BMI 
greater than 30 is obese. In the US, nearly 70% of adults are classified as overweight or obese 
(Flegal, Carroll et al. 2010). Obesity is associated with cardiovascular disease, Type II diabetes, 
and certain cancers (Kastarinen, Nissinen et al. 2000, Grundy 2007, Hossain, Kawar et al. 2007). 
Obesity decreases quality of life, life expectancy, and its prevalence causes a sizable economic 
burden (Peeters, Barendregt et al. 2003, Wang, McPherson et al. 2011, Warkentin, Das et al. 
2014). 
1.2 Central Hypothesis and Specific Aims 
Inflammation links obesity to various chronic diseases (Lumeng and Saltiel 2011). In 
obese humans and other animals, proinflammatory markers at both protein and the 
transcriptional level are increased in systemic circulation and various tissues (Kern, Ranganathan 
et al. 2001, De Souza, Araujo et al. 2005, Brake, Smith et al. 2006, Kim, Park et al. 2006, Ehses, 
Perren et al. 2007). Several inflammatory mechanisms in obesity have been proposed. Obesity-
associated inflammation is considered to originate from the interplay between immune cells and 
metabolic tissues in response to excessive nutrients intake, resulting in increased secretion of 
inflammatory cytokines (Gregor and Hotamisligil 2011). In addition, persistent postprandial 
dysmetabolism-induced inflammation, which is exacerbated in obese population, also leads to 
chronic inflammatory status (Burdge and Calder 2005, Esposito, Ciotola et al. 2007, Calder, 
Ahluwalia et al. 2011). Furthermore, obesity is associated with impaired intestinal barrier 
function, leading to increased endotoxin which effectively induces inflammation in humans 
(Kemna, Pickkers et al. 2005, Andreasen, Larsen et al. 2010, Pei, Martin et al. 2015). 
3 
 
Intervention studies report the anti-inflammatory effects of yogurt in children and the 
elderly (Sakamoto, Igarashi et al. 2001, Schiffrin, Parlesak et al. 2009, Yang and Sheu 2012). 
Animal and human studies suggest that yogurt consumption is beneficial for intestinal barrier 
function, thus reducing the risk of endotoxin exposure (Isolauri, Kaila et al. 1993, Matsumoto, 
Aranami et al. 2007, Schiffrin, Parlesak et al. 2009). Yogurt consumption might reduce body 
weight and blood pressure, and weight loss is associated with reduced chronic inflammation 
(Ziccardi, Nappo et al. 2002, Zemel, Richards et al. 2005, Thomas, Wideman et al. 2011, 
Drouin-Chartier, Gigleux et al. 2014). However, evidence from randomized, controlled studies 
on the anti-inflammatory effects of low-fat yogurt in healthy premenopausal women is still 
lacking. Most yogurt intervention studies are relatively small in sample size and have lacked 
proper dietary controls for yogurt. In addition, yogurt intervention studies in obese population 
usually do not include the non-obese control, and some of these studies incorporate yogurt in 
calorie-restricted diets which may obscure the effect of yogurt consumption in a free-living 
population. Furthermore, the possible dietary change brought by yogurt intervention is not 
considered. 
 Therefore, the objective of this dissertation research is to better define how low-fat 
yogurt consumption affects body weight, blood pressure, postprandial inflammation, intestinal 
barrier function, and chronic inflammation in apparently healthy premenopausal women using a 
randomized, controlled, isocaloric study design. We selected a non-dairy control food with 
similar macronutrient and micronutrient content, total calories and texture, and also included a 
group of non-obese control participants. The central hypothesis is that low-fat yogurt 
consumption reduces postprandial and chronic inflammation by decreasing metabolic 
endotoxemia. The central hypothesis was assessed by evaluating the following specific aims: 
4 
 
Aim 1: Define the effects of low-fat yogurt consumption on weight, blood pressure and 
dietary pattern. The working hypothesis is that isocaloric low-fat yogurt intervention will 
improve weight status and reduce blood pressure without changing dietary pattern. This 
hypothesis was tested by evaluating the changes in body weight, waist circumference, blood 
pressure, and dietary pattern. 
Aim 2: Determine how pre-meal consumption of low-fat yogurt affects postprandial 
metabolism after a high-fat, high-carbohydrate meal. The working hypothesis is that pre-meal 
consumption of low-fat yogurt will reduce postprandial inflammation by improving postprandial 
metabolism and suppressing metabolic endotoxemia. This hypothesis was tested by measuring 
the postprandial changes in glucose, triglyceride (TG), insulin, interleukin-6 (IL-6), 
lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14) after consuming low-fat 
yogurt followed by a high-fat, high-carbohydrate meal. 
Aim 3: Define the effects of low-fat yogurt consumption on chronic inflammation and 
endotoxemia. Building on the findings under Aim 2, the working hypothesis is that low-fat 
yogurt consumption will reduce chronic inflammation and metabolic endotoxemia. This 
hypothesis was tested by determining the changes in markers for inflammation and endotoxemia 
before and after yogurt intervention.  
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2.1 Introduction 
Yogurt has been consumed for centuries. As early as 1908, Metchnikoff ascribed the 
prolonged life of the Bulgarians to consumption of sour milk fermented by lactic acid bacteria 
(O'Sullivan, Thornton et al. 1992). Yogurt is a milk product fermented by L. bulgaricus, S. 
thermophilus and L. acidophilus (CODEX STAN 243-2003). In addition to these Lactic acid 
bacteria (LAB), other strains of Lactobacillus and Bifidobacterium are commonly used as yogurt 
starter cultures (Desobry-Banon, Vetier et al. 1999). Yogurts may also be enriched in other 
probiotic strains that convey additional health benefits beyond those of traditional yogurt cultures 
(Shah 2007). 
The global rise in obesity is an increasing health concern. The causes of obesity and 
approaches needed to reduce obesity are multifactorial in nature (Holes-Lewis, Malcolm et al. 
2013).  Effective social, behavioral, and dietary interventions are needed to mitigate the adverse 
effects of obesity on personal health outcomes (Wadden, Webb et al. 2012). Obesity impairs gut 
health, which may be a potential target for therapeutic dietary interventions (Tilg and Kaser 
2011). Yogurt is rich with potential bioactive components and emerging evidence points toward 
the efficacy of yogurt and its components to improve gut health in obesity.   
2.2 Yogurt Bioactives 
2.2.1 Nutrients in yogurt 
Dairy products are rich in high-quality proteins, calcium, potassium, phosphorus, 
magnesium, zinc and B vitamins (Table 2.1) (Buttriss 1997). Fermentation can improve the 
nutrient content of dairy products. For example, some bacteria synthesize B vitamins. S. 
thermophilus can produce folate during yogurt fermentation, and certain inoculations can 
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increase folate levels 6-fold (Crittenden, Martinez et al. 2003). Yogurt also contains conjugated 
linoleic acid (CLA), a derivative of linoleic acid (Shahani and Chandan 1979, Aneja and Murthi 
1990). CLA may improve body composition by increasing lean body mass while decreasing fat 
mass, and has immunostimulatory and anticarcinogenic effects (Park, Albright et al. 1997, 
Whigham, Cook et al. 2000).  
Table 2.1 Representative nutrient data bank values for plain yogurts in the U.S.1 
Nutrient (per 6 oz.) Whole Low-fat Fat-free Fat-free (Greek) 
calories  104 107 95 100 
total fat (g) 5.9 2.64 0.31 0.66 
saturated fat (g) 3.56 1.7 0.12 0.20 
MUFA (g) 1.52 0.72 0.05 0.09 
PUFA (g) 0.16 0.08 0.01 0.02 
cholesterol (mg) 22 10 2 8 
carbohydrates (g) 7.92 11.97 13.06 6.12 
sugar (g)2 7.92 11.97 13.06 5.51 
dietary fiber (g) 0.0 0.0 0.0 0.0 
protein (g) 5.9 6.77 5.73 17.32 
thiamin (mg) 0.05 0.08 0.08 0.04 
riboflavin (mg) 0.24 0.36 0.40 0.47 
niacin (mg) 0.13 0.19 0.21 0.35 
vitamin B6 (mg) 0.05 0.08 0.09 0.11 
folate (mcg) 12 19 20 12 
vitamin  B12 (μg) 0.63 0.95 1.04 1.28 
vitamin A (RAE3) 46 24 3 2 
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vitamin C (mg) 0.8 1.4 1.50 0.0 
vitamin D (μg) 3.0 2.0 0.0 0.0 
vitamin E (mg) 0.1 0.05 0.0 0.02 
vitamin K (μg) 0.3 0.3 0.30 0.0 
calcium (mg) 206 311 338 187 
phosphorus (mg) 162 245 267 230 
magnesium (mg) 20 29 32 19 
sodium (mg) 78 119 131 61 
potassium (mg) 264 398 434 240 
iron (mg) 0.08 0.14 0.15 0.12 
zinc (mg) 1 1.51 1.65 0.88 
1 Derived from USDA National Nutrient Database for Standard Reference, Release 26.  
2Sweetened or fruit yogurts typically have an additional 20 g sugars per 6 oz. 
3Retinol activity equivalents 
Fermentation also improves the digestibility of milk proteins. LAB proteolytic enzymes 
and peptidases increase free amino acids in yogurt (Gorbach 1990). Upon digestion, yogurt had 
smaller clots of curd than milk, which facilitated digestive enzyme activity (Breslaw and Kleyn 
1973). In addition, the viscous texture of yogurt might decrease the gastric emptying rate, which 
increases duration of the enzymatic hydrolysis (Shahani and Chandan 1979, Gaudichon, Roos et 
al. 1994).  
Yogurt is also considered to be a good source of minerals. Dairy products are a good 
source of calcium, not just because of the abundance of calcium but also because of the high 
 13 
 
absorbability of calcium from yogurt. The presence of lactose, phosphopeptides, and amino acids 
derived from casein in dairy products facilitates the absorption of calcium by promoting its 
active transport or passive diffusion (Gueguen and Pointillart 2000). Although intervention 
studies have not demonstrated greater bioavailability of dairy calcium than supplemental calcium, 
dairy calcium was more effective than supplementary calcium in reducing weight and fat in 
energy-restricted adults (Sheikh, Santa Ana et al. 1987, Recker, Bammi et al. 1988, Zemel, Shi et 
al. 2000, Zemel, Thompson et al. 2004, Zhao, Martin et al. 2005). Although there is no evidence 
showing that yogurt serves as a better source of calcium than milk or other dairy products, yogurt 
has the advantage of being well tolerated by lactase-deficient individuals (Smith, Kolars et al. 
1985). 
2.2.2 Other bioactives 
Dairy products contain bioactive proteins, such as immunoglobulins, α-lactoglobulin, β-
lactoglobulin, lactoferrin, and phosphopeptides, which may regulate immune response, modulate 
blood pressure, and facilitate mineral absorption (Ebringer, Ferenčík et al. 2008). Bacterial 
hydrolysis of milk protein can yield oligopeptides with additional biological activities. For 
instance, some peptides (e.g. Val-Pro-Pro and Ile-Pro-Pro) have hypotensive effects via 
inhibiting angiotensin-converting-enzyme (Nakamura, Mizutani et al. 2009). A pentapeptide 
hydrolyzed from casein, Ile-Ile-Ala-Glu-Lys, has hypocholesterolemic effects in vitro 
(Morikawa, Kondo et al. 2007). Other effects of bioactive peptides such as antithrombotic, 
antioxidant, antimicrobial and antifungal activities have also been reported (Ebringer, Ferenčík et 
al. 2008).  
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Dairy products also contain various bioactive lipids and oligosaccharides. Phospho- and 
sphingolipids may reduce blood cholesterol, enhance brain function, and inhibit colon cancer 
(Rombaut, Camp et al. 2005, Ebringer, Ferenčík et al. 2008). Some short chain fatty acids in 
dairy products such as butyric acid (C4:0), caprylic acid (C8:0), capric acid (C10:0), lauric acid 
(C12:0) have anticarcinogenic, antiviral and antibacterial activities (Ebringer, Ferenčík et al. 
2008). In addition, dairy products contain some oligosaccharides such as lactulose, which could 
serve as prebiotics to support the growth of commensal bacteria (Marconi, Messia et al. 2004). 
2.2.3 Microorganisms 
S. thermophilus and L. bulgaricus are the most frequent microorganisms used to produce 
yogurt. In the United States, some yogurts have additional L. acidophilus, B. bifidum, B. lactis, L. 
casei, and/or L. rhamnosus content, among others, and are branded as ‘probiotic yogurts.’ The 
most basic definition of probiotics is, “live microorganisms which when administered in 
adequate amounts confer a health benefit on the host” (Pineiro and Embarek 2002). However, 
others have proposed that probiotics must originate from humans, be viable through the 
gastrointestinal tract, adhere to the intestinal wall to facilitate colonization, produce 
antimicrobials, and provide a demonstrable health effect (Guarner, Perdigon et al. 2005).  
It is commonly thought that 105 - 107 CFU/mL living probiotic bacteria are needed to 
confer a health benefit to the host (Schillinger 1999, Vélez, Hermans et al. 2007). Yogurt culture 
content ranges from 104 to 108 CFU/g/strain (Dunlap, Yu et al. 2009). In the US, yogurt can be 
certified with a “live and active culture” seal from the National Yogurt Association if it contains 
108 CFU/g at the time of manufacture (National-Yogurt-Association 2008). While the viability 
of yogurt microorganisms may be enumerated at manufacture, viability declines throughout the 
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shelf-life of products. For example, L. acidophilus, a culture commonly added to yogurt post-
fermentation, is relatively unstable in yogurt. This is likely due to hydrogen peroxide produced 
by L. bulgaricus during yogurt production (Gilliland and Speck 1977). A survey of yogurts in 
Columbia found poor survival and inconsistent labeling of strains (Vélez, Hermans et al. 2007). 
In a study of yogurts of European origin, bacterial counts in some products were as low as 104 
CFU per gram per strain by the sell-by date (Schillinger 1999). Temperature fluctuations may 
also reduce viability of yogurt probiotics. After 6 h at room temperature, reductions of 9-46.2% 
were seen in the CFU count for L. GG, L. johnsonii, and L. acidophilus (Scharl, Geisel et al. 
2010). Thus, it is expected that the amount of traditional and probiotic strains present in yogurt 
varies considerably by manufacturer, storage conditions, and time of consumption. Despite this, 
yogurt cultures may not need to be viable to confer a health benefit. For example, a preparation 
of mixed DNA from various probiotic strains inhibited colitis in IL-10-/- mice (Jijon, Backer et al. 
2004). Conventional yogurt LAB improve lactose digestion, despite poor viability and the 
inability to survive the digestive process (Martini, Lerebours et al. 1991).  
2.3 Obesity, Yogurt and Chronic Disease Risk 
Obesity is an abnormal or excessive accumulation of fat that poses a risk to health. A 
person with a body mass index (BMI) between 25 and 30 is classified as overweight and a BMI 
greater than 30 is obese. The International Obesity Task Force estimates that at least 1.1 billion 
adults are overweight, with 312 million of those obese (Haslam and James 2005). In the US, 
nearly 70% of adults are classified as overweight or obese (Flegal, Carroll et al. 2010). Obesity is 
a major risk factor for a number of chronic diseases such as diabetes, cardiovascular disease 
(CVD) and certain cancers. Furthermore, obese adults are projected to lose 7 years of life 
expectancy (Peeters, Barendregt et al. 2003). The morbidity associated with obesity accounts for 
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2-7% of health care costs in the developed world (Hossain, Kawar et al. 2007). Morbidities 
attributed to obesity include CVD, type 2 diabetes, hypertension, cancer, chronic inflammation, 
and compromised gut health. A limited number of yogurt intervention studies relevant to obesity 
and chronic disease risk have demonstrated positive outcomes on lipid profiles and chronic 
inflammation (Table 2.2). 
2.3.1 Cardiovascular diseases 
CVD is one of the leading causes of death and premature mortality. Ischemic heart 
diseases and stroke account for nearly one in four deaths worldwide (Lozano, Naghavi et al. 
2012). Visceral obesity has a critical role in the development of CVD (Grundy 2007).  Mathieu 
et al. reviewed how inflammation linked obesity and CVD (Mathieu, Lemieux et al. 2010). 
Briefly, excessive accumulation of fat in the adipose tissue leads to macrophage infiltration and 
elevated production of proinflammatory cytokines, which contribute to the development of 
atherosclerosis. In addition, obesity is related to atherogenic dyslipidemia characterized by 
increased levels of triglyceride (TG), small dense low-density lipoprotein (sdLDL) particles, as 
well as decreased level of high-density lipoprotein cholesterol (HDL-C) (Tenenbaum and Fisman 
2012). Obesity can also directly affect the structure and functions of the cardiovascular system. 
Obese individuals have increased cardiac output which can lead to left ventricular hypertrophy 
and other structural abnormalities (Lavie, Milani et al. 2009). Obesity also causes left atrial 
enlargement due to increased circulating blood volume and abnormal left ventricular diastolic 
filling (Lavie, Milani et al. 2009). These abnormalities compromise cardiovascular function and 
increase CVD risk for obese individuals (Lavie, Milani et al. 2009). 
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Table 2.2 Clinical studies of yogurt on biomarkers relevant to obesity and chronic disease risk. 
Category Reference Population Treatment Outcome 
Lipid profiles  (Schaafsma, Meuling et 
al. 1998) 
n = 30 healthy men 375 mL/d for 3 wk, 0.5% 
fat, + L. acidophilus 
↓ serum total cholesterol, ↓ LDL, and ↓ 
LDL/HLD-ratio. 
  (Anderson and Gilliland 
1999) 
n = 40 
hypercholesterolemic 
individuals 
200 mL/d for 4 wk, + L. 
acidophilus, unspecified fat 
content 
↓  serum cholesterol by 3.2% 
  (Kießling, Schneider et 
al. 2002) 
n = 29 women (14 
hypercholesterolemic) 
300 g/day for 6 mo, 3.5% 
fat, + L. acidophilus and B. 
longum 
↑ HDL 
  (Fabian and Elmadfa 
2006) 
n = 33 lean women 100 g/d for 2 wk and then 
200 g/d for another 2 wk, 
3.6% fat 
↓ LDL/HLD ratio 
  (Sadrzadeh-Yeganeh, 
Elmadfa et al. 2010) 
n = 90 lean women 300 g/d for 6 wk, 2.5% fat ↓ total cholesterol and ↓ total:HDL 
cholesterol ratio 
Inflammation  (Matsumoto, Ohishi et 
al. 2001) 
n = 6 elderly (3 M, 3 F) 100 g/day for 2 wk, + L. 
acidophilus and B. lactis, 
unspecified fat content 
↓ haptoglobin in feces  
  (Sakamoto, Igarashi et 
al. 2001) 
n = 31 elderly (29 M, 2 F) 180 g/day for 8 wk, + L. 
gasseri, unspecified fat 
content 
↓ H. pylori-induced gastric mucosal 
inflammation  
  (Schiffrin, Parlesak et 
al. 2009) 
n = 36 elderly  (9 M, 27 
F) 
300 g/day for 4 wk, + L. 
johnsonii, unspecified fat 
content 
↓ plasma LBP, sCD14 and surrogate 
markers of LPS permeability  
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  (Yang and Sheu 2012) n = 38 children 400 mL/day for 4 wk, + L. 
acidophilus and B. lactis, 
unspecified fat content 
↓ serum IL-6  
Appetite (Tsuchiya, Almiron-
Roig et al. 2006) 
n = 32 healthy men and 
women 
acute yogurt intake (200 
Kcal)  
↓ hunger, ↑ fullness, ↔ subsequent food 
intake 
 (Chapelot and Payen 
2010) 
n = 18 lean men acute yogurt intake (287 
Kcal)  
↑ satiety, ↔ subsequent food intake 
 (Dougkas, Minihane et 
al. 2012) 
n = 40 overweight men acute yogurt intake (201 
Kcal)  
↓ appetite, ↓ subsequent energy intake 
 (Douglas, Ortinau et al. 
2013) 
n = 15 women acute yogurt intake (160 
Kcal)  
↓ hunger, ↑ fullness, and delayed 
subsequent eating 
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Several recent expert reviews have summarized the potential benefits of dairy 
consumption on CVD risk. Van Meijl et al. reviewed the physiological effects of dairy 
consumption on metabolic syndrome and concluded that dairy calcium and protein had important 
roles in reducing metabolic syndrome risk (Van Meijl, Vrolix et al. 2008). In a prospective, 
matched case-control study using serum milk fat biomarkers, it was found that biomarkers of 
milk fat were inversely associated with the first myocardial infarction in Swedish women after 
multivariable adjustment for confounders (OR 0.74, 95% CI: 0.58, 0.94); moreover, reported 
intake of fermented milk products were inversely related to the first myocardial infarction (P < 
0.05 for trend) (Warensjö, Jansson et al. 2010). German et al. reviewed the effects of dairy foods 
and dairy fats on CVD risk (German, Gibson et al. 2009). They suggested that although dairy 
products contributed to saturated fat intake, there was no consistent association between dairy 
consumption and risk of CVD (German, Gibson et al. 2009). Similarly, another group examined 
the influence of milk fat containing dairy foods and CVD health and concluded that dairy 
consumption did not increase the risk of CVD, coronary heart disease or stroke, regardless of 
milk fat levels (Huth and Park 2012). Most research on dairy and CVD risk have not evaluated 
yogurt specifically. Given the differences in nutrient and bioactive content between yogurt and 
other dairy products, more attention is needed on this specific product category.   
Conventional yogurt consumption may improve lipid profiles in healthy and 
hypercholesterolemic adults. The effects of conventional yogurt, yogurt with L. acidophilus and 
B. lactis, or no yogurt on blood lipids were evaluated in healthy Iranian women (n = 90) 
(Sadrzadeh-Yeganeh, Elmadfa et al. 2010). Consumption of 300 g/d of conventional and 
probiotic yogurt for 6 wk reduced the total cholesterol and total:HDL cholesterol ratio relative to 
the control group (Sadrzadeh-Yeganeh, Elmadfa et al. 2010). The probiotic yogurt-consuming 
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group also experienced an 8.8% increase in HDL cholesterol (Sadrzadeh-Yeganeh, Elmadfa et al. 
2010). Probiotic or prebiotic containing yogurt may also further improve lipid profiles in adults. 
A randomized cross-over study of 40 hypercholesterolemic US adults consuming 200 g yogurt 
with L. acidophilus L1 for 4 wk reduced serum cholesterol by 3.2% relative to a yogurt prepared 
with an L. acidophilus strain with poor viability and low in vitro cholesterol-lowering activity  
(Anderson and Gilliland 1999). In a cross-over study of 29 healthy women, which included 
hypercholesterolemic individuals, 300 g of yogurt with L. acidophilus and B. longum for 7 weeks 
increased serum HDL cholesterol by 0.3 mmol/L relative to a control yogurt without these 
strains (Kießling, Schneider et al. 2002). In a parallel study of 33 normocholesterolemic women, 
consumption of 100 g/d yogurt for 2 wk and 200 g/d for another 2 wk reduced the LDL/HDL 
cholesterol ratio in healthy women, with no differences from the probiotic culture L. casei 
containing yogurt (Fabian and Elmadfa 2006). Consumption of 375 mL of yogurt containing L. 
acidophilus and fructo-oligosaccharides for 3 wk lowered serum total cholesterol, LDL-
cholesterol, and the LDL/HDL-ratio in 30 healthy men relative to conventional yogurt (Fabian 
and Elmadfa 2006).  
2.3.2 Hypertension 
Hypertension is associated with vascular disease mortality, CVD, and renal diseases 
(Lewington, Clarke et al. 2002, Chobanian, Bakris et al. 2003). Hypertension in US adults 
increased from 23.9% in 1988-1994 to 29% in 2007-2008 based on data from the National 
Health and Nutrition Examination Survey (NHANES) (Egan, Zhao et al. 2010). Previous studies 
have indicated a strong relationship between obesity and hypertension. Cross-sectional studies 
indicate that more than 85% of hypertensive individuals have a BMI of over 25 kg/m2 
(Kastarinen, Nissinen et al. 2000). Several mechanisms are involved in the pathogenesis of 
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obesity-related hypertension. The sympathetic nervous system, the renin-angiotensin system 
(RAS), and aldosterone contribute to the development of hypertension in obesity (Rahmouni, 
Correia et al. 2005). Long-term over-activation of sympathetic nervous system which is found in 
obesity could raise arterial pressure by inducing peripheral vasoconstriction and increasing 
sodium reabsorption in the renal tubules (Rahmouni, Correia et al. 2005). Adipose RAS is 
activated in obesity; animal models of visceral obesity suggest that adipose RAS contributes to 
obesity-associated hypertension (Massiéra, Bloch-Faure et al. 2001). Plasma aldosterone levels 
were elevated in obese hypertensive patients (Goodfriend and Calhoun 2004); on the other hand, 
an aldosterone antagonist was found to inhibit the development of high blood pressure in dietary-
induced obese dog models (De Paula, Da Silva et al. 2004). 
Therefore, given the need for dietary strategies to mitigate hypertension, the 
antihypertensive effects of dairy consumption have been investigated. The Dietary Approaches 
to Stop Hypertension (DASH) trial showed that a diet rich in fruits and vegetables lowered blood 
pressure and that additional inclusion of low-fat dairy products with reduced saturated and total 
fat further augmented these blood pressure-lowering effects (Appel, Moore et al. 1997). A recent 
review and meta-analysis of five cohort studies involving nearly 45,000 subjects revealed an 
inverse association between dairy consumption and development of elevated blood pressure, 
defined as ≥ 130 mm Hg systolic and/or ≥84 mm Hg diastolic blood pressure (RR 0.87, 0.81-
0.94 95% CI) (Ralston, Lee et al. 2012). Another meta-analysis of prospective cohort studies 
similarly reported that increased consumption of 200 g/d of low-fat dairy products reduced the 
risk of hypertension (RR 0.96, 95% CI, 0.93-0.99) (Soedamah-Muthu, Verberne et al. 2012). 
Based on these data, low-fat dairy consumption appears protective against hypertension in adults, 
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but well-designed randomized, controlled trials (RCTs) are needed to confirm if yogurt is also 
antihypertensive. 
2.3.3 Cancer 
In 2010, 8 million people died from cancer globally, accounting for 15.1% of all deaths 
worldwide (Lozano, Naghavi et al. 2012). Overweight and obesity are estimated to contribute to 
14% of all cancer deaths in men and 20% of deaths in women (Calle, Rodriguez et al. 2003). 
Meta-analyses indicate that higher BMI is associated with an increased incidence of endometrial, 
colorectal, and postmenopausal breast cancer (Larsson and Wolk 2007, Moghaddam, Woodward 
et al. 2007, Reeves, Pirie et al. 2007). It is hypothesized that obesity disturbs the physiological 
function of adipose tissue, which leads to insulin resistance, chronic inflammation, and 
dysregulation of adipokine secretion, factors contributing to the promotion and progression of 
cancer (Van Kruijsdijk, Van Der Wall et al. 2009). 
Accumulating evidence indicates potential beneficial effects of yogurt consumption on 
cancers. A prospective study involving 82,220 Swedish individuals found that the risk for 
bladder cancer was lowest in individuals consuming the highest levels of sour milk and yogurt 
(RR 0.62, 95% CI, 0.46-0.85; ≥ 2 servings/d vs. 0 serving/d) (Larsson, Andersson et al. 2008). In 
another prospective study in an Italian cohort involving 45,241 volunteers, after adjusting for 
energy, simple sugar, calcium, fiber, animal fat, alcohol and red meat intake, body mass index, 
smoking, education, and physical activity, the hazard ratio for colorectal cancer in the highest 
versus lowest tertile of yogurt intake was 0.65 (95% CI, 0.48-0.89) (Pala, Sieri et al. 2011). 
Animal studies support the beneficial effects of yogurt. For example, LABs from yogurt were 
shown to effectively inhibit the genotoxic effects of heterocyclic aromatic amines on rats 
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(Zsivkovits, Fekadu et al. 2003). L. acidophilus isolated from yogurt reduced tumor growth rate 
and increased lymphocyte proliferation in a mouse model of breast cancer (Maroof, Hassan et al. 
2012). A potential mechanism for reduced cancer risk is lower fecal mutagenicity, as 
demonstrated by consumption of yogurt with B. lactis by elderly individuals (Matsumoto, Ohishi 
et al. 2001). Given these promising results for yogurt intake and reduced risk for bladder and 
colon cancers, further work is warranted to evaluate if yogurt is similarly protective against other 
cancers.  
2.3.4 Diabetes 
The worldwide prevalence of diabetes in adults was estimated at 6.4% in 2010, and is 
projected to increase to 7.7% by 2030 (Shaw, Sicree et al. 2010). Excess weight may contribute 
to 90% of type 2 diabetes cases (Hossain, Kawar et al. 2007). More than 197 million people 
worldwide have impaired glucose tolerance attributed to obesity or metabolic syndrome (Hossain, 
Kawar et al. 2007). Many studies have illustrated the mechanisms linking obesity and type 2 
diabetes. Adipose tissue has a pivotal role in type 2 diabetes by releasing non-esterified fatty 
acids (NEFAs), hormones, and various proinflammatory cytokines (Shoelson, Lee et al. 2006). 
Overabundant intracellular NEFAs inhibit key enzymes involved in glucose metabolism (Kahn, 
Hull et al. 2006). Furthermore, the corresponding intracellular fatty acid metabolites activate the 
serine/threonine kinase cascade which disturbs the insulin signaling pathway (Shulman 2000). 
To compensate for insulin resistance, the pancreatic β-cells secrete more insulin, eventually 
causing endoplasmic reticulum stress and protein misfolding which lead to β-cell apoptosis 
(Muoio and Newgard 2008). 
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Dairy consumption may reduce risk of type 2 diabetes. For example, an 8 yr prospective 
cohort study of 82,076 postmenopausal women demonstrated that low-fat dairy products were 
inversely associated with the risk of type 2 diabetes (RR 0.65; 95% CI: 0.44-0.96 for the highest 
quintile of intake) (Margolis, Wei et al. 2011). A recent meta-analysis of cohort studies showed 
that the adjusted relative risk of type 2 diabetes for highest versus lowest quartiles of dairy intake 
was 0.86 (95% CI, 0.79-0.92) (Tong, Dong et al. 2011). A subgroup analysis revealed a relative 
risk of 0.83 (95% CI, 0.74-0.93) for the intake of yogurt (Tong, Dong et al. 2011). A newer 
prospective study including 340,234 subjects did not find an association between total dairy 
products and diabetes. However, in the dairy subtype analysis, a higher combined intake of 
fermented dairy products (cheese, yogurt and thick fermented milk) was inversely associated 
with diabetes (HR, 0.88; 95% CI, 0.79-0.99) (Sluijs, Forouhi et al. 2012). In another smaller-
sized prospective study, fermented dairy intake was inversely associated with fasting plasma 
glucose and HbA1c, although no significant association between intake and incidence of diabetes 
was found (Struijk, Heraclides et al. 2013). Although epidemiological studies support the 
beneficial effects of yogurt consumption on reduced type 2 diabetes risk, RCTs are needed to 
confirm the causal effects of dairy consumption on improved diabetes outcomes.  
2.4 Obesity, Yogurt and Chronic Inflammation 
2.4.1 Obesity is associated with elevated chronic inflammation 
The anti-inflammatory effects of low-fat dairy products have been well documented 
(Sakamoto, Igarashi et al. 2001, Schiffrin, Parlesak et al. 2009, Yang and Sheu 2012). The 
classic signs of inflammation are characterized by redness, swelling, heat, and pain and the 
inflammation is typically resolved shortly after the insult or stimuli are removed (Hotamisligil 
2006). In contrast, obesity-associated chronic inflammation is unresolved, low-grade 
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inflammation that originates from metabolic cells (e.g. adipocytes) in response to excessive 
nutrient intake (Gregor and Hotamisligil 2011). Overactive metabolic signals induce the 
activation of proinflammatory pathways, which cause low-level induction of cytokines in 
metabolic tissues; these inflammatory signals recruit immune cells into metabolic tissues and 
disrupt the normal metabolic cell functions (Gregor and Hotamisligil 2011).  
Obesity leads to increased levels of inflammatory biomarkers in a variety of tissues 
(Table 2.3). For example, protein kinases such as c-Jun N-terminal kinases (JNK) and inhibitor 
of κ kinase (IKK) induce the expression of proinflammatory cytokines (Solinas and Karin 2010). 
Obese women had a significantly higher amount of phosphorylated (active form) JNK in omental 
fat compared with lean women (Bashan, Dorfman et al. 2007). In rodents, Hirosumi et al. 
observed significant increases in total JNK activity in liver, muscle and adipose tissues of both 
dietary and genetic (ob/ob) obesity models (Hirosumi, Tuncman et al. 2002). Increased 
activation of JNK and nuclear factor kappa B (NF-κB) pathways were also detected in the 
hypothalamus of high-fat-fed mice, accompanied by increased secretion of proinflammatory 
cytokines (De Souza, Araujo et al. 2005). Elevated NF-κB and IKK activities were found in the 
livers of both genetic and diet-induced obese mice (Cai, Yuan et al. 2005). In high-fat-fed mice, 
increased IKK activity and downstream products of NF-κB pathway were observed in lysates of 
the thoracic aorta (Kim, Pham et al. 2007).  
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Table 2.3 Obesity-related changes in biomarkers of inflammation. 
Reference Samples Population Markers 
(Hotamisligil, Arner 
et al. 1995) 
adipose tissue premenopausal 
women, n = 18 
lean/n = 19 obese 
↑ TNF-α mRNA; 
body weight reduction  ↓ TNF-α 
mRNA 
(Kern, Ranganathan 
et al. 2001) 
adipose tissue  n = 50 lean/n = 50 
obese 
↑ TNF-α secretion 
 plasma  ↑ IL-6    
(Panagiotakos, 
Pitsavos et al. 2005) 
serum 3042 adults ↑ CRP,  ↑ TNF-α, ↑ amyloid A, ↑ IL-6 
in subjects with central adiposity 
(Kim, Park et al. 
2006) 
serum 50 obese and 50 lean 
adults 
↑ MCP-1, ↑ IL-8 and ↑ CRP  
(Herder, Schneitler et 
al. 2007) 
serum 519 adolescents IL-6, IL-18 and interferon-γ-inducible 
protein-10 positively associated with 
BMI and waist circumference 
(Mauras, DelGiorno 
et al. 2010) 
plasma 203 children ↑ hsCRP, ↑ fibrinogen, ↑ IL-6 and ↑ 
plasminogen activator inhibitor-1 
(Brake, Smith et al. 
2006) 
adipose tissue High-fat-fed male 
mice 
↑ ICAM-I, ↑ IL-6 and ↑ MCP-1 mRNA 
(Ehses, Perren et al. 
2007) 
pancreatic 
islets 
High-fat-fed mice ↑ IL-6, ↑ IL-8 and ↑ macrophage 
inflammatory protein 1α 
(De Souza, Araujo et 
al. 2005) 
hypothalamus High-fat-fed rats ↑ TNF-α, ↑ IL-1β, and ↑ IL-6 
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Obesity increases the infiltration of immune cells into various metabolic tissues. 
Macrophages infiltrate adipose tissue in obese individuals and are responsible for nearly all 
adipose-derived TNF-α expression (Weisberg, McCann et al. 2003). Similarly, obesity leads to 
increased inflammatory macrophages in visceral adipose tissue (Curat, Wegner et al. 2006). 
Macrophage-derived proinflammatory cytokines can subsequently initiate insulin resistance and 
compromise β-cells (Solinas and Karin 2010). 
Animal models of obesity corroborate the infiltration of macrophages and other 
immunocytes. Macrophages and microphages were increased in white adipose tissue in both 
genetic and high-fat diet-induced models of obese mice (Xu, Barnes et al. 2003). Ehses et al. 
observed increased islet-associated macrophages in high-fat-fed mice and db/db obese mice 
(Ehses, Perren et al. 2007).  Diet-induced obese mice had increased accumulation of T cells in 
adipose tissue relative to lean mice (Wu, Ghosh et al. 2007). Likewise, natural killer T (NKT) 
cells infiltrated visceral adipose tissue in high-fat-fed mice (Ohmura, Ishimori et al. 2010). In the 
same model, depletion of NKT cells ameliorated visceral adipose tissue inflammation (Ohmura, 
Ishimori et al. 2010). Therefore, the metabolic and inflammatory consequences of obesity affect 
a wide variety of tissues. Animal and a limited number of human studies indicate a potential role 
for dairy or yogurt consumption to mitigate chronic inflammation associated with obesity, as 
detailed below. 
2.4.2 Increased infiltration of immune cells into metabolic tissues 
Yogurt and LAB can modulate the immune response through cytokine production. 
However, studies have not focused on the role of yogurt or dairy on obesity-associated 
immunocyte dysregulation. In diet-induced obese mice, compared to the high calcium diet, a 
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nonfat dry milk-supplemented diet reduced weight gain and associated adipose tissue 
inflammation as shown by decreased mRNA abundance of (monocyte chemoattractant protein) 
MCP-1, TNF-α, and IL-6; this suggested that some active components in dairy other than 
calcium could modulate the immune response (Thomas, Dunn et al. 2012).  
Yogurt and its associated cultures also have immunostimulatory effects in healthy 
individuals. Consumption of yogurt containing L. bulgaricus and S. thermophilus increased 
production of IFN-γ by T cells in young adults (Halpern, Vruwink et al. 1991). IFN-γ regulates 
the induction of pro-inflammatory cytokines and the activation of macrophages and natural killer 
cells. LAB directly stimulates human lymphocyte IFN-γ in vitro (De Simone, Bianchi Salvadori 
et al. 1986).  An observational retrospective study showed that supplementation with yogurt 
containing L. rhamnosus increased the CD4 count in a group of people living with HIV (Irvine, 
Hummelen et al. 2010). Consumption of fermented milk containing L. acidophilus significantly 
increased the phagocytosis of E. coli in adults (Schiffrin, Brassart et al. 1997). Likewise, 
fermented milk with L. casei, L. acidophilus, or a mixture of both increased phagocytic 
lymphocytic activities in Swiss mice (Perdigon, Alvarez et al. 1995). Oral administration of L. 
acidophilus alone improved immunoreactivity of peripheral blood leukocytes and peritoneal 
phagocytes and enhanced serum antibody response to orally and systemically administrated 
antigens in mice (Gill, Rutherfurd et al. 2000). Since yogurt consumption in obese individuals 
does not produce pro-inflammatory effects (Labonté, Couture et al. 2013), further work is needed 
to identify how yogurt modulates immune cells in obesity, and whether these effects are 
localized to the gut or have broader activities at metabolic tissues.  
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2.5 Obesity, Yogurt and Intestinal Barrier Function 
The chronic inflammation associated with obesity may be exacerbated by impaired 
intestinal barrier function. Leptin-deficient and hyperleptinemic obese mice have increased 
intestinal permeability, modified distribution of junction proteins in the intestinal mucosa, as 
well as increased circulating levels of inflammatory cytokines compared with lean control mice 
(Brun, Castagliuolo et al. 2007). Diet-induced obese mice fed high-fat diets had increased 
intestinal permeability assessed by gavage of fluorescent-dextran, increased plasma LPS levels, 
and reduced expression of genes for tight junction proteins (Cani, Bibiloni et al. 2008). Obese 
women had increased paracellular permeability measured by lactulose excretion relative to lean 
women (Teixeira, Souza et al. 2012).  Intestinal paracellular permeability was correlated with 
waist circumference and homeostatic model assessment (HOMA) values (Teixeira, Souza et al. 
2012). Likewise, intestinal barrier function was more strongly correlated with central adiposity 
than BMI in overweight adults (Gummesson, Carlsson et al. 2011). Dysregulation of intestinal 
barrier function may be attributed to dysregulation of gut microbiota, endotoxin exposure, the 
mucus bilayer, secretory immunoglobulin A (sIgA), antimicrobial peptides, and tight junction 
proteins. Emerging evidence supports the ability of yogurt consumption to modulate these 
functions, as discussed below.   
2.5.1 Dysregulation of gut microbiota 
The intestine is essential for nutrient absorption and host defense. Gut microbiota 
facilitate these functions by fermenting non-digestible nutrients, vitamin synthesis, and 
participating in host defense (Salzman, Underwood et al. 2007). Favorable gut microbiota may 
compete with pathogens for space and nutrients and produce anti-microbial compounds such as 
bacteriocins and lactic acids (O'Hara and Shanahan 2006). Gut microbiota also contribute to 
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energy homeostasis and fat storage. Interestingly, germ-free mice were protected against diet 
induced obesity (Bäckhed, Manchester et al. 2007). On the other hand, conventionalization of 
germ-free mice with a normal microbiota harvested from the cecum of conventionally raised 
mice caused a 60% increase in body fat within 14 d despite reduced food consumption (Bäckhed, 
Ding et al. 2004). The authors proposed that the gut microbiota helped to absorb 
monosaccharides from the lumen which further induced de novo hepatic lipogenesis (Bäckhed, 
Ding et al. 2004). Colonization of germ-free mice with microbiota from obese mice induced a 
more significant increase in total body fat than colonization with microbiota from lean mice 
(Turnbaugh, Ley et al. 2006). This suggested that the composition of gut microbiota affects the 
development of obesity. In both mice and humans, Bacteroidetes and Firmicutes are the major 
species comprising the microbiota (Bäckhed 2009). Obese adults have a lower proportion of 
Bacteroidetes to Firmicutes than lean, although this ratio can be improved with weight loss from 
energy restriction (Ley, Turnbaugh et al. 2006).  
Conventional yogurt cultures have limited viability in the gut and a limited ability to 
influence the composition of the gut microbiota. Adults consuming yogurt with S. thermophilus 
and L. bulgaricus had less than 103 CFU/g of these cultures in feces (Del Campo, Bravo et al. 
2005). In another study, participants consumed 125 g of a commercial yogurt twice per day for 
one week, providing 108 CFU of S. thermophilus and L. bulgaricus (Elli, Callegari et al. 2006). S. 
thermophilus was not present in feces, although L. bulgaricus was present in about 70% of the 
fecal samples provided on days 2 and 7 of the yogurt-consumption period. However, the levels 
of L. bulgaricus detected on average did not exceed the 105 CFU/g minimum deemed necessary 
to exert beneficial effects (Elli, Callegari et al. 2006). Another study providing a higher dose of 
yogurt cultures (375 g yogurt, 108 CFU/g) for two weeks, reported a median value of 
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approximately 104 CFU each of S. thermophilus and L. bulgaricus per gram of feces (Mater, 
Bretigny et al. 2005). Although yogurt cultures have apparently low viability through the entire 
gastrointestinal tract, more information is needed about their small intestine viability. 
Certain probiotic strains may have improved viability in the gut relative to S. 
thermophilus and L. bulgaricus. Healthy adults that consumed 230 mL yogurt with additional L. 
acidophilus and B. bifidum at 107 CFU/g daily for 10 days had decreased aerobic bacteria and 
increased anaerobic bacteria in fecal samples (Chen, Wu et al. 1999). Additionally, the bifidus to 
coliform ratio favorably increased and B. bifidum was measurable for up to 8 days after 
consumption (Chen, Wu et al. 1999). In contrast, L. acidophilus, S. thermophilus, and L. 
bulgaricus, were not detectable in feces (Chen, Wu et al. 1999).   
McNulty et al (2011) investigated the effect of B. animalis subsp. lactis on the gut 
microbiota of mice and humans. Healthy pairs of monozygotic twins consumed a fermented milk 
product (FMP) with L. bulgaricus and B. animalis subsp. lactis or no product daily for seven 
weeks. Fecal samples analyzed before, during, and after the intervention did not show a 
statistically significant change in the microbiota composition (McNulty, Yatsunenko et al. 2011). 
Additionally, the FMP cultures did not persist in the microbiota longer than two weeks after 
ceasing its consumption. In the same study, human-gut-derived bacterial strains and FMP strains 
were transplanted into germ-free mice. Similar to humans, the humanized intestinal microbiota 
was not drastically altered by FMP, but genes related to carbohydrate metabolism were up-
regulated by FMP consumption (McNulty, Yatsunenko et al. 2011). 
Animal models suggest that yogurt-induced improvements in intestinal permeability are 
associated with changes to gut microbiota. In Wistar rat pups, consumption of yogurt with L. 
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casei counteracted acute gastroenteritis-induced barrier dysfunction (Isolauri, Kaila et al. 1993).  
In atopic dermatitis (AD) patients with increased intestinal permeability, 4 wk consumption of 
yogurt with B. lactis, L. bulgaricus, and S. thermophilus increased polyamine-producing 
bacterial species which was associated with improved intestinal barrier function (Matsumoto, 
Aranami et al. 2007).  
Cultures used in yogurt may also be modified to improve their viability in the gut by 
protecting cultures from stomach acid. For example, yogurt with encapsulated or free L. 
acidophilus ATCC 4356 was subjected to a simulated human digestive system (Ortakci and Sert 
2012). Encapsulated L. acidophilus had improved viability up to 2 h of incubation in artificial 
human gastric juice.  
Thus, conventional yogurt cultures have low to no viability in the gut. Probiotic or 
encapsulated strains may have greater viability, and their metabolic effects or competition with 
coliforms in the intestine are apparent. These studies suggest that strains may not need to adhere 
to the intestinal epithelium and proliferate in order to exert the desired health effects. If this is the 
case, it suggests that consistent and prolonged probiotic consumption may be needed to achieve 
measurable health benefits from these strains. 
2.5.2 Contribution of bacterial endotoxin to chronic inflammation 
Gut microbiota contribute to systemic low-grade inflammation by increasing the 
exposure to proinflammatory bacterial products, especially the Gram-negative-derived LPS 
among others (Okamura, Watari et al. 2001, Rallabhandi, Bell et al. 2006). LPS typically 
consists of a hydrophobic domain known as lipid A, a non-repeating core oligosaccharide, and a 
distal polysaccharide (Raetz and Whitfield 2002). LPS initiates inflammatory signaling through 
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lipopolysaccharide binding protein (LBP), CD14, Toll-like receptor 4 (TLR4) and MD2. LBP is 
thought to extract LPS and subsequently deliver it to CD14 or lipoprotein; the former may lead 
to the activation of target cells while the latter may result in the clearance by liver (Van Bossuyt, 
De Zanger et al. 1988). CD14 serves as a pattern-recognition receptor in proinflammatory 
signaling which can be stimulated by various ligands (Pugin, Heumann et al. 1994, Park, Song et 
al. 2009). MD2 physically associates with TLR4 on the cell surface and acts as co-receptor with 
TLR4 for the detection of LPS (Manco, Putignani et al. 2010). Once activated by LPS, TLR4 
undergoes oligomerization and recruits its two adaptor protein pairs, TRAM-TRIF and MAL-
MyD88, ultimately activating the NF-κB pathway (Manco, Putignani et al. 2010).  Human and 
animal studies have shown LPS as a strong inducer of proinflammatory cytokines such as IL-6 
and TNF in most tissues including adipocytes (Stoll, Denning et al. 2004, Kemna, Pickkers et al. 
2005, Cani, Amar et al. 2007, Creely, McTernan et al. 2007, Andreasen, Larsen et al. 2010).  
Overweight and obese adults have increased endotoxin exposure (Sun, Yu et al. 2010). 
Acute and chronic fat consumption is associated with increased exposure to endotoxin. A cross-
sectional study of 201 healthy French men reported that total energy and fat, but not 
carbohydrate or protein were correlated with plasma LPS (Amar, Burcelin et al. 2008). These 
observations were confirmed in mice and indicated fat was more efficient in facilitating 
translocation of LPS into circulation than carbohydrate (Amar, Burcelin et al. 2008). In addition, 
a single high-fat meal can induce postprandial endotoxemia and inflammation (Erridge, Attina et 
al. 2007, Ghanim, Sia et al. 2010, Laugerette, Vors et al. 2011). Obesity-associated dysregulation 
of gut microbiota may also increase endotoxin exposure (Cani, Amar et al. 2007, Cani, Bibiloni 
et al. 2008).  
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Preliminary studies in elderly individuals have demonstrated that yogurt consumption 
inhibits markers of endotoxin exposure in elderly individuals (Schiffrin, Parlesak et al. 2009). 
Elderly individuals (n = 23) with small-intestinal bacterial overgrowth consumed 300 g/d of 
yogurt with 109 CFU L. johnsonii La1 for 4 wk.  By the end of the trial, yogurt consumption 
decreased plasma levels of LBP and sCD14, LPS pattern recognition receptors in elderly with 
small-intestinal bacterial overgrowth (Schiffrin, Parlesak et al. 2009). Furthermore, yogurt 
consumption also reduced plasma endotoxin in healthy elderly participants (Schiffrin, Parlesak et 
al. 2009). Small intestinal bacterial overgrowth may affect 41% of obese individuals (Jouet, 
Coffin et al. 2011). Therefore, further studies are warranted to evaluate the ability of yogurt to 
reduce endotoxin exposure in obese individuals.  
2.5.3 Mucus bilayer 
The mucus bilayer is produced by goblet cells and separates gut microbiota from 
endothelial cells. This bilayer is formed by a mesh-like structure of mucins, high molecular 
weight glycoproteins with increased hydration capacity due to negative surface charges 
(Dharmani, Srivastava et al. 2009). Mucins lubricate and maintain the hydrated layer of the 
epithelium, as well as create a permeable unstirred, gel-like layer that facilitates nutrient 
exchange (Dharmani, Srivastava et al. 2009). The mucus bilayer is essential to the innate host 
defense. The outer mucus layer provides space and nutrients for the residence of commensal 
microflora which might inhibit the growth and invasion of pathogens; the inner layer is 
impervious to bacteria and acts like a protective barrier for the epithelium (Turner 2009, Kim and 
Ho 2010). The goblet cells also produce intestinal trefoil factor and resistin-like molecule-β, 
proteins that strengthen the barrier by stabilizing the mucin polymers or regulating mucin 
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secretions (Dharmani, Srivastava et al. 2009). Additionally, the mucus layer contains other 
defensive components such as secretory IgA and antimicrobial peptides.  
Probiotics associated with yogurt may stimulate the production of intestinal mucins and 
improve host defense. For example, L. plantarum 299 v incubated with HT-29 intestinal 
epithelial cells increased mucin mRNA expression and inhibited the adherence of an attaching 
and effecting pathogenic E. coli. in vitro (Mack, Michail et al. 1999). Similarly, in Wistar rats, 7 
d consumption of Lactobacilli, Bifidobacteria, and Streptococci increased basal luminal mucin 
content by 60% (Caballero-Franco, Keller et al. 2007). Whey peptides derived from α- and β- 
caseins also increased mucin secretion in HT29-MTX cells (Martínez-Maqueda, Miralles et al. 
2012). Thus, this emerging evidence suggests that dairy products or their associated probiotics 
could be of benefit to the mucus bilayer. A recent diet-induced obese mice model showed that 
obesity was associated with decreased mucus layer thickness due to the decreased level of 
Akkermansia muciniphila, a mucus layer resident that played an essential role in mucus turnover 
(Everard, Belzer et al. 2013). Thus, it appears worthwhile to further investigate the effects of 
yogurt on the obese-compromised mucus layer.  
2.5.4 Secretory IgA (sIgA) 
sIgA is the major effector of the mucosa-associated lymphoid tissue (MALT) and 
protects against commensal bacterial penetration of the lumen (Brandtzaeg, Baekkevold et al. 
1999). MALT consists of lymphocytes such as T cells and B cells, as well as plasma cells and 
macrophages, which are stimulated by antigens. sIgA, dimeric or polymeric IgA, is produced by 
plasma cells in the intestinal mucosa and is the predominant antibody class in the intestinal 
lumen (Macpherson and Uhr 2004, Woof and Ken 2006). Interstitial sIgA inhibits pathogens and 
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toxins by 1) preventing the adhesion and entry of pathogens and toxins by interfering with 
epithelial receptor recognition, 2) binding pathogens and promoting their clearance, or 3) 
inhibiting virus production (Corthésy 2007). Low serum IgA may indicate compromised immune 
function, while high serum IgA is associated with chronic inflammation, central adiposity, and 
advanced age (Gonzalez-Quintela, Alende et al. 2008).  
Yogurt consumption appears to modulate the gut immune function by increasing sIgA. 
For example, consumption of yogurt with L. acidophilus by 30 healthy adults increased total 
serum IgA and the production of specific serum IgA against an attenuated strain of S. 
typhimurium (Link-Amster, Rochat et al. 1994). Consuming 400 mL yogurt with L. acidophilus 
daily for 4 wk reduced H. pylori and increased the serum IgA level in 38 infected children (Yang 
and Sheu 2012). Rodent studies also support the IgA-promoting effects of yogurt. In a mouse 
model, orally administrated LAB alone and in yogurt increased the intestinal IgA producing cells 
and IgA (Perdigon, Alvarez et al. 1995). Furthermore, a 7 d yogurt treatment partially prevented 
the infection of S. typhimurium and inhibited intestinal carcinomas induced by 1-2-
dimethylhydrazine (Perdigon, Alvarez et al. 1995). Similarly, mice fed yogurt for 4 wk had 
increased serum IgA after a S. typhimurium challenge, relative to the milk-treated control group 
(Puri, Rattan et al. 1996). Thus, both animal and human studies have demonstrated induction of 
sIgA defenses following yogurt consumption, which may improve immunity.  
2.5.5 Antimicrobial peptides 
Defensins are antimicrobial peptides secreted by Paneth cells located in the crypts of the 
small intestinal mucosa (Porter, Bevins et al. 2002). Defensins have bactericidal activity against 
various Gram-positive and Gram-negative bacteria (Salzman, Underwood et al. 2007). These 
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peptides facilitate bacterial membrane collapse through electrostatic and hydrophobic 
interactions (Zasloff 2002). Paneth cell function and defensin levels are compromised in obese 
individuals, which may be explained by activated unfolded protein response in the intestine 
(Hodin, Verdam et al. 2011). In healthy women, consumption of 200 mL yogurt with or without 
B. lactis Bb12 for 3 wk did not alter fecal β-defensin-2, although both treatments increased fecal 
sIgA from baseline (Kabeerdoss, Shobana Devi et al. 2011). However, the probiotic 
Lactobacillus and E.coli Nissle 1917 increased β-defensin 2 expression in Caco-2 cells (Schlee, 
Wehkamp et al. 2007, Schlee, Harder et al. 2008). Further work is needed to determine if dietary 
approaches are feasible to overcome obesity-compromised defensin production. 
2.5.6 Mucosal cells and tight junctions 
The innermost layer of the intestine is a monolayer of enterocytes, endocrine cells, 
microfold cells, G cells, and Paneth cells (Scaldaferri, Pizzoferrato et al. 2012). Enterocytes are 
the most abundant cells and are connected by apical junctions, which are mainly adherent or tight 
junctions (Hartsock and Nelson 2008). Adherent junctions consist of the transmembrane protein 
E-cadherin and the catenin family members, including p120-catenin, β-catenin, and α-catenin 
(Hartsock and Nelson 2008). Adherent junctions initiate and stabilize cell-cell adhesion, regulate 
the actin cytoskeleton, and contribute to intracellular signaling (Hartsock and Nelson 2008). 
Tight junctions are composed of occludins, claudins, and junction adhesion molecules (JAM), 
transmembrane proteins that are linked to the cytoskeleton through zonula occludens (ZO) 
scaffolding proteins (Hartsock and Nelson 2008). Tight junctions are the primary barrier to 
intestinal intercellular space, but are not impermeable. The paracellular pathway is selective to 
ions and other small molecules, and depends on the cell type (Tsukita, Furuse et al. 2001).  
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Increased plasma endotoxin levels suggest that obese individuals have compromised 
intestinal barrier function (Sun, Yu et al. 2010). Compromised intestinal barrier function is 
proposed to contribute to chronic inflammation in obesity by initiating inflammation through 
endotoxin exposure (Cani, Amar et al. 2007). The perturbation of proinflammatory cytokines, 
gastrointestinal peptides, and endocannabinoids associated with obesity can compromise tight 
junctions (Blüher, Engeli et al. 2006, Côté, Matias et al. 2007, Cluny, Reimer et al. 2012). In 
rodents, glucagon-like peptide-2 (GLP-2) protects barrier function, while melatonin can increase 
permeability (Cameron, Yang et al. 2003, Cameron and Perdue 2005, Sommansson, Nylander et 
al. 2013). IFN-γ (Youakim and Ahdieh 1999, Yang, Kiristioglu et al. 2002, Bruewer, Utech et al. 
2005, Clark, Hoare et al. 2005), TNF-α (Schmitz, Fromm et al. 1999, Mankertz, Tavalali et al. 
2000, Li, Zhang et al. 2008, Al-Sadi, Boivin et al. 2009), and IL-6 (Yang, Han et al. 2003, Al-
Sadi and Ma 2007) can disrupt barrier function. In contrast, IL-10 (Madsen, Lewis et al. 1997, 
Oshima, Laroux et al. 2001), transforming growth factor beta (TGF-β) (Howe, Reardon et al. 
2005), and IL-17 (Kinugasa, Sakaguchi et al. 2000) improve barrier function in human T84 
colonic epithelial cells. Obese ob/ob mice had improved barrier function and lower plasma LPS 
when treated with a CB receptor 1 antagonist (Muccioli, Naslain et al. 2010).  
Yogurt and its associated probiotics may improve intestinal barrier function by maintaining the 
expression of tight junction proteins. Yogurt with B. lactis prevented the increase in intestinal 
permeability induced by partial restraint stress in rats, and restored occludin and JAM-A 
expression (Agostini, Goubern et al. 2012). In addition, calcium, which is rich in yogurt, plays a 
critical role in tight junction biogenesis and supplementation of calcium was shown to be able to 
inhibit alteration in tight junction function in a diabetic rat model (Stuart, Sun et al. 1994, Leal, 
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Martins et al. 2010). Therefore, these rodent studies suggest that dairy calcium or probiotic 
yogurt could be beneficial for maintaining function of tight junctions. 
2.6 Other Potential Benefits of Yogurt Consumption on Gut Health 
Increased yogurt consumption has the potential to improve intestinal health, ameliorate 
lactose intolerance, prevent constipation and diarrheal diseases, decrease allergies in vulnerable 
populations, and reduce the risks of colon cancer and inflammatory bowel diseases (Adolfsson, 
Meydani et al. 2004, Parvez, Malik et al. 2006). The mechanisms for these actions are not fully 
described, but may include modulating gut pH, inhibiting the proliferation and adhesion of 
pathogenic bacteria, secreting antibacterial substances, and regulating immune function. 
2.6.1 Lactose intolerance 
In lactase-deficient individuals, lactose enters the colon and is fermented by colonic 
bacteria. The colonic metabolites of lactose include short-chain fatty acids which, together with 
electrolytes, introduce an osmotic load that can cause diarrhea and discomfort (Lomer, Parkes et 
al. 2008). In a cross-sectional study, subjects with self-perceived lactose intolerance had a 
significantly lower calcium intake from dairy foods and reported higher rate of physician-
diagnosed diabetes and hypertension (Nicklas, Qu et al. 2011). Early studies indicated that 
subjects with lactase deficiency had better digestion and absorption of lactose from yogurt than 
the lactose in milk (Kolars, Levitt et al. 1984). After ingestion of around 18 g of lactose in water, 
milk, or yogurt, subjects receiving yogurt had only one third of the hydrogen excretion, an 
indicator of undigested lactose, compared with those receiving lactose in water or milk (Kolars, 
Levitt et al. 1984).  Furthermore, the consumption of yogurt led to fewer symptoms of diarrhea 
and flatulence relative to milk (Kolars, Levitt et al. 1984). 
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2.6.2 Diarrhea 
Diarrhea is the leading cause of morbidity and death of children in developing countries 
(Boschi-Pinto, Velebit et al. 2008). Emerging evidence suggests that consumption of yogurt and 
its related probiotic cultures prevent or treat diarrhea. In a double-blind, placebo-controlled trial, 
infants that received formula with B. bifidum and S. thermophilus reduced the incidence of acute 
diarrhea and rotavirus shedding (Saavedra, Bauman et al. 1994). A meta-analysis of RCTs 
published from 1966 to 2000 suggested that Lactobacillus supplementation (108 to 1011 CFU 
daily) safely reduced the frequency and duration of acute infectious diarrhea in children (Van 
Niel, Feudtner et al. 2002). Moreover, a more recent meta-analysis of RCTs showed that 
administration of Lactobacillus through capsules or fermented milk during antibiotic treatment 
significantly reduced the risk of developing antibiotic-associated diarrhea (RR 0.35, 0.19-0.67 95% 
CI) (Kale-Pradhan, Jassal et al. 2010). However, the risk reduction was only significant in adults 
after subgroup analysis (Kale-Pradhan, Jassal et al. 2010).   
2.6.3 H. pylori infection 
Consumption of yogurt with L. gasseri for 8 wk significantly suppressed H. pylori-
induced gastric mucosal inflammation in the elderly (Sakamoto, Igarashi et al. 2001). In children 
affected by H. pylori, yogurt consumption decreased serum IL-6 level after 4 wk (Yang and Sheu 
2012). 
2.6.4 Inhibition of Colitis 
The prevalence of the inflammatory bowel diseases (IBD) Crohn’s disease (CD) and 
ulcerative colitis (UC) is increasing in industrialized nations, and although the cause(s) are 
unknown, they likely result from an aberrant immune response to intestinal microbiota (Chaves, 
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Perdigon et al. 2011). Probiotics administered to murine models of IBD improve disease 
outcomes; this has been reviewed elsewhere (Claes, De Keersmaecker et al. 2011). Yogurt 
consumption also inhibits experimental IBD in mice. Consumption of yogurt with eight L. 
bulgaricus strains and two S. thermophilus strains decreased mortality rate and prevented 
intestinal inflammation and tissue damage in mice with trinitrobenzene sulfonic acid (TNBS)-
induced intestinal inflammation (Chaves, Perdigon et al. 2011). Yogurt consumption prevented 
an increase in colonic CD4+ and CD8+ T cell numbers, decreased TLR4 positive cells at 14 days, 
but not 3 or 7 days post TNBS administration (Chaves, Perdigon et al. 2011).  Yogurt without 
added probiotic strains inhibited TNBS-induced colitis in mice, increased the number of IgA 
producing cells, and decreased CD8+ T cells two wk after TNBS administration (Gobbato, 
Rachid et al. 2008). 
Clinical studies have mixed outcomes for the probiotic treatment of IBD and are strain-
dependent (Kato, Mizuno et al. 2004, Hedin, Whelan et al. 2007, Lorea Baroja, Kirjavainen et al. 
2007, Miele, Pascarella et al. 2009, Sood, Midha et al. 2009, Jonkers, Penders et al. 2012). 
Clinical studies have not used conventional yogurt as an intervention for IBD, despite self-
reported benefits of yogurt reported by IBD patients (Cohen, Lee et al. 2013). Consumption of 
yogurt with L rhamnosus GR-1 and L. reuteri RC-14 improved markers of inflammation in 
monocytes from 20 patients with IBD, including increasing CD4+CD25 high T cells (Lorea Baroja, 
Kirjavainen et al. 2007). Yogurt could be an effective delivery vehicle for probiotic strains for 
treatment of IBD. However, more work is needed to identify clinically-significant probiotic 
strains for inhibiting colonic inflammation.  
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2.6.5 Appetite control 
Obesity is a result of positive energy balance. Some studies have demonstrated that 
yogurt might help reduce energy intake by suppressing appetite. For example, consumption of 
yogurt either in semisolid or liquid form led to lower hunger and higher fullness feeling, 
compared with a fruit drink or dairy fruit drink (Tsuchiya, Almiron-Roig et al. 2006). Similarly, 
subjects felt higher satiety after consumption of yogurt as evidenced by rating of hunger, appetite, 
desire to eat, and fullness, compared with ingestion of chocolate bars (Chapelot and Payen 2010). 
Yogurt consumption also suppressed appetite rating and reduced subsequent food intake or 
delayed subsequent eating, compared with isovolumetric water (Dougkas, Minihane et al. 2012, 
Douglas, Ortinau et al. 2013). Therefore, yogurt consumption may provide a further benefit of 
appetite-suppression, although the molecular mechanisms for this effect remain uncharacterized.  
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Chapter 3: Effects of Low-fat Yogurt 
Consumption on Weight, Blood Pressure and 
Dietary Pattern 
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3.1 Abstract 
Background: Increasing dairy consumption may help obese individuals lose weight and lower 
blood pressure. However, the effect of increased yogurt consumption on weight, blood pressure, 
and diet quality without weight reduction is poorly understood.  
Objective: Our objective was to determine how increased low-fat yogurt consumption affects 
body weight, body mass index (BMI), waist circumference (WC), blood pressure (BP), and diet 
in obese and non-obese women maintaining normal dietary patterns.  
Design: Apparently healthy premenopausal women with BMI of 18.5 to 27 (lean) or 30 to 40 
kg/m2 (obese) participated in a 9-week randomized, controlled intervention study. Participants in 
each BMI range were randomly assigned to either a low-fat yogurt-supplemented group (Y, 
yogurt lean; YO, yogurt obese) or a soy pudding-supplemented control group (C, control lean; 
CO, control obese), with n = 30/group. Participants were advised to consume 12 oz. of yogurt or 
the control food daily for 9 weeks while maintaining their usual caloric intake. Weight, WC, and 
BP of participants were determined at wk 0, 3, 6 and 9, and 3-day food records were completed 
at baseline and the end of intervention.  
Results: All groups maintained isocaloric intake with addition of the intervention foods, based 
on dietary records. Y and C maintained initial weights, but YO and CO had increased body 
weight by wk 9 (YO: 0.91 ± 0.31 kg, P = 0.0023; CO: 0.94 ± 0.42 kg, P = 0.0215). In YO, 
diastolic BP was lowest at wk 3 (-2.82 ± 0.90 mm Hg, P = 0.0062) with a reduced effect at wk 6 
(-2.1 ± 0.83 mm Hg, P = 0.1078) and wk 9 (-1.90 ± 0.95 mm Hg, P = 0.1833) relative to baseline. 
In contrast, C and Y did not have consistent BP changes. Calcium intake increased 69% in Y and 
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57% in YO, and was higher than that in the control groups. Sugar and added sugar consumption 
increased by 48 - 317% in all groups by the end of the intervention. 
Conclusion: Consumption of low-fat yogurt lowered blood pressure in obese premenopausal 
women within 3 weeks, but this effect decreased by wk 9, and coincided with ~ 0.9 kg increased 
body mass. Yogurt consumption induced a slight decrease in waist circumference but had no 
effect on blood pressure in lean premenopausal women. This trial was registered at 
clinicaltrials.gov as NCT01686204. 
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3.2 Introduction  
Obesity is associated with increased risk of cardiovascular disease, type 2 diabetes, and 
certain cancers (Kastarinen, Nissinen et al. 2000, Grundy 2007, Hossain, Kawar et al. 2007). 
Hypertension is also linked to increased obesity, as more than 85% of hypertensive individuals 
have a BMI > 25 kg/m2 (Kastarinen, Nissinen et al. 2000). Obesity decreases quality of life, life 
expectancy, and its prevalence causes a sizable economic burden (Peeters, Barendregt et al. 2003, 
Wang, McPherson et al. 2011, Warkentin, Das et al. 2014). Dietary and lifestyle changes that 
lead to weight loss are necessary approaches to reduce obesity-associated chronic disease risk. 
 Epidemiological studies and meta-analyses suggest that increased dairy consumption 
might benefit obese individuals by increasing weight loss and reducing blood pressure 
(Mozaffarian, Hao et al. 2011, Ralston, Lee et al. 2012, Soedamah-Muthu, Verberne et al. 2012). 
Furthermore, yogurt consumption is associated with lower BMI (28.0 ± 5.4 kg/m2 in yogurt non-
consumer vs. 26.9 ± 5.5 kg/m2 in yogurt consumer, P < 0.001), and better diet quality and 
metabolic profile in US adults (Wang, Livingston et al. 2013).  
 Intervention studies also suggest that yogurt consumption aids weight loss while 
maintaining lean tissue and reducing diastolic BP in overweight and obese individuals when 
consumed with energy-restricted diets (Zemel, Richards et al. 2005, Thomas, Wideman et al. 
2011). The design of these studies did not isolate the effect of weight loss and yogurt 
consumption on metabolic effects. Without energy restriction, intervention studies with dairy or 
fermented dairy consumption for BP reduction are equivocal (Maki, Rains et al. 2013, Drouin-
Chartier, Gigleux et al. 2014, Hove, Brøns et al. 2015). 
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These prior intervention studies did not utilize conventional yogurt directly in a healthy, 
obese population, or include a non-obese control population. Therefore, we characterized the 
effect of yogurt consumption on body weight, WC, and BP as part of a larger randomized control 
trial investigating the anti-inflammatory mechanisms of yogurt consumption. To account for 
other potential dietary changes given the intervention, we further examined the nutrient intakes 
and diet composition of study participants.  
3.3 Materials and Methods 
3.3.1 Study participants 
The study protocol was approved by the Institutional Review Boards at the University of 
Connecticut (#H12-168) and University of Wisconsin-Madison (#2014-0669) and participants 
were provided written consent before participating in study procedures. The study was also 
registered at ClinicalTrials.gov as NCT01686204. 
Apparently healthy premenopausal women aged 21 to 55 years were recruited from the 
Storrs, CT and Madison, WI area by mass emails, flyers, announcement in newspapers. After 
consent, participants completed a questionnaire that included demographic health information. 
Study personnel then measured participants’ height, weight, WC and BP. The study inclusion 
criteria included BMI from 18.5 to 27 or from 30 to 40 kg/m2,  an age of 21 to 55 years, stable 
body weight for the previous 2 months, willing to avoid yogurt and probiotic-containing foods 
and consume the provided 1.5 servings of yogurt or soy pudding (control treatment) for the 
duration of the study, no previous diagnosis of CVD, diabetes or arthritis, not being currently 
treated for cancer, not taking any anti-inflammatory drugs, not under prescribed estrogen 
replacement therapy, not on sliming, vegetarian or vegan diets, not currently taking dietary 
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supplements or smoking, not allergic to soy, egg or milk, not pregnant, lactating, or seeking to 
become pregnant. 
3.3.2 Dietary treatment 
Commercially available low-fat yogurts (Yoplait, General Mills, Inc. Minneapolis, MN) 
and soy puddings (ZenSoy, South Hackensack, NJ) packaged in 4 oz. containers were purchased 
from local suppliers. The soy pudding served as a non-dairy control food with macronutrient and 
micronutrient content, total calories and texture matched to yogurt. The yogurt had strawberry, 
strawberry banana, raspberry, and peach flavors, which was representative of most commercial 
low-fat yogurt. The detailed nutrient content of yogurt and control are listed in Table 3.1. Soy 
pudding contained 2.00 ± 0.09 mg/100g of daidzein, 1.64 ± 0.01 mg/100g of glycitein, and 5.34 
± 0.16 mg/100g of genistein (Appendix A.1.1). Therefore, 12 oz. soy pudding provided a small 
amount of isoflavones that were equivalent to that in ~ 5.0 g of soy bean (Franke, Custer et al. 
1994). In addition, 12 oz. soy pudding provided much less than the 25 g of soy protein estimated 
to lower coronary heart disease risk (FDA 21 CFR 101.82). Further, 4 wk consumption of 10 
g/day of soy protein, delivered as a soy-based smoothie, did not alter biomarkers of oxidative 
stress or inflammation in obese and overweight subjects (Zemel, Sun et al. 2010). 
3.3.3 Experimental design 
A randomized, controlled study was performed to test the impact of yogurt consumption 
on intestinal barrier function and chronic inflammation relative to consumption of a non-dairy 
control food. The sample size calculation was based on detecting an 8.2% difference in soluble 
CD14 (sCD14), the primary outcome (Laugerette, Vors et al. 2011). Measurement of weight, BP, 
and nutrient intake were nested in the study protocol as depicted in Figure 3.1.  
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Table 3.1 Nutrient comparison of low-fat yogurts and the soy pudding control food. 
Nutrients/serving Low-fat yogurts (Yoplait) 1 Control food (ZenSoy) 
Serving size (oz.) 4 3.8 
Calories (kcal) 110 110 
Total Fat (g) 1 1 
Carbohydrate (g) 22 22 
Protein (g) 3 2-3 2 
Cholesterol (mg) 5 0 
Sodium (mg) 60 55-70 3 
Calcium (mg) 150 60-150 3 
Vitamin A (IU) 500 200 
Vitamin D (μg) 2.25 2.25 
1 Contained the active cultures L. Bulgaricus, S. Thermophilus, and L. acidophilus. 
2 Different flavors of pudding contained either 2 or 3 g of protein per cup. 
3 Due to the reformulation by the manufacture during the intervention, the sodium content decreased from 
70 to 66 mg per cup; the calcium decreased from 150 to 60 mg per cup (n = 24, on the old formulation; n 
= 36, on the new formulation). 
To avoid confounding by probiotic or dairy consumption, the participants restricted 
consumption of dietary supplements, fermented foods and limited their dairy consumption to ≤ 4 
servings/day for 2 weeks before the intervention (washout period, wk -2 to wk 0) and throughout 
the intervention. From the beginning of wk 0 to the end of wk 9 (intervention period), the 
subjects consumed 12 oz. of yogurt or the control food daily. The lids of consumed yogurt and 
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pudding cups were collected weekly for assessment of compliance. Participants visited the study 
center at wk 0, 3, 6 and 9 for anthropometric and BP measurements. 
After the initial consent and screening visit, 128 subjects were enrolled and randomly 
assigned to either the yogurt group or the soy pudding control group, in blocks of 6 (Figure 3.2). 
Participants were randomized upon enrollment by assigning random numbers generated by 
Minitab 17.0 (Minitab Inc., State College, PA) (Campbell and Swinscow 2009). After enrollment, 
8 subjects were excluded or dropped from the study because of the following reasons: not able to 
obtain blood samples (n = 1), not able to eat pudding (n = 2), not compliant (n = 1), prescribed 
anti-inflammatory drug (n = 1), family emergency (n = 1), not specified (n = 2). At the end of the 
study, 60 obese (BMI 30-40 kg/m2) and 60 lean (BMI 18.5-27 kg/m2) participants completed the 
study, with n = 30/group (YO, yogurt obese; CO, control obese; Y, yogurt lean; C, control lean).  
3.3.4 Anthropometric measurements 
Participants were asked to remove shoes, jacket, phones, keys, or other extraneous mass 
before measurements. Body weight and height were measured on a digital physician scale (Rice 
Lake H150-10-5, Rice Lake, WI). WC was determined by placing a measuring tape evenly 
around a bare abdomen at hip bone level. BP was measured using an Omron HEM-780 with 
ComFit cuff for participants in Y and C, or an Omron BP710 with Omron H003D large adult 
cuff for YO and CO (Omron Healthcare, Inc. Lake Forest, IL). Before BP readings, participants 
were instructed to sit upright in a phlebotomy chair for a minimum of 5 min with their back 
supported, feet on the floor, legs uncrossed, bladder empty, and their upper arm supported at 
heart level (Pickering, Hall et al. 2005). BP was measured twice, at least 3 min apart. If BP 
readings were more than 5 mm Hg apart, a third reading was taken. 
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Figure 3.1 Experimental design.  
After 2 weeks of washout, lean and obese participants were randomly assigned to either yogurt or the control food for 9 weeks. Starting from 
baseline (wk 0), subjects came to the study center to have their height, weight, waist circumference, blood pressure measured. The week before the 
start and end of intervention, participants completed a 3-day food record. 
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Figure 3.2 Enrollment and follow-up of participants.
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3.3.5 Dietary analysis 
Participants were instructed to maintain their usually dietary pattern and caloric intake, 
accounting for the additional ~ 300 calories provided by the intervention foods. Dietary records 
were used to examine if the intervention changed participants’ nutrients intakes or dietary 
patterns and to determine their compliance to the requested dietary restrictions. Participants were 
instructed to complete two separate 3-day food records on two nonconsecutive weekdays and 
one weekend day during the washout period and near the end of the intervention. Participants 
were given detailed instructions on how to complete the record by study staff. The food records 
were reviewed by study staff upon submission and any incomplete or inaccurate information was 
corrected with participant input. The self-reported dietary intakes were analyzed by 2013 
Nutrition Data System for Research (NDSR) (NCC, Minneapolis, MN). Because the NDSR did 
not include the exactly matched food item for yogurt and soy pudding, a similar alternative was 
used with nutrients corrected according to the nutrition facts label. The detailed NDSR nutrient 
content of the alternative is listed at Appendix A.1.2. The NDSR program output daily nutrient 
intakes and food group servings. 
3.3.6 Statistical analysis 
All data are expressed as mean ± standard error unless otherwise indicated. Statistical 
analysis was conducted on SAS 9.4 software (Cary, NC). The significance level was set at α = 
0.05 for all tests. At baseline, the difference of Y vs. C, and YO vs. CO were analyzed by 
independent T-test for numerical variables and Chi-square test for categorical variables, 
respectively. The effects of treatment (yogurt vs. control), time (wk 0, 3, 6 and 9) and treatment 
× time on weight, BMI and BP in the obese and lean groups were determined by repeated-
measures ANOVA. The means of baseline and intervention dietary intakes within each group 
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were assessed by paired T-test. The significance of differences between group means was 
determined by analysis of covariance (ANCOVA) with baseline values as the covariate. 
3.4 Results 
Participants complied with consuming the study intervention foods. The compliance rates 
of returned cup lids were > 95% for all groups (data not shown). However, it should be noted 
that two participants could not comply with the control snack consumption, and dropped from 
the study. In addition, all participants reported adhering to the study dietary restrictions on food 
records. 
3.4.1 Baseline characteristics of the study population 
The baseline characteristics of lean and obese participants differed (Table 3.2). The mean 
age of obese participants was nearly 9 years older than the lean participants at 34.3 ± 1.3 and 
25.1 ± 0.7 years, respectively (P < 0.0001). Compared to lean participants, obese participants had 
49% greater weight, 51% higher BMI, and 33% greater WC. Systolic and diastolic BP were 12% 
and 10% higher in the obese than lean group, but the mean obese BP was less than 
prehypertension. Within each BMI group, the yogurt and control groups had no differences in 
weight, BMI, or BP.  However, the WC of Y was 4.2 cm more than that of C (P = 0.0424). 
Participant demographics were also different between lean and obese groups (Table 3.3). 
Obese participants were married at a greater rate than lean (22/60 vs. 11/60, P = 0.0053) and less 
likely to be at the lower income category (30/60 vs. 10/60 in the under $20,000 category, P = 
0.0001) than the lean individuals. In addition, more obese participants reported more frequently 
reported non-disqualifying medical conditions than the lean (23/60 vs. 9/60, P = 0.0039). 
Although YO had more participants in the highest income category than the CO group (P = 
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0.0457), no differences in ethnicity, education, supplement use, smoking status, or medication 
use were found between yogurt and control treatment groups within each BMI group. 
3.4.2 Changes in body weight, BMI and WC during dietary intervention 
In Y and C, treatment, time or treatment × time did not affect weight, BMI or WC (Table 
3.4). However, Y had a slight but statistically significant decrease in WC of -0.77 ± 0.33 cm at 
wk 6 (P = 0.0226) that was not maintained at wk 9 (-0.70 ± 0.32 cm, P =0.0647). In contrast to Y 
and C, both YO and CO gained BMI and body weight by wk 9, increasing 0.91 ± 0.31 kg (P = 
0.0023) and 0.94 ± 0.42 kg (P = 0.0215) respectively. Despite weight gain, YO and CO WC did 
not increase significantly. 
3.4.3 Changes in participants’ BP during dietary intervention 
Y and C BP were not significantly affected by treatment, time or treatment × time (Table 
3.5). Within YO and CO, yogurt consumption significantly reduced the diastolic BP (P = 0.0023) 
and tended to lower the systolic BP (P = 0.0910) in YO, in comparison with CO. Within YO, 
diastolic BP decreased 2.82 ± 0.90 mm Hg at wk 3 (P = 0.0062). At wk 6, YO diastolic BP also 
decreased 2.10 ± 0.83 mm Hg from baseline, although this change did not achieve statistical 
significance (P = 0.1078). In addition, the changes in diastolic and systolic BP in YO were 
correlated (r = 0.6828, P < 0.001 at wk 3; r = 0.7452, P < 0.001 at wk 6; r = 0.6534, P = 0.001 at 
wk 9). 
3.4.4 Baseline diet composition and nutrient intake in study participants 
Prior to the intervention, the obese participants consumed 13% more total energy, 18% 
more total fat, 12% more total carbohydrate, 9% more total protein, 21% more total saturated 
fatty acids (SFA), 13% more sodium, 17% more sugar, and 41% more added sugar than the lean 
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participants (Table 3.6). YO had 18% greater intake of riboflavin than CO. No differences in 
other nutrients between the yogurt and control treatment groups within each BMI group achieved 
statistical significance. 
3.4.5 Changes in diet and nutrient intake near the end of intervention 
The average percentage of calories from fat decreased 7% - 15% from baseline among all 
groups, while the percentage of calories from carbohydrate increased 9% - 18% in C, CO, and 
YO (Table 3.7). Y also had 6.1 ± 3.1% increased percentage of calories from carbohydrate, 
although this change did not achieve statistical significance (P = 0.0916). The intakes of vitamin 
D, riboflavin, and pantothenic acid also increased 182% - 279%, 22% - 45%, and 22% - 36%, 
respectively in all groups. The calcium intake increased 21% - 69% in C, Y, and YO. CO also 
had 13.4 ± 8.3% calcium increase, but this was statistically insignificant (P = 0.2736). In all 
groups, total sugar intake increased 48% - 86% and added sugar intakes increased 102% - 317%. 
Within Y and C, Y had 16% higher intake of calcium but 22% lower intake of iron than C, when 
adjusting for baseline. Relative to CO nutrient intake YO had 37% more vitamin A, 94% more 
vitamin K, 24% more calcium, and 16% more potassium. 
3.4.6 Food group consumption at baseline 
Obese and lean participants had similar proportional food group consumption. At 
baseline, YO and CO consumed 32% more servings of dietary fat and 22% more beverages than 
Y and C (Table 3.8). The proportional food group consumption between yogurt and control 
treatment groups within each BMI group did not differ. 
 76 
 
3.4.7 Changes in food group consumption near the end of intervention 
Each group substituted the yogurt and control food into their diets differently (Table 3.9). 
Y, YO, and CO daily fruit consumption decreased by 0.50 - 0.78 servings/d. Y and C daily 
vegetable consumption decreased by 0.73 and 1.05 servings, respectively. YO and CO 
consumption of meat, eggs and nuts decreased by 1.20 - 1.56 servings/d, respectively. Y and YO 
had increased daily dairy consumption (1.15 - 1.33 servings) but decreased daily sweet 
consumption (0.38 - 0.79 servings). Daily dairy serving were < 4 in all groups, indicating 
compliance with the study’s dietary restrictions. 
After adjusting for baseline, Y consumed 1.22 servings of dairy products more than C 
daily. YO consumed more vegetable (+ 0.74 servings/day) and dairy (+ 1.45 servings/day) than 
CO. 
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Table 3.2 Baseline anthropometric and blood pressure values of enrolled participants (mean ± standard error, n = 30/group). 
Characteristic (unit) 
Group Significance (P) 1 
C CO  Y YO C vs. Y CO vs. YO 
Obese vs. 
Lean 
Age (year) 25.3 ± 1.1 31.9 ± 1.6 24.8 ± 0.8 36.7 ± 2.0 0.7603 0.0606 <.0001 
Height (m) 1.66 ± 0.01 1.65 ± 0.01 1.67 ± 0.01 1.65 ± 0.01 0.7534 0.6489 0.2883 
Weight (kg) 62.0 ± 1.5 93.4 ± 2.2 64.3 ± 1.5 94.2 ± 1.8 0.3020 0.7894 <.0001 
BMI (kg/m2) 22.4 ± 0.4 34.4 ± 0.5 23.1 ± 0.4 34.4 ± 0.6 0.2546 0.9476 <.0001 
Waist circumference (cm) 69.5 ± 1.4 96.3 ± 1.6 73.7 ± 1.4 94.6 ± 1.4 0.0424 0.4206 <.0001 
Systolic blood pressure (mm Hg) 105.5 ± 2.1 116.9 ± 2.2 103.5 ± 2.0 116.8 ± 2.1 0.4985 0.9609 <.0001 
Diastolic blood pressure  (mm Hg) 73.3 ± 1.7 79.0 ± 1.5 71.3 ± 1.5 79.3 ± 1.3 0.3843 0.8918 <.0001 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; BMI, body mass index. 
1 Differences between yogurt and control treatment groups in non-obese [P (C vs. Y)] and obese individuals [P (CO vs. YO)], and the differences 
between obese and non-obese subjects [P (Obese vs. Lean)] were determined by independent T-test (PROC TTEST).  
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Table 3.3 Baseline demographics of study participants (n = 30/group). 
Characteristic (unit) 
  Group Significance (P)1 
  C CO Y YO C vs. Y 
CO vs. 
YO 
Obese vs. 
Lean 
Ethnicity [n(%)]  
Caucasian 22 (18.3) 24 (20.0) 23 (19.2) 26 (21.7) 
0.7656 0.4884 0.2611 
Others2 8 (6.7) 6 (5.0) 7 (5.8) 4 (3.3) 
Marital status [n(%)]  
Married 6 (5.0) 11 (9.2) 5 (427) 11 (9.2) 
0.7386 0.9162 0.0053 Single 24 (20.0) 16 (13.3) 25 (20.8) 15 (12.5) 
Others3 0 (0.0) 3 (2.5) 0 (0.0) 4 (3.3) 
Annual Income [n(%)]  
under $20000 12 (10.0) 8 (6.67) 18 (15.0) 2 (1.7) 
0.2886 0.0457 0.0001 $20000-$65000 10 (8.3) 18 (15.0) 6 (5.0) 18 (15.0) 
$65000+ 8 (6.7) 4 (3.3) 6 (5.0) 10 (8.3) 
Education [n(%)]  
Undergraduate 10 (8.3) 12 (10.0) 12 (10.0) 14 (11.7) 
0.5464 0.4986 0.0761 Graduate 19 (15.8) 16 (13.3) 18 (15.0) 12 (10.0) 
Others4 1 (0.8) 2 (1.7) 0 (0.0) 4 (3.3) 
Supplement use [n(%)]  
Never used 23 (19.2) 23 (19.2) 19 (15.8) 18 (15.0) 
0.2598 0.1652 0.8433 
Will stop 7 (5.8) 7 (5.8) 11 (9.2) 12 (10.0) 
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Smoking status [n(%)]  
Never smoked 29 (24.7) 26 (21.7) 27 (22.5) 27 (22.5) 
0.3006 0.6876 0.3426 
Already quit 1 (0.8) 4 (3.3) 3 (2.5) 3 (2.5) 
Medication [n(%)]  
None 16 (13.3) 13 (10.8) 14 (11.7) 14 (11.7) 
0.6056 0.7952 0.5834 
Yes5 14 (11.7) 17 (14.2) 16 (13.3) 16 (13.3) 
Medical condition [n(%)]  
None 25 (20.8) 16 (13.3) 26 (21.7) 21 (17.5) 
0.7177 0.1843 0.0039 
Yes5 5 (4.2) 14 (11.7) 4 (3.3) 9 (7.5) 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
1 Differences between yogurt and control treatment groups in non-obese [P (C vs. Y)] and obese individuals [P (CO vs. YO)], and the differences 
between obese and lean subjects [P (Obese vs. Lean)] were determined by Chi-square test (PROC FREQ). 
2 Others included African American (n = 5), Asian (n = 9), Hispanic (n = 3), mixed (n = 8). 
3 Others included divorced (n = 4), engaged (n = 2), domestic partner (n = 1). 
4 Others included high school (n = 1), attended college (n = 5), some grad work (n = 1). 
5 Not include any inflammatory medication or medical condition. 
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Table 3.4 Changes from baseline in body weight, BMI and waist circumference (WC) of participants during the 9-wk consumption of 
12 oz. yogurt or control snack (mean ± standard error, n = 30/group). 
    
Group 
Time (wk) Significance (P)1 
0 3 6 9 Treatment Time 
Treatment × 
Time 
Lean 
(n=60) 
Δ Weight (kg) 
C 0 ± 0 -0.07 ± 0.22 0.19 ± 0.22 0.05 ± 0.26 
0.6323 0.4862 0.1400 
Y 0 ± 0 -0.17 ± 0.16 -0.29 ± 0.29 0.22 ± 0.29 
Δ BMI (kg/m2) 
C 0 ± 0 0.00 ± 0.08 0.10 ± 0.09 0.02 ± 0.10 
0.8400 0.9365 0.7614 
Y 0 ± 0 -0.07 ± 0.06 -0.04 ± 0.09 0.08 ± 0.11 
Δ WC (cm) 
C 0 ± 0 0.08 ± 0.31 -0.06 ± 0.30 -0.22 ± 0.33 
0.2088 0.0679 0.3173 
Y 0 ± 0 -0.12 ± 0.13 -0.77 ± 0.33 * -0.70 ± 0.32 
Obese 
(n=60) 
Δ Weight (kg) 
CO 0 ± 0 0.37 ± 0.22 0.55 ± 0.32 0.94 ± 0.42 * 
0.8240 0.0015 0.8504 
YO 0 ± 0 0.37 ± 0.21 0.51 ± 0.24 0.91 ± 0.31 * 
Δ BMI (kg/m2) 
CO 0 ± 0 0.14 ± 0.08 0.30 ± 0.13 0.37 ± 0.16 * 
0.7451 0.0008 0.8054 
YO 0 ± 0 0.15 ± 0.08 0.19 ± 0.09 0.33 ± 0.11 * 
Δ WC (cm) 
CO 0 ± 0 -0.32 ± 0.20 -0.22 ± 0.17 -0.55 ± 0.27 
0.4029 0.2816 0.7815 
YO 0 ± 0 0.03 ± 0.16 -0.03 ± 0.36 -0.27 ± 0.43 
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Abbreviations: C, control & lean; CO, control & obese; Y, yogurt & lean; YO, yogurt & obese; BMI, body mass index; WC, waist circumference. 
* Changes in each group were determined by repeated-measure ANOVA (PROC MIXED) with time as independent variable. 
1 The effects of treatment, time and treatment × time were determined by repeated-measure ANOVA (PROC MIXED).  
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Table 3.5 Change from baseline in blood pressure of participants during 9-wk consumption of 12 oz. yogurt or control snack (mean ± 
standard error, n = 30/group). 
  
  
Group 
Time (wk) Significance (P)1 
0 3 6 9 Treatment Time 
Treatment × 
Time 
Lean 
(n=60) 
Δ SysBP (mm Hg) 
C 0 ± 0 0.23 ± 1.48 -1.73 ± 1.04 0.33 ± 1.57 
0.7011 0.4607 0.2104 Y 0 ± 0 0.13 ± 1.29 -0.72 ± 1.46 -2.45 ± 1.64 
Δ DiaBP (mm Hg) 
C 0 ± 0 1.57 ± 1.22 -1.48 ± 1.05 0.15 ± 1.14 
0.8907 0.3449 0.0574 Y 0 ± 0 0.02 ± 0.77 0.50 ± 1.09 -0.75 ± 1.11 
Obese 
(n=60) 
Δ SysBP (mm Hg) 
CO 0 ± 0 2.57 ± 1.22 1.71 ± 1.39 1.12 ± 1.70 
0.0910 0.9057 0.2816 YO 0 ± 0 -1.13 ± 1.48 -0.68 ± 1.29 -0.25 ± 1.17 
Δ DiaBP (mm Hg) 
CO 0 ± 0 0.78 ± 0.91 1.02 ± 0.91 0.77 ± 1.22 
0.0023 0.5319 0.0710 YO 0 ± 0 -2.82 ± 0.90 * -2.1 ± 0.83 -1.90 ± 0.95 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; SysBP, systolic blood pressure; DiaBP, diastolic blood 
pressure. 
* Changes in each group were determined by repeated-measure ANOVA (PROC MIXED) with time as independent variable. 
1 The effects of treatment, time and treatment × time were determined by repeated-measure ANOVA (PROC MIXED).   
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Table 3.6 Self-reported dietary intakes at the start of intervention, determined by 3-day food record (mean ± standard error). 
Intakes (unit) 
Group Significance (P)1 
C (n = 29) CO (n = 30) Y (n = 30) YO (n = 30) C vs. Y 
CO vs. 
YO 
Obese 
vs. Lean 
Energy (kcal) 1657 ± 54 1869 ± 61 1666 ± 60 1893 ± 69 0.9996 0.9921 0.0004 
Total Fat (g) 67.4 ± 3.1 75.2 ± 3.6 62.8 ± 3.7 77.5 ± 3.8 0.7935 0.9684 0.0016 
Total Carbohydrate (g) 197.1 ± 7.8 226.4 ± 8.4 205.7 ± 6.4 223.7 ± 9.6 0.8781 0.9954 0.0039 
Total Protein (g) 71 ± 2.8 78 ± 3.5 72.8 ± 3.4 78.6 ± 3.1 0.9797 0.9992 0.0457 
% Calories from Fat 35.7 ± 1.1 34.8 ± 1.0 31.8 ± 0.9 35.4 ± 1.0 0.0328 0.9757 0.1732 
% Calories from 
Carbohydrate 46.0 ± 1.2 48.0 ± 1.1 49.8 ± 1.1 46.0 ± 1.1 0.0874 0.5950 0.3977 
% Calories from Protein 17.3 ± 0.7 16.7 ± 0.5 17.7 ± 0.7 17.3 ± 0.6 0.9779 0.9157 0.4048 
Cholesterol (mg) 268 ± 23 249 ± 22 258 ± 21 332 ± 25 0.9895 0.0481 0.2288 
SFA (g) 22.5 ± 1.2 25.4 ± 1.7 20.9 ± 1.5 27.2 ± 1.4 0.8588 0.8289 0.0019 
Dietary Fiber (g) 22.0 ± 1.1 19.6 ± 1.1 19.3 ± 0.9 21.1 ± 1.3 0.3406 0.7767 0.8264 
Vitamin A (IU) 11955 ± 1442 8545 ± 1974 10573 ± 1306 8373 ± 955 0.9107 0.9998 0.0570 
Vitamin D  (μg) 5.4 ± 0.6 4.5 ± 0.5 4.2 ± 0.5 4.4 ± 0.4 0.3036 0.9992 0.4747 
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Vitamin E (mg AT2) 11 ± 0.8 12.4 ± 1.1 9.8 ± 0.7 9.4 ± 0.5 0.7202 0.0457 0.5390 
Vitamin K 211.7 ± 27.4 165.5 ± 32 182.7 ± 30.2 151 ± 21.4 0.8861 0.9830 0.1672 
Vitamin C  (mg) 93.6 ± 9.0 88.7 ± 7.8 99.6 ± 7.2 76.2 ± 8.8 0.9550 0.6995 0.0839 
Thiamin  (mg) 1.6 ± 0.1 1.6 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 0.8362 0.9946 0.4096 
Riboflavin (mg) 1.8 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 2.0 ± 0.1 0.9948 0.0467 0.4668 
Niacin  (mg) 21.5 ± 0.9 23.2 ± 1.3 22.8 ± 1.2 21.9 ± 1.1 0.8473 0.8511 0.7199 
Pantothenic Acid (mg) 4.9 ± 0.2 4.9 ± 0.3 4.7 ± 0.2 5.0 ± 0.2 0.9563 0.9998 0.4057 
Vitamin B-6 (mg) 1.9 ± 0.1 1.8 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 0.9963 0.6839 0.0803 
Total Folate (μg) 434 ± 24 369 ± 20 397 ± 16 404 ± 22 0.5804 0.6192 0.1555 
Vitamin B-12 (μg) 4.0 ± 0.3 3.6 ± 0.3 3.8 ± 0.4 4.4 ± 0.5 0.9630 0.4781 0.7447 
Calcium (mg) 819 ± 36 811 ± 45 713 ± 35 835 ± 47 0.2999 0.9764 0.1423 
Phosphorus (mg) 1119 ± 37 1130 ± 44 1072 ± 40 1218 ± 50 0.8665 0.4616 0.0660 
Sodium (mg) 2751 ± 135 3350 ± 185 2989 ± 187 3116 ± 175 0.7647 0.7707 0.0366 
Potassium (mg) 2492 ± 101 2476 ± 140 2433 ± 85 2473 ± 107 0.9817 1.0000 0.9102 
Magnesium (mg) 290 ± 11 279 ± 13 283 ± 11 293 ± 14 0.9732 0.8572 0.9573 
Iron (mg) 13.9 ± 0.7 14.3 ± 0.7 13.6 ± 0.6 15.3 ± 0.8 0.9920 0.7539 0.1394 
Zinc (mg) 9.1 ± 0.4 9.6 ± 0.5 9.3 ± 0.5 10.1 ± 0.5 0.9930 0.9136 0.1860 
Copper (mg) 1.3 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 0.9982 0.9032 0.9155 
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Selenium (μg) 106.0 ± 5.2 112.1 ± 6.3 104.7 ± 4.9 112.7 ± 5.4 0.9986 0.9998 0.1989 
Manganese (mg) 4.0 ± 0.2 3.4 ± 0.2 4.7 ± 1.1 3.8 ± 0.2 0.8097 0.9754 0.1685 
Alcohol (g) 2.9 ± 0.9 1.4 ± 0.5 2.7 ± 1.3 3.8 ± 1.2 0.9993 0.3794 0.8617 
Total Sugars (g) 71.7 ± 3.7 87.2 ± 4.4 77.7 ± 3.7 87.7 ± 5.0 0.7561 0.9997 0.0029 
Added Sugars (g) 37.2 ± 3.3 54.5 ± 4.1 38.8 ± 3.2 52.8 ± 5.2 0.9919 0.9901 0.0001 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; SFA, total saturated fatty acids. 
1 Differences between yogurt and control treatment groups in non-obese [P (C vs. Y)] and obese individuals [P (CO vs. YO)], and the differences 
between obese and lean subjects [P (Obese vs. Lean)] were determined by independent T-test (PROC TTEST).  
2 alpha-tocopherol. 
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Table 3.7 Self-reported dietary intakes near the end of 9-wk daily consumption of 12 oz. yogurt or control snack (mean ± standard 
error). 
Intakes (unit) 
Group Significance (P)1 
C (n = 29) CO (n = 30) Y (n = 30) YO (n = 30) C vs. Y CO vs. YO 
Energy (kcal) 1733 ± 48 1900 ± 67 1727 ± 60 1962 ± 63 0.9135 0.5634 
Total Fat (g) 58.8 ± 2.7 ↓ 67.6 ± 3.7 59.7 ± 3.5 71.8 ± 3.8 0.5588 0.5067 
Total Carbohydrate (g) 234.2 ± 7.5 ↑ 251.6 ± 9.2 226.7 ± 6.7 255.1 ± 8.1 ↑ 0.3965 0.7003 
Total Protein (g) 70.2 ± 2.5 72.9 ± 3.0 70.9 ± 3.3 76.4 ± 3.0 0.9518 0.4045 
% Calories from Fat 29.3 ± 0.9 ↓ 30.4 ± 0.9 ↓ 28.8 ± 0.9 ↓ 31.3 ± 0.9 ↓ 0.8026 0.5401 
% Calories from Carbohydrate 52.2 ± 1.0 ↑ 51.7 ± 1.1 ↑ 52.3 ± 1.1 50.6 ± 0.9 ↑ 0.6085 0.6162 
% Calories from Protein 18.1 ± 0.6 17.1 ± 0.6 17.8 ± 0.5 17.1 ± 0.5 0.6227 0.9250 
Cholesterol (mg) 223 ± 22 240 ± 23 256 ± 22 255 ± 20 ↓ 0.2640 0.8294 
SFA (g) 20.5 ± 1.1 23.4 ± 1.7 19.7 ± 1.4 24.0 ± 1.3 0.9842 0.9653 
Dietary Fiber (g) 19.1 ± 0.9 19.7 ± 1.0 15.7 ± 0.8 ↓ 20.4 ± 1.4 0.1056 0.9763 
Vitamin A (IU) 8613 ± 968 ↓ 6806 ± 928 8272 ± 825 10841 ± 1367 0.9738 0.0366 
Vitamin D  (μg) 10.9 ± 0.5 ↑ 9.3 ± 0.3 ↑ 9.9 ± 0.4 ↑ 10.1 ± 0.3 ↑ 0.5067 0.1400 
Vitamin E (mg AT2) 8.2 ± 0.6 ↓ 10.3 ± 1.3 8.3 ± 0.6 9.9 ± 0.6 0.7608 0.9085 
  
8
7
 
Vitamin K (μg) 127.2 ± 14.8 ↓ 88.5 ± 10 ↓ 132.2 ± 16.3 171.9 ± 22 0.7737 0.0019 
Vitamin C (mg) 72.8 ± 5.9 75.1 ± 7.3 64.9 ± 6.1 ↓ 75.5 ± 8.3 0.4246 0.7941 
Thiamin (mg) 1.5 ± 0.1 1.6 ± 0.1 1.4 ± 0.1 1.6 ± 0.1 0.4310 0.6851 
Riboflavin (mg) 2.3 ± 0.1 ↑ 2.4 ± 0.1 ↑ 2.1 ± 0.1 ↑ 2.3 ± 0.1 ↑ 0.1087 0.2302 
Niacin (mg) 19.6 ± 0.9 20.5 ± 1.6 18.9 ± 1.0 ↓ 19.3 ± 1.0 0.5099 0.8813 
Pantothenic Acid (mg) 5.7 ± 0.2 ↑ 5.8 ± 0.2 ↑ 5.9 ± 0.3 ↑ 6.2 ± 0.2 ↑ 0.4979 0.3208 
Vitamin B-6 (mg) 1.7 ± 0.1 1.8 ± 0.2 1.6 ± 0.1 ↓  1.6 ± 0.1 0.5198 0.8110 
Total Folate (μg) 380 ± 21 381 ± 23 364 ± 17 437 ± 30 0.8956 0.4583 
Vitamin B-12 (μg) 4.3 ± 0.3 4.5 ± 0.5 4.8 ± 0.4 ↑ 4.6 ± 0.2 0.2023 0.7645 
Calcium (mg) 926 ± 38 ↑ 887 ± 49 1058 ± 38 ↑ 1166 ± 38 ↑ 0.0179 0.0012 
Phosphorus (mg) 1209 ± 37 1207 ± 41 1203 ± 44 ↑ 1332 ± 46 ↑ 0.7880 0.2263 
Sodium (mg) 2492 ± 96 2823 ± 131 2573 ± 140 ↓ 2954 ± 175 0.9322 0.3572 
Potassium (mg) 2186 ± 80 ↓ 2264 ± 96 2425 ± 89 2695 ± 101 ↑ 0.0839 0.0113 
Magnesium (mg) 274 ± 11 275 ± 12 280 ± 12 309 ± 12 0.6105 0.1798 
Iron (mg) 14.7 ± 0.8 14.3 ± 0.7 12.1 ± 0.6 13.3 ± 0.7 ↓ 0.0426 0.2313 
Zinc (mg) 10.0 ± 0.4 11.2 ± 0.5 ↑ 10.7 ± 0.5 ↑ 11.7 ± 0.5 ↑ 0.3535 0.6024 
Copper (mg) 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.5 ± 0.1 ↑ 0.7283 0.1868 
Selenium (μg) 102.1 ± 4.0 107.0 ± 5.0 106.5 ± 5.6 111.3 ± 5.7 0.5457 0.5310 
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Manganese (mg) 3.3 ± 0.2 ↓ 3.1 ± 0.2 3.7 ± 0.5 3.6 ± 0.2 0.7679 0.2668 
Alcohol (g) 1.1 ± 0.4 ↓ 2.2 ± 0.7 2.8 ± 1.3 2.8 ± 0.8 0.1833 0.3267 
Total Sugars (g) 111.3 ± 3.3 ↑ 116.6 ± 4.4 ↑ 104.6 ± 3.5 ↑ 115.1 ± 4.1 ↑ 0.1317 0.7887 
Added Sugars (g) 70.3 ± 2.5 ↑ 83.4 ± 4.3 ↑ 71.2 ± 3.2 ↑ 81.6 ± 3.6 ↑ 0.9538 0.8408 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; SFA, total saturated fatty acids. 
↓ Significant decrease from baseline determined by paired T-test (PROC TTEST). 
↑ Significant increase from baseline determined by paired T-test (PROC TTEST). 
1 Dietary intakes at the end of intervention between yogurt and control treatment groups in non-obese [P (C vs. Y)] and obese individuals [P (CO 
vs. YO)] was determined by ANCOVA with baseline intakes as covariate (PROC GLM). 
2 alpha-tocopherol. 
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Table 3.8 Self-reported food groups consumption at start of intervention, determined by 3-day dietary records (mean ± standard error). 
Food group 
Group Significance (P)1 
C (n=29) CO (n=30) Y (n=30) YO (n=30) C vs. Y CO vs. YO Obese vs. Lean 
Fruit 1.73 ± 0.22 1.48 ± 0.15 1.84 ± 0.24 1.47 ± 0.25 0.9877 1.0000 0.1482 
Vegetable 3.85 ± 0.32 3.99 ± 0.45 3.36 ± 0.26 3.38 ± 0.38 0.7866 0.6277 0.8250 
Grains 5.59 ± 0.39 5.99 ± 0.45 5.69 ± 0.37 6.51 ± 0.53 0.9985 0.8310 0.1667 
Meat, egg, nuts 5.19 ± 0.50 6.50 ± 0.65 5.91 ± 0.50 6.02 ± 0.51 0.7835 0.9211 0.1971 
Dairy2 1.40 ± 0.13 1.62 ± 0.13 1.19 ± 0.13 1.52 ± 0.22 0.7795 0.9662 0.0800 
Fat 3.29 ± 0.46 4.44 ± 0.59 3.45 ± 0.49 4.63 ± 0.42 0.9954 0.9934 0.0185 
Sweet 1.17 ± 0.19 1.43 ± 0.28 1.24 ± 0.18 1.66 ± 0.35 0.9970 0.9241 0.2003 
Beverages 4.60 ± 0.58 6.35 ± 0.57 6.17 ± 0.70 6.90 ± 0.59 0.2743 0.9190 0.0473 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
1 Differences between yogurt and control treatment groups in non-obese [P (C vs. Y)] and obese individuals [P (CO vs. YO)], and the differences 
between obese and lean subjects [P (Obese vs. Lean)] were determined by independent T-test (PROC TTEST).  
2 Included various types of milk, cheese, yogurt, dairy dessert, and certain nondairy alternative, etc.  
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Table 3.9 Self-reported food groups consumption near the end of 9-wk consumption of 12 oz. yogurt or control snack (mean ± 
standard error). 
Food group 
Group Significance (P)1 
C (n=29) CO (n=30) Y (n=30) YO (n=30) C vs. Y CO vs. YO 
Fruit 1.50 ± 0.21 0.97 ± 0.15 ↓ 1.05 ± 0.20 ↓ 0.82 ± 0.16 ↓ 0.0749 0.4892 
Vegetable 2.80 ± 0.27 ↓ 3.22 ± 0.33 2.64 ± 0.26 ↓ 3.96 ± 0.47 0.9065 0.0218 
Grains 5.47 ± 0.32 5.60 ± 0.48 5.08 ± 0.38 5.45 ± 0.45 ↓ 0.3980 0.4651 
Meat, egg, nuts 4.36 ± 0.48 4.94 ± 0.41 ↓  4.91 ± 0.59 4.82 ± 0.45 ↓ 0.7894 0.9710 
Dairy2 1.19 ± 0.14 1.11 ± 0.18 ↓ 2.41 ± 0.13 ↑ 2.56 ± 0.14 ↑ <.0001 <.0001 
Fat 3.61 ± 0.54 3.96 ± 0.54 2.96 ± 0.32 4.09 ± 0.37 0.2199 0.8884 
Sweet 1.00 ± 0.34 1.27 ± 0.37 0.87 ± 0.18 ↓  0.86 ± 0.18 ↓  0.6352 0.1500 
Beverages 5.19 ± 0.60 5.81 ± 0.62 7.02 ± 0.95 7.60 ± 0.99 0.5630 0.1511 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
↓ Significant decrease from baseline determined by paired T-test (PROC TTEST). 
↑ Significant increase from baseline determined by paired T-test (PROC TTEST). 
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1 Food group consumption at the end of intervention between yogurt and control treatment groups in non-obese [P (C vs. Y)] and obese individuals 
[P (CO vs. YO)] was determined by ANCOVA with baseline intakes as covariate (PROC GLM). 
2 NDSR includes various types of milk, cheese, yogurt, dairy dessert, and certain dairy replacements, etc. The control food was not considered a 
dairy serving for this analysis. 
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3.5 Discussion 
3.5.1 Anthropometric changes 
In this study, obese and lean women consumed an additional 1.5 servings of yogurt or a 
control snack for 9 weeks, while maintaining usual dietary patterns. While yogurt consumption 
decreased WC initially in lean women, the magnitude of change might not be clinically 
significant. A WC less than 88 cm is considered to be the cutoff point for increased chronic 
disease (Klein, Allison et al. 2007). 
Yogurt consumption over 4 years was associated with a 0.82 lb weight loss in a 
prospective cohort study of 120,877 US adults ( P ≤ 0.005) (Mozaffarian, Hao et al. 2011). 
However, data from human intervention studies suggest that weight-loss from increased dairy 
consumption is dependent on energy restriction (Abargouei, Janghorbani et al. 2012, Chen, Pan 
et al. 2012). The present study suggests that obese individuals could be at risk for weight gain 
when consuming additional calories from yogurt or similar non-dairy control food.  
Yogurt and control food consumption increased body weight in obese participants by a 
similar amount. The interventions supplied an additional ~ 300 kcal/day, but dietary records near 
the end of the intervention did not indicate increased caloric intake among participants. It is 
possible that the timing of dietary record collection may not have captured increased caloric 
intake throughout the study. Underreporting is found to be the most prevalent cause of inaccurate 
dietary reports among women (Archer, Hand et al. 2013). In addition, the degree of 
underreporting is associated with higher BMI (Nielsen, Nielsen et al. 2009, Meng, Kerr et al. 
2013). Most obese participant reported a calorie intake below the calculated Estimated Energy 
Requirements (EER) based on their age, weight, height and physical activity in the present study. 
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YO and CO had increased ratios of carbohydrate intake at the expense of lipid intake. The 
interventions supplied 54 g of added sugar, which contributed to the increased added sugar 
consumption by YO and CO. It is estimated that individuals having higher sugar intake have 
0.75 kg (0.30 - 1.19 kg, 95% CI; P = 0.001) more body weight than those consuming lower 
sugars intake during short-term interventions (Morenga, Mallard et al. 2012).  
As we did not determine body composition, it is unclear if YO and CO weight gains are 
associated with changes to fat or lean mass. Also, the weight gain did not appear to be 
detrimental as it was not correlated with the reduction in the antihypertensive effect of yogurt in 
YO at week 6 and 9 (data not shown). The mechanism by which increased body weight can 
affect hypertension is well-described. Obesity is associated with long-term over-activation of 
sympathetic nervous system which could raise arterial pressure by inducing peripheral 
vasoconstriction and increasing sodium reabsorption in the renal tubules (Rahmouni, Correia et 
al. 2005). Furthermore, activated renin-angiotensin system and increased plasma aldosterone 
levels found in obesity also contribute to the development of hypertension (Massiéra, Bloch-
Faure et al. 2001, Goodfriend and Calhoun 2004).  
3.5.2 Blood pressure 
Obese individuals had lower BP after yogurt consumption. Even small BP decreases 
might promote cardiovascular health. A decrease as small as of 5.6 mm Hg in systolic BP and 
2.2 mm Hg in diastolic BP may reduce the relative risk of major macrovasular or microvacular 
event by 9% (Patel, MacMahon et al. 2007). 
This study adds to the existing evidence that increased dairy consumption can reduce BP 
in obese individuals. The Dietary Approaches to Stop Hypertension (DASH) trial demonstrated 
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that inclusion of low-fat dairy products with reduced saturated and total fat augmented the 
antihypertensive effects of a diet rich in fruits and vegetables (Appel, Moore et al. 1997). A 
meta-analysis of ~ 45,000 subjects determined an inverse association between dairy consumption 
and development of elevated BP, defined as ≥ 130 mm Hg systolic and/or ≥ 84 mm Hg diastolic 
BP (RR 0.87, 0.81 - 0.94, 95% CI) (Ralston, Lee et al. 2012). Another meta-analysis of 
prospective cohort studies associated an increased daily intake of 200 g of low-fat dairy products 
with decreased risk of hypertension (RR 0.96, 95% CI, 0.93 - 0.99) (Soedamah-Muthu, Verberne 
et al. 2012).  
Intervention studies with dairy or fermented dairy consumption for BP management of 
prehypertension or hypertension are equivocal. Consumption of 3 daily servings of dairy 
products decreased mean daytime ambulatory systolic BP by 2 mm Hg (P = 0.05) in men with 
mild to moderate essential hypertension (Drouin-Chartier, Gigleux et al. 2014). However, 
ingestion of 300 mL fermented milk for 12 weeks did not reduce BP in patients with type 2 
diabetes and high systolic baseline BP (143 ± 18 mm Hg) (Hove, Brøns et al. 2015). Furthermore, 
individuals with prehypertension or stage 1 hypertension did not have a reduction in BP after 
consuming 2 servings of low-fat dairy products for 5 weeks (Maki, Rains et al. 2013).  
The potential antihypertensive mechanism of yogurt has not been adequately investigated. 
Some peptides (e.g. Val-Pro-Pro and Ile-Pro-Pro) derived from bacterial hydrolysis of milk 
protein may have hypotensive effects via inhibiting angiotensin-converting-enzyme (Nakamura, 
Mizutani et al. 2009). Low potassium intake might contribute to the genesis of high BP (Whelton, 
He et al. 1997).  However, the potassium content of yogurt does not appear to be sufficient to 
solely be responsible for reduce BP in obese individuals. Potassium consumption in the YO 
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group increased by 9.0% during the intervention, and was higher than the CO group (2695 ± 101 
vs. 2264 ± 96 mg/d, P = 0.0113). However, this level was still well below the Recommended 
Dietary Allowance (RDA) of 4700 mg/d for potassium in adults.  
3.5.3 Dietary intakes 
At baseline, the average intakes of total carbohydrate and total protein in each group met 
Dietary Reference Intake recommendations (Otten, Hellwig et al. 2006).  However, the total 
fiber intake was below 25 g/d in all participants. YO had higher cholesterol intake exceeding 300 
mg/d, while the other groups were below this level. For vitamins, all groups met vitamin A, C, 
thiamin, riboflavin, niacin, B6, folate, and B12 requirements. However, the vitamin D and E 
intakes were considerably below the recommended intake in all groups. For minerals, the intakes 
of calcium, magnesium, potassium, iron were moderately lower than recommended, while the 
average intakes of sodium in each group were above the upper limit. All groups met the 
recommended intakes of phosphorus, zinc, copper, selenium, and manganese. 
Although both the yogurt and control food provided 6.75 μg of vitamin D per day, final 
vitamin D intake was less than 15 μg/d. YO and Y calcium intakes reached 1000 mg/d. The 
increase might be partly from the yogurt intervention which provided 450 mg calcium/d. C and 
CO had lower calcium intakes than the corresponding yogurt treatment groups. The original 
control snack contained the same level of calcium with yogurt. However, the control was 
reformulated by the manufacturer during the intervention, which decreased the calcium content 
from 150 to 60 mg/cup. This partially explained the difference in calcium intakes between the 
yogurt and treatment groups. 
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3.5.4 Intakes by food group 
 At baseline, YO and CO consumed more servings of dietary fat and beverages than Y and 
C, but no difference in any food group category between the yogurt and control treatment groups 
was found. Both Y and YO increased the dairy consumption by about 1 serving/d, which was 
moderately lower than the 1.5 servings yogurt intervention. This suggested participants 
substituted the yogurt for part of their usual dairy consumption. Y and YO but not C and CO had 
decreased sweet consumption. It was possible that yogurt was more likely to be considered as a 
sweet than the soy pudding, despite equivalent sugar content. Incorporating yogurt into diets 
might help to curb sweet consumption, although this needs replication in other studies. 
Both Y and YO had decreased in fruit consumption after the intervention. The fruit flavor 
of yogurt may have impacted the tendency of participants to replace the fruit with yogurts. The 
lean, but not obese groups had decreased vegetable consumption after consuming the 
intervention foods. Previous studies supported the health benefits of adequate consumption of 
fruits and vegetables (Liu, Manson et al. 2000, Bazzano, He et al. 2002). Therefore, it will be 
important to advise participants to maintain the adequate consumption of fruits and vegetables 
when conducting yogurt intervention studies in the future. However, it is important to consider 
the inadequacy of NDSR to categorize all recipes and foods into food groups. Nevertheless, it 
provided insight on how the participants adapted to the intervention.  
3.6 Conclusion 
 This study demonstrated 9-week consumption of 12 oz. of low-fat yogurt lowered 
diastolic blood pressure in obese premenopausal women within 3 wk, but this effect decreased 
by 9 wk, which coincided with modest weight gain. Yogurt consumption led to a slight decrease 
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in waist circumference but had no effect on blood pressure in the lean premenopausal women. 
Although yogurt consumption increased calcium and vitamin D intake, reduction of fruit and 
vegetables is potentially concerning and should be monitored in future studies to avoid the 
possible interfering effects on study outcomes. Potential metabolic differences resulting from 
increased weight gain in obese individuals will be considered in later research chapters. 
Although the soy pudding control food caused an increase in body weight in obese participants, a 
similar increase was observed in obese participants consuming yogurt. The soy pudding did not 
affect other study outcomes such as BP and inflammatory biomarkers which will be discussed 
subsequent chapters. Therefore, soy pudding should be considered as an adequate control food 
for low-fat yogurt consumption. 
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Chapter 4: Effect of Pre-meal Low-fat Yogurt 
Consumption on Postprandial Metabolism 
Following a High-fat, High-carbohydrate Meal 
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4.1 Abstract 
Background: Postprandial dysmetabolism causes inflammation and is associated with increased 
risk for insulin resistance and atherosclerosis. 
Objective: Our objective was to determine the effects of pre-meal yogurt consumption on 
postprandial intestinal barrier function, inflammation, glycemia, lipidemia, and insulin secretion. 
Design: Apparently healthy premenopausal women with body mass index (BMI) values of 18.5 
to 27 (lean) or 30 to 40 kg/m2 (obese) participated in a 9-week randomized, controlled study. 
Participants in each BMI group were randomly assigned to either a low-fat yogurt-supplemented 
group (Y, yogurt lean; YO, yogurt obese) or a soy pudding-supplemented control group (C, 
control lean; CO, control obese) with n = 30/group. Participants were advised to consume 12 oz. 
of yogurt or the control food daily for 9 weeks while maintaining their usual caloric intake. At 
the start and end of the intervention, participants consumed 8 oz. of the yogurt or control food, 
followed by a high-fat, high-carbohydrate challenge meal. Plasma concentrations of glucose, 
triglyceride (TG), insulin, interleukin 6 (IL-6), lipopolysaccharide-binding protein (LBP) and 
soluble CD14 (sCD14) were measured at baseline and at 1, 2, 3, and 4 h after the meal. 
Results: The obese participants had fasting baseline values indicative of metabolic dysfunction, 
with 5% higher glucose, 32% higher TG, 89% higher insulin, 111% higher IL-6, 28% higher 
LBP, and 27% higher LBP/sCD14 ratio than the lean participants. The two challenge meal tests 
had similar results. The postprandial LBP/sCD14 ratio increased by an average of 10% in CO, 
but did not change in YO. Y and C did not have a consistent change in LBP/sCD14 ratio. The 
challenge meal induced an average of 80% increase in CO IL-6 at 4 h compared to 34% increase 
in YO IL-6. YO had a 15% decrease in IL-6 area under the curve (AUC)0-4h at the second 
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challenge meal test. CO postprandial glucose increased by an average of 16% at 1 h, but was 
unchanged in YO. Glucose decreased by 14% - 21% in C and 8% - 13% in Y within two hours. 
Y had less postprandial insulin over-secretion than C, while postprandial insulin was similar in 
YO and CO. Postprandial TG changes were similar between YO and CO, as well Y and C. 
Conclusion: Yogurt consumption before a challenge meal improves metabolic dysfunction in 
lean and obese women. In obese participants, yogurt consumption reduces postprandial 
inflammation and improves biomarkers of intestinal barrier function. This trial was registered at 
clinicaltrials.gov as NCT01686204. 
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4.2 Introduction 
Obesity leads to metabolic dysfunction and chronic inflammation. Consumption of high-
calorie challenge meals can be used to assess the role of diet in preventing inflammation and 
metabolic dysfunction (Ghanim, Abuaysheh et al. 2009, Ghanim, Sia et al. 2010, Ghanim, Sia et 
al. 2011). Insulin resistance and arteriosclerosis are closely associated with postprandial 
inflammation (Burdge and Calder 2005, O'Keefe, Gheewala et al. 2008). Low-grade postprandial 
inflammation is usually transient and results from postprandial hyperglycemia and 
hyperlipidemia (Nappo, Esposito et al. 2002, Ceriello, Quagliaro et al. 2004, Ceriello, Assaloni 
et al. 2005). In the postprandial state, increased glucose and free fatty acids enter the Krebs cycle, 
overcoming the capacity for oxidative phosphorylation, leading to oxidative stress (O'Keefe and 
Bell 2007). Oxidative stress is a strong stimulator of inflammation, via activating the mitogen-
activated protein kinases (MAPK) family and nuclear factor kappa B (NF-κB) pathway (Rahman 
2002, Leung and Chan 2009).  
Acute, low-grade endotoxemia also contributes to postprandial inflammation (Erridge, 
Attina et al. 2007). Bacterial endotoxins could circumvent the intestinal barrier and induce 
systemic inflammation (Kemna, Pickkers et al. 2005, Andreasen, Larsen et al. 2010). 
Lipopolysaccharide (LPS) inflammatory signaling is mediated by binding to lipopolysaccharide-
binding protein (LBP), and membrane-bound or soluble CD14 (sCD14) before activating Toll-
like receptor 4 (TLR4)/MD2 complex (Van Bossuyt, De Zanger et al. 1988, Park, Song et al. 
2009, Manco, Putignani et al. 2010). The intestinal barrier function of obese individuals is 
compromised, leading to increased endotoxin exposure and chronic inflammation (Sun, Yu et al. 
2010). The obesity-associated endotoxemia is characterized by two- to threefold increase in 
circulating endotoxin, usually referred as metabolic endotoxemia (Cani, Amar et al. 2007).  
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 Dairy proteins and calcium attenuate postprandial hyperlipidemia and hyperglycemia by 
insulinotropic activity, delaying gastric emptying, and decreasing fat absorption (Westphal, 
Kästner et al. 2004, Lorenzen, Nielsen et al. 2007, Mortensen, Hartvigsen et al. 2009). In 
addition, prior studies suggest that yogurt may improve intestinal barrier function by modifying 
gut microbiota, stimulating the production of intestinal mucins, increasing secretory 
immunoglobulin A and antimicrobial peptides secretion, and maintaining function of tight 
junctions (Pei, Martin et al. 2015). Therefore, we hypothesized that pre-meal yogurt consumption 
could alleviate postprandial inflammation by reducing postprandial dysmetabolism and 
endotoxemia. 
4.3 Materials and Methods 
4.3.1 Study participants 
Obese and lean women were recruited to participate in the study as described in Section 
3.3.1. 
4.3.2 Postprandial challenge meal and treatment 
The composition of the challenge meal was formulated to induce metabolic dysfunction 
as previously described (Ghanim, Abuaysheh et al. 2009, Ghanim, Sia et al. 2010). The high-fat, 
high-carbohydrate challenge meal consisted of two sausage, egg and cheese sandwiches (Jimmy 
Dean, Peoria, IL) and two hash browns (obtained from local stores). The meal provided 56-60 g 
of total fat (~ 54% of total energy), 82 g of carbohydrates (~ 34% of total energy), and 28-30 g of 
protein (~ 12% of total energy), supplying a total of ~ 960 kcal.  
The intervention consisted of commercially available low-fat yogurt (Yoplait, General 
Mills, Inc. Minneapolis, MN) and soy pudding as control food (ZenSoy, South Hackensack, NJ) 
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as described in Section 3.3.2. Prior to the challenge meals, participants consumed 8 oz. of the 
intervention foods, providing an additional 330 kcal. Throughout the 9-week intervention, 
participants ate 12 oz. of yogurt or the control food daily. 
4.3.3 Experimental design 
A randomized, controlled study was used to characterize the effects of yogurt 
consumption on intestinal barrier function and chronic inflammation relative to consumption of a 
non-dairy control food. This study was powered to detect an 8.2% difference in sCD14, the 
primary outcome (Laugerette, Vors et al. 2011). The recruitment, initial prescreening, enrollment, 
compliance, and completion rate of 128 subjects were previously described in Section 3.3.3.  
Briefly, n = 30 participants from each group: YO, yogurt obese; CO, control obese; Y, yogurt 
lean; C, control lean completed all study visits.  
Two identical challenge meal tests were conducted at the beginning (wk 0) and end of 
intervention (wk 9) as depicted in Figure 4.1. On each test day, participants were instructed to 
arrive at the study center in the fasted state (10 - 12 h) in the morning. Fasting blood samples (0 
h) were collected from the antecubital vein into evacuated tubes containing sodium heparin or 
ethylenediaminetetraacetic acid (EDTA) (Becton, Dickinson and Company, Franklin Lakes, NJ). 
The participants were instructed to consume one serving (8 oz.) of yogurt or control food 
followed by the challenge meal. Blood samples were collected at 1, 2, 3 and 4 h after the test 
meal was finished. All blood samples were placed in ice bath immediately and centrifuged (4°C, 
15 min, 1500 × g) within 20 min of collection. Aliquots of the upper layer of plasma were snap-
frozen in liquid nitrogen. All samples were stored at -80 °C until analysis. During the 
postprandial phase, the subjects were asked to stay at the study center and avoid exercise. 
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Figure 4.1 Experimental design of challenge meal tests. 
After 2 weeks of washout, lean and obese participants were randomly assigned to either yogurt or the 
control treatment for 9 weeks. At the beginning and end of intervention, participants consumed challenge 
meals. At each test, the participants were instructed to consume one serving of yogurt or control food, 
followed by a high-fat, high-carbohydrate test meal. Blood samples were collected at baseline (0), 1, 2, 3, 
and 4 h after the meal. 
4.3.4 Biomarker analysis 
Glucose was determined in sodium heparin plasma by a commercial colorimetric 
enzymatic assay kit (Cat # 10009582; Cayman Chemical, Ann Arbor, MI). Total TG in sodium 
heparin plasma was measured by a commercial enzymatic kit (Cat # 461-08992 and 461-09092; 
Wako Diagnostics, Richmond, VA). Insulin in sodium heparin plasma was determined by 
immunoassay (Cat # 80-INSHU-E01.1; Alpco Diagnostics, Salem, NH). IL-6 and sCD14 were 
measured by immunoassay in EDTA and sodium heparin plasma, respectively (IL-6, Cat # 
SS600B, high-sensitivity; sCD14, Cat # DC140; R&D System, Minneapolis, MN).  LBP was 
determined in EDTA plasma by ELISA (Cat # HK315-02; Hycult Biotech, Uden, Netherlands). 
All the measurements were performed on a SpectraMax M2 microplate reader (Molecular 
Devices, Sunnyvale, CA) according to manufacturers’ instructions. To estimate insulin resistance, 
the homeostatic model assessment of insulin resistance (HOMA-IR) index was calculated as 
InterventionWashout
wk 9
Fasting blood & 
challenge meal test
wk -2
Screening
wk 0
Fasting blood & 
challenge meal test
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fasting insulin concentration (μIU/mL) × fasting glucose concentration (mg/dL)/405 (Wallace, 
Levy et al. 2004). The ratio between LBP and sCD14 was calculated as a marker for 
endotoxemia.  
4.3.5 Statistical analysis 
All results were expressed as mean ± standard error. Statistical analysis was conducted on 
SAS 9.4 software (Cary, NC). The significance level was set at α = 0.05 for all statistical tests. 
At baseline, the differences between Y and C, and YO and CO were analyzed by independent T-
test. The effects of treatment (yogurt vs. control), time (0, 1, 2, 3 and 4 h) and treatment × time 
on glucose, TG, insulin, IL-6, LBP, sCD14, and LBP/sCD14 ratio were determined by repeated-
measures ANOVA. Time-dependent changes in each group were determined by repeated-
measures ANOVA with Dunnett's test for multiple comparisons. Area under the curve (AUC) 
was calculated using the trapezoidal rule and compared by independent T-test for group 
comparisons or paired T-test for time-dependent changes. 
4.4 Results 
At baseline, obese participants had 5% higher glucose, 32% higher TG, 89% higher 
insulin, 111% higher IL-6, 28% higher LBP, and 27% plasma LBP/sCD14 ratio in fasting 
plasma than lean participants (Table 4.1). However, the fasting plasma glucose, TG, insulin, IL-
6, LBP, sCD14, and LBP/sCD14 ratio in the yogurt treatment group did not differ from that in 
the control treatment group within lean and obese groups. 
The average postprandial concentrations of glucose, TG, insulin, IL-6, LBP, sCD14 and 
the ratio of LBP/sCD14 for each group and challenge meal are presented in Appendix A.2 
Supplementary Table 4.1-4.7. 
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4.4.1 Postprandial glucose changes 
In YO and CO, treatment, time and treatment × time effects were all significant at both 
challenge meals (Figure 4.2 A and B). At 1 h, CO plasma glucose increased by 15% after the 
first challenge meal, and by 17% after the second challenge meal. In contrast, YO postprandial 
plasma glucose did not change from baseline at any of the time points examined, up to 4 h. 
Chronic consumption of yogurt did not markedly improve postprandial glucose response. At 1 h, 
CO had 16% and 20% higher glucose than YO at the first and second challenge meal tests, 
respectively. 
Y and C plasma glucose had significant time and treatment × time effects after the first 
challenge meal, and significant treatment and time effects after the second challenge meal 
(Figure 4.2 C and D). C plasma glucose decreased a maximum of 21% and 14% at 2 h after the 
first and second challenge meal, respectively. Y exhibited a smaller decrease in plasma glucose 
of 13% and 8% from baseline at the first and second challenge meal, respectively. Y postprandial 
plasma glucose returned to baseline by 2 h, whereas C returned at 3 h.  
The mean postprandial glucose AUC0-4h of YO and CO was 17% and 19% higher than 
that of Y and C after the first and second challenge meals, respectively (Table 4.2). YO 
postprandial glucose AUC0-4h was 8% lower than CO after the first challenge meal and tended to 
be lower after the second challenge meal (349.4 ± 9.2 vs. 391.3 ± 19.0 mg/dL·h, P = 0.0543). 
The plasma glucose AUC0-4h of Y was not significantly different than that of C after both 
challenge meals. 
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Figure 4.2 Change of plasma glucose in the obese groups at the first (A) and second (B) 
challenge meal, and in the lean groups at the first (C) and second (D) challenge meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures ANOVA with 
Dunnett's test for multiple comparison was performed to evaluate time and treatment effects. * 
Significantly different from baseline in the control treatment groups, P < 0.05. # Significantly different 
from baseline in yogurt treatment groups, P < 0.05. $ Significantly different between the yogurt and 
control treatment groups at different time points, P < 0.05. 
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Table 4.1 Baseline fasting characteristics of participants completing all visits (mean ± standard error, n = 30/group). 
Characteristic (unit) 
Group Significance (P)1 
C CO Y YO P vs. C 
CO vs. 
YO 
Obese vs. 
Lean 
Age (year) 25.3 ± 1.1 31.9 ± 1.6 24.8 ± 0.8 36.7 ± 2.0 0.7603 0.0609 <.0001 
Weight (kg) 62.3 ± 1.6 93.5 ± 2.2 64.7 ± 1.5 94.1 ± 1.9 0.2788 0.8336 <.0001 
Height (m) 1.66 ± 0.01 1.65 ± 0.01 1.67 ± 0.01 1.65 ± 0.01 0.7534 0.6489 0.2883 
BMI (kg/m2) 22.5 ± 0.4 34.3 ± 0.5 23.3 ± 0.5 34.4 ± 0.7 0.2603 0.9670 <.0001 
Glucose (mg/dL) 86.1 ± 2.2 89.4 ± 1.6 84.2 ± 1.1 89.4 ± 1.4 0.4498 0.9871 0.0104 
TG (mg/dL) 66.9 ± 5.1 94.9 ± 7.4 72.0 ± 7.1 90.9 ± 7.6 0.5684 0.5934 0.0014 
Insulin (μIU/mL)2 7.0 ± 0.5 13.6 ± 1.3 7.7 ± 0.7 14.2 ± 1.5 0.7607 0.4180 <.0001 
HOMA-IR2 1.48 ± 0.11 3.25 ± 0.43 1.69 ± 0.18 3.21 ± 0.32 0.3364 0.9389 <.0001 
IL-6 (pg/mL) 0.74 ± 0.08 1.56 ± 0.13 0.88 ± 0.13 1.86 ± 0.22 0.3941 0.2487 <.0001 
LBP (μg/mL) 9.9 ± 0.9 12.4 ± 0.7 9.3 ± 0.6 12.3 ± 0.9 0.6044 0.9302 0.0010 
sCD14 (ng/mL) 1421 ± 50 1481 ± 45 1402 ± 59 1388 ± 45 0.7993 0.1539 0.6579 
LBP/sCD14 7.14 ± 0.69 8.62 ± 0.58 6.89 ± 0.44 9.13 ± 0.73 0.7584 0.5881 0.0032 
  
1
1
3
 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; BMI, body mass index; TG, triglyceride; HOMA-IR, 
homeostatic model assessment of insulin resistance; IL-6, interleukin 6; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14. 
1 Baseline differences between yogurt and pudding treatment groups in non-obese [P (C vs. Y)] and obese participants [P (CO vs. YO)], and the 
differences between obese and non-obese participants [P (Obese vs. Lean)] were determined by independent T-test (PROC TTEST).  
2 Determined at the second challenge meal (wk 9). 
  
  
1
1
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Table 4.2 AUC comparisons (mean ± standard error). 
Markers' AUC 
(unit) 
Group 
AUC0-4 h Significance (P) 
wk 0  wk 9 
Group difference1 
at wk 0 
Group difference1 
at wk 9 
Time difference2 
(wk 0 vs. wk 9) 
Glucose AUC0-4 
h (mg/dL·h) 
C (n = 30) 299.5 ± 7.9 303.0 ± 8.0 
0.1245 0.0813 
0.8129 
Y (n=  30) 317.4 ± 8.3 320.7 ± 5.9 0.6204 
CO (n = 30) 374.5 ± 10.5 391.3 ± 19.0 
0.0307 0.0543 
0.1359 
YO (n = 30) 346.8 ± 6.7 349.4 ± 9.2 0.9833 
Lean (n = 60) 308.4 ± 5.8 311.8 ± 5.1 
<.0001 <.0001 
0.1909 
Obese (n = 60) 360.4 ± 6.4 370.0 ± 10.7 0.5414 
TG AUC0-4 h 
(mg/dL·h) 
C (n = 30) 390.0 ± 25.7 390.7 ± 23.2 
0.9316 0.6959 
0.7961 
Y (n=  30) 393.8 ± 35.3 375.8 ± 30.3 0.5965 
CO (n = 30) 528.9 ± 39.4 538.5 ± 36.8 
0.8453 0.7348 
0.2952 
YO (n = 30) 540.6 ± 45.1 560.3 ± 53.2 0.4654 
Lean (n = 60) 392.0 ± 21.9 383.4 ± 18.8 
0.0002 <.0001 
0.5941 
Obese (n = 60) 534.7 ± 29.6 549.0 ± 31.7 0.4097 
IL-6 AUC0-4 h 
(pg/mL·h) 
C (n = 30) 4.04 ± 0.38 4.05 ± 0.60 
0.7151 0.734 
0.9213 
Y (n=  30) 4.24 ± 0.40 4.01 ± 0.37 0.5283 
CO (n = 30) 7.96 ± 0.66 7.55 ± 0.54 
0.9249 0.4946 
0.4522 
YO (n = 30) 8.05 ± 0.77 6.87 ± 0.83 0.0232 
Lean (n = 60) 4.14 ± 0.27 4.03 ± 0.35 
<.0001 <.0001 
0.4619 
Obese (n = 60) 8.00 ± 0.50 7.21 ± 0.49 0.0355 
  
1
1
5
 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; TG, triglyceride; IL-6, interleukin 6. 
1 Group differences of AUCs [P (C vs. Y), P (CO vs. YO), and P (Lean vs. Obese)] at wk 0 and wk 9 were compared by independent T-test. 
2 Time difference of AUCs between wk 0 and wk 9 in each group were compared by paired T-test. 
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4.4.2 Postprandial TG changes 
Consumption of yogurt or the control food did not significantly change the postprandial 
TG response for any group at either challenge meal (Figure 4.3). Although there was a 
significant treatment × time effect (P = 0.0350) on postprandial plasma TG in the obese groups 
after the second challenge meal, group differences were not significant at any time point. 
Postprandial plasma TG increased continuously and remained above the baseline at all selected 
time points in all groups. At 4 h after the two challenge meals, plasma TG was increased by 48% 
- 77% within groups.  
Obese participants had higher postprandial lipid exposure than lean participants. Relative 
to lean groups, obese groups had 36% and 43% greater plasma TG AUC0-4h after the first and 
second challenge meals, respectively (Table 4.2). Postprandial TG AUC0-4h was not significantly 
different between treatment groups within each BMI group or between challenge meals in any 
group. 
4.4.3 Postprandial insulin changes 
Because the postprandial changes in plasma glucose and TG for each group were similar 
after both challenge meals, plasma insulin was characterized only at the second challenge meal 
(Figure 4.4). YO and CO postprandial plasma insulin were largely similar. CO insulin was 
increased from baseline at 1, 2, and 3 h, and YO at 1 and 2 h. YO and CO postprandial insulin 
were similar and peaked 1 h at around 6.5-fold of baseline. In lean individuals, yogurt 
consumption reduced the postprandial insulin secretion relative to the control food. Y and C 
plasma insulin was increased from baseline at 1, 2, and 3 h. Y and C postprandial plasma insulin 
was highest at 1 h, at 7.2-fold of baseline in C and 5.4-fold of baseline in Y. At 3 h, C had 30% 
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higher insulin than Y. Also, insulin AUC0-4h of C tended to be higher than that of Y (128.9 ± 
15.3 vs. 100.5 ± 5.8 μIU/mL·h, P = 0.0907). Obesity also increased postprandial insulin. 
Relative to lean individuals, the obese groups had 1.3-fold greater insulin AUC0-4h. 
 
Figure 4.3 Postprandial plasma TG in obese participants after the first (A) and second (B) 
challenge meal, and in lean participants after the first (C) and second (D) meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures ANOVA with 
Dunnett's test for multiple comparison was performed to evaluate time and treatment effects. * 
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Significantly different from baseline in the control treatment groups, P < 0.05. # Significantly different 
from baseline in the yogurt treatment groups, P < 0.05. 
 
Figure 4.4 Postprandial plasma insulin in obese participant (A) and in the lean groups (B), after 
the second challenge meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures ANOVA with 
Dunnett's test for multiple comparison was performed to evaluate time and treatment effects. * 
Significantly different from baseline in the control treatment groups, P < 0.05. # Significantly different 
from baseline in the yogurt treatment groups, P < 0.05. $ Significantly different between the yogurt and 
control treatment groups at different time points, P < 0.05. 
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4.4.4 Postprandial IL-6 changes 
Yogurt consumption inhibited postprandial increases in IL-6 in obese participants. YO 
and CO postprandial plasma IL-6 had a significant treatment × time effect at the first challenge 
meal (P = 0.037) and a significant treatment effect after the second challenge meal (P = 0.021) 
(Figure 4.5). CO plasma IL-6 was increased above baseline by 3 and 4 h after both challenge 
meals. YO plasma IL-6 was also increased above baseline at 3 and 4 h after the first challenge 
meal, but was only increased at 4 h after the second challenge meal. At 4 h, the increase of IL-6 
in YO was 42% and 53% of that in CO after the first and second challenge meal, respectively. In 
contrast to obese participants, Y and C postprandial IL-6 were not significantly different. Both 
challenge meals increased lean postprandial plasma IL-6 at 3 or 4 h. For example, in the second 
test, C and Y IL-6 increased 62% and 49% from baseline at 4 h, respectively. 
Obesity also increased chronic postprandial inflammation. Relative to lean participants, 
obese participants had 93% and 79% greater plasma IL-6 AUC0-4h after the first and second 
challenge meals, respectively (Table 4.2). In each BMI group, IL-6 AUC0-4h was not different 
between the yogurt and control treatment groups after either challenge meal. Daily low-fat 
yogurt consumption appeared to decrease postprandial inflammation in YO, as indicated by 15% 
less IL-6 AUC0-4h at wk 9 than at wk 0. 
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Figure 4.5 Postprandial plasma IL-6 change from baseline (0 h) in obese participants at the first 
(A) and second (B) challenge meal, and in lean participants after the first (C) and second (D) 
challenge meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures 
ANOVA with Dunnett's test for multiple comparison was performed to evaluate time and treatment 
effects. * Significantly different from baseline in the control treatment groups, P < 0.05. # Significantly 
different from baseline in the yogurt treatment groups, P < 0.05. $ Significantly different between the 
yogurt and control treatment groups at different time points, P < 0.05. 
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4.4.5 Postprandial LBP and sCD14 changes  
 YO and CO had similar postprandial LBP responses (Figure 4.6). After both challenge 
meals, YO plasma LBP was lower than CO, but this difference was not statistically significant. 
YO plasma LBP decreased 3% and 6% at 2 and 3 h at the second challenge meal. In Y and C, 
postprandial plasma LBP did not change after the first challenge meal. After the second 
challenge meal, Y LBP was 5% - 9% below baseline at 1, 3, and 4 h and was lower than C at 1 to 
4 h. 
 YO and CO had different postprandial plasma sCD14 responses after both challenge 
meals (Figure 4.7). After both meals, CO plasma sCD14 was decreased at 1 and 2 h, with an 
average of 5% decrease at 2 h; in contrast, YO plasma sCD14 was unchanged. Also, CO had less 
plasma sCD14 than YO at 1 and 2 h. These differences were apparent in obese participants only. 
Y and C postprandial sCD14 were not significantly different after either challenge meal. 
However, within Y, sCD14 decreased by around 4% at 1 h after both challenge meals. 
 Yogurt consumption changed LBP/sCD14 ratio in obese participants relative to the 
control (Figure 4.8). CO LBP/sCD14 increased postprandially by a maximum of 12% and 7% 
after the first and second challenge meals, respectively. YO postprandial LBP/sCD14 did not 
change after either challenge meal. Y and C postprandial LBP/sCD14 changes were not affected 
by treatments. 
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Figure 4.6 Relative change of plasma LBP from baseline (0 h) in the obese groups at the first (A) 
and second (B) challenge meal, and in the lean groups at the first (C) and second (D) challenge 
meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures ANOVA with 
Dunnett's test for multiple comparison was performed to evaluate time and treatment effects. # 
Significantly different from baseline in the yogurt treatment groups, P < 0.05. $ Significantly different 
between the yogurt and control treatment groups at different time points, P < 0.05.  
T im e  (h )

 L
B
P
 (

g
/m
L
)
0 1 2 3 4
-1 .5
-1 .0
-0 .5
0 .0
0 .5
1 .0
C O
Y O
T re a tm e n t: P =  0 .1 4 42
T im e: P =  0 .4 3 94
T re a tm e n t   tim e: P =  0 .3 9 36
A
T im e  (h )

 L
B
P
 (

g
/m
L
)
0 1 2 3 4
-1 .5
-1 .0
-0 .5
0 .0
0 .5
1 .0
C O
Y O
T re a tm e n t: P =  0 .1 4 56
T im e: P =  0 .0 2 58
T re a tm e n t   tim e: P =  0 .5 3 78
#
#
B
T im e  (h )

 L
B
P
 (

g
/m
L
)
0 1 2 3 4
-1 .5
-1 .0
-0 .5
0 .0
0 .5
1 .0
C
Y
T re a tm e n t: P =  3051
T im e: P =  0 .0 2 70
T re a tm e n t   tim e: P =  0 .0 7 31
C
T im e  (h )

 L
B
P
 (

g
/m
L
)
0 1 2 3 4
-1 .5
-1 .0
-0 .5
0 .0
0 .5
1 .0
C
Y
T re a tm e n t: P =  0 .0 0 02
T im e: P =  0 .0 0 04
T re a tm e n t   tim e: P =  0 .1 1 49
$
$
$
$
#
#
#
D
 123 
 
 
Figure 4.7 Relative change of plasma sCD14 from baseline (0 h) in the obese groups at the first 
1 (A) and second (B) challenge meal, and in the lean groups at the first (C) and second (D) 
challenge meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures ANOVA with 
Dunnett's test for multiple comparison was performed to evaluate time and treatment effects. * 
Significantly different from baseline in the control treatment groups, P < 0.05. # Significantly different 
from baseline in the yogurt treatment groups, P < 0.05. $ Significantly different between the yogurt and 
control treatment groups at different time points, P < 0.05.  
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Figure 4.8 Changes in LBP/sCD14 ratio normalized to 0 h in the obese groups at the first (A) 
and second (B) challenge meal, and in the lean groups at the first (C) and second (D) challenge 
meal. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Repeated-measures ANOVA with 
Dunnett's test for multiple comparison was performed to evaluate time and treatment effects. * 
Significantly different from baseline in the control treatment groups, P < 0.05. # Significantly different 
from baseline in the yogurt treatment groups, P < 0.05. $ Significantly different between the yogurt and 
control treatment groups at different time points, P < 0.05. 
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4.5 Discussion 
 We examined the effects of pre-meal consumption of yogurt on postprandial intestinal 
barrier function, inflammation, glycemia, lipidemia, and insulin secretion in apparently healthy 
premenopausal women. In obese participants, low-fat yogurt consumption reduced postprandial 
increases of glucose, IL-6 and LPB/sCD14 ratio, suggesting lower inflammatory status and 
reduced endotoxemia. In lean participants, yogurt consumption attenuated postprandial 
hypoglycemia, possibly by reducing insulin over-secretion.  
4.5.1 Postprandial glycemia, lipidemia and insulin secretion 
The data from the present study support prior observations that obese individuals have 
dysregulated postprandial metabolism and insulin resistance (Esposito, Ciotola et al. 2007, 
Calder, Ahluwalia et al. 2011). After consuming the same high-fat, high-calorie challenge meal, 
the obese participants secreted more insulin than lean participants. Despite increased insulin, 
plasma glucose was also increased in obese compared to lean participants. This hyperglycemia 
was suppressed by pre-meal consumption of yogurt, although yogurt did not affect the TG 
response and insulin secretion.  
Dairy protein alone may improve postprandial metabolism. In healthy, normal-weight 
adults, co-ingestion 50 g of casein, the major protein in dairy products, reduced the increase of 
free fatty acids after a fatty meal (Westphal, Kästner et al. 2004). In healthy, normal-weight men, 
a preload of whey protein as low as 10 g reduced postprandial blood glucose concentration and 
the ratio of cumulative blood glucose to insulin AUCs (Akhavan, Luhovyy et al. 2010). In type-2 
diabetics, co-ingestion of 45 g of whey protein improved postprandial response by suppressing 
the increases in glucose, TG and free fatty acids (Mortensen, Hartvigsen et al. 2009).  
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Pre-meal consumption low-fat yogurt consumption might attenuate postprandial 
hyperglycemia by several mechanisms. Dairy calcium, but not calcium carbonate, diminished 
postprandial lipidemia, possibly via inhibiting fat absorption (Lorenzen, Nielsen et al. 2007). 
Casein may also be insulinotropic (Westphal, Kästner et al. 2004). An anti-inflammatory effect 
might also improve insulin resistance. IL-6 induces suppressor of cytokine signaling-3 (SOCS-3), 
which could interfere with insulin signaling (Ueki, Kondo et al. 2004, Ghanim, Abuaysheh et al. 
2009). However, these do not appear to be the primary mechanisms by which yogurt inhibits 
postprandial hyperglycemia, as YO and CO postprandial TG and insulin were similar and plasma 
IL-6 increased after the hyperglycemia was evident.  
Alternatively, yogurt consumption has the potential to modulate incretin function. Dairy 
proteins inhibit dipeptidyl peptidase-4 (DPP4) activity, a serine protease that inactivates 
Glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) (Lacroix and Li-Chan 
2013, Silveira, Martínez-Maqueda et al. 2013). GLP-1 increases glucose uptake and decreases 
hepatic glucose production (Opinto, Natalicchio et al. 2013). GIP is not only insulinotropic, but 
also shows insulin-like activity on glucose metabolism (Hauner, Glatting et al. 1988, Gault, 
O'Harte et al. 2003).  
Consumption of yogurt or dairy protein may also decrease the gastric emptying rate, 
which is regulated by GLP-1 (Sanggaard, Holst et al. 2004, D'Alessio, Sandoval et al. 2005, 
Akhavan, Luhovyy et al. 2010, Opinto, Natalicchio et al. 2013). Gastric emptying rate affects the 
magnitude and timing of postprandial glucose and insulin response by influencing the absorption 
of ingested nutrients (Rayner, Samsom et al. 2001). Rapid gastric emptying is also associated 
with postprandial hypoglycemia induced by excessive insulin release (Permutt 1976).  
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Pre-meal yogurt consumption might prevent over-secretion of insulin in lean individuals, 
thus attenuating the postprandial hypoglycemia. However, it is noteworthy that we did not 
observe the postprandial glucose peak in YO, C or Y. It is possible that the peak occurred 
between 0 and 1 h and was not captured by the selected study time points. In a postprandial study 
using a challenge meal that was similar to the present study, the glucose peaked at 30 min, and 
returned to baseline at 60 min (Dandona, Ghanim et al. 2015). 
4.5.2 Postprandial inflammation 
 Circulating IL-6 increases postprandially within 4 hours in many postprandial studies 
using different challenge meals (Alvarez, Higgins et al. 2009, Laugerette, Vors et al. 2011, 
Burton-Freeman, Talbot et al. 2012). On the other hand, other classical inflammatory markers 
like TNF-α and hsCRP did not increase postprandially, possibly due to their delayed response 
(Poppitt, Keogh et al. 2008, Alvarez, Higgins et al. 2009, Biasillo, Leo et al. 2010, Schmid, Petry 
et al. 2015). Obesity-associated postprandial metabolic dysregulation is accompanied by 
increased inflammation compared to lean individuals, as indicated by greater incremental AUC 
of IL-6 (Manning, Sutherland et al. 2008). Similarly, obese participants in the present study had 
higher postprandial IL-6 exposure than lean participants. Pre-meal low-fat yogurt consumption 
was able to suppress the increased postprandial IL-6 in obese participants. 
The yogurt-induced suppression IL-6 in obese participants may be related to reduced 
postprandial hyperglycemia in this group. Postprandial glucose induces oxidative stress (O'Keefe 
and Bell 2007). Yogurt consumption also inhibited postprandial plasma malondialdehyde, a 
biomarker of lipid oxidation, in obese women (DiMarco 2014). Postprandial oxidative stress and 
inflammation have been reported in many intervention studies (Anderson, Evans et al. 2001, 
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Nappo, Esposito et al. 2002, Ceriello, Quagliaro et al. 2004, Ceriello, Assaloni et al. 2005, 
Monnier, Mas et al. 2006). Oxidative stress stimulates inflammation by increasing MAPK and 
NF-κB signaling (Rahman 2002, Leung and Chan 2009). Also, antioxidant consumption reduces 
postprandial oxidative stress and inflammation (Edirisinghe, Banaszewski et al. 2011, Burton-
Freeman, Talbot et al. 2012). It is plausible that yogurt and its bioactive components such as 
probiotics and protein exhibit antioxidant activity (Ebringer, Ferenčík et al. 2008).  
4.5.3 Postprandial endotoxemia 
Reduced endotoxin exposure may also explain the reduction of YO postprandial IL-6. 
LPS is a potent proinflammatory molecule (Cani, Amar et al. 2007, Andreasen, Larsen et al. 
2010). Pre-meal consumption of low-fat yogurt might reduce endotoxin exposure in obese 
individuals, as indicated by lower postprandial LBP, LBP/sCD14 ratio, but higher sCD14 in the 
yogurt-consuming group than in the control group. LBP and sCD14 have been proposed as 
surrogate markers for endotoxemia, due to their roles in translocating LPS and other bacterial 
compounds to inflammatory signaling pathways (Schroder and Schumann 2005). Healthy 
overweight/obese individuals have higher LBP than lean individuals (Sun, Yu et al. 2010). 
Similarly, obese LBP was higher than lean in the present study. 
A few intervention studies report sCD14 and LBP as biomarkers for low-grade, 
postprandial endotoxemia. A high-fat, high-calorie meal increased plasma LBP in 10 healthy, 
normal weight adults, which was suppressed by supplemental grape polyphenols (Ghanim, Sia et 
al. 2011). A mixed meal with emulsified fat increased plasma sCD14 and LPS in 12 healthy 
young normal weight men (Laugerette, Vors et al. 2011). However, such increases in plasma 
sCD14 and LBP were not observed in some other challenge meals studies (Clemente-Postigo, 
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Queipo-Ortuno et al. 2013, Laugerette, Alligier et al. 2014). In the present study, postprandial 
LBP decreased in both Y and YO, suggesting reduced endotoxin exposure. However in obese 
individuals, postprandial sCD14 also decreased upon in those consuming the control, but was 
unchanged after yogurt consumption. In the presence of LPS and LBP, sCD14 can form a ternary 
sCD14·LBP·LPS complex which is bound and internalized by cells (Tapping and Tobias 1997). 
Ingesting a meal containing 40 g fat induced higher postprandial LPS than after a meal 
containing 10 g fat in healthy obese adults (Vors, Pineau et al. 2015). The decreased sCD14 
observed in the obese control group may have resulted from increased LPS and LBP which was 
complexed with sCD14 and subsequently cleared from circulation. 
Circulating sCD14 is positively associated with insulin sensitivity in morbidly obese 
individuals (de Courten, Moreno-Navarrete et al. 2015). This is supported by one animal study 
that recombinant human sCD14 improved insulin action in high-fat-fed mice and ob/ob mice 
(Fernandez-Real, del Pulgar et al. 2011). On the other hand, circulating LBP is associated with 
insulin resistance and inflammatory marker in cross-sectional studies (Gubern, Lopez-Bermejo et 
al. 2006, Moreno-Navarrete, Ortega et al. 2012). Therefore, the improved postprandial glucose 
response in obese participants consuming yogurt might be partly explained by the higher level of 
postprandial sCD14 and lower LBP than those consuming the control. 
In mice, a higher plasma LBP/sCD14 ratio is correlated with higher level of inflammation 
and higher endotoxin exposure (Laugerette, Furet et al. 2012). Similarly, a high-fat, high-calorie 
challenge meal increased the postprandial LBP/sCD14 ratio (Laugerette, Alligier et al. 2014). 
We observed a postprandial increase in CO LBP/sCD14 only. In contrast, the YO LBP/sCD14 
did not increase, indicating suppressed postprandial endotoxemia. Yogurt consumption might 
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improve the impaired intestinal barrier function of obese individuals and reduce postprandial 
endotoxemia. Probiotics and whey peptides enhanced mucin secretion in vitro (Mack, Michail et 
al. 1999, Martínez-Maqueda, Miralles et al. 2012). In addition, yogurt consumption increased 
sIgA production in both adults and children (Link-Amster, Rochat et al. 1994, Yang and Sheu 
2012). Moreover, yogurt and its associated probiotics could help maintain tight junction integrity. 
For example, in a rat model, yogurt with B. lactis prevented the increase in intestinal 
permeability induced by partial restraint stress by restoring expression of occludins and 
junctional adhesion molecules (Agostini, Goubern et al. 2012). Supplemental calcium also 
inhibited loss of tight junction function in diabetic rats (Stuart, Sun et al. 1994, Leal, Martins et 
al. 2010). 
Data on plasma LPS would improve our ability to interpret LBP and sCD14 changes. 
However, direct measurement of low-levels of plasma LPS is challenging, due to its short half-
life, low blood concentration and the difficulty of removing interferences in blood (Novitsky 
1998, Munford 2005). LPS measurement also does not take into account of other bacterial 
compounds such as glycolipids and lipoproteins derived from pathogenic Gram-positive bacteria 
that can stimulate inflammation (Schroder and Schumann 2005). In addition, direct measure of 
gut permeability with sugar (lactulose and mannitol) absorption test, and the expression of tight 
junction proteins might also facilitate the assessment of endotoxemia and intestinal barrier 
function (Gummesson, Carlsson et al. 2011, Teixeira, Souza et al. 2012). 
4.6 Conclusion 
 Yogurt consumption suppressed the postprandial increases of IL-6 and LBP/sCD14 ratio 
in obese participants. Pre-consumption of yogurt also reduced the postprandial increase in 
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glucose in the obese participants and attenuated the postprandial hypoglycemia in lean 
participants. A further 9-week consumption of yogurt seemed to further improve the acute 
benefits of pre-meal yogurt consumption on postprandial inflammation. Thus, pre-meal yogurt 
consumption is a feasible strategy to improving postprandial metabolism in lean and obese 
individuals. Because increased postprandial dysmetabolism and endotoxin exposure contribute to 
chronic inflammation, we examined the effect of yogurt consumption on chronic inflammatory 
status, as discussed in Chapter 5. 
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Chapter 5: Effects of Low-fat Yogurt 
Consumption on Chronic Inflammation and 
Endotoxemia in Apparently Healthy 
Premenopausal Women 
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5.1 Abstract 
Background: Diet may prevent low-grade endotoxemia and chronic inflammation associated 
with obesity. Increased dairy consumption prevents chronic inflammation in obese individuals, 
but the mechanisms for this effect are unknown. 
Objective: Our objective was to determine how increased low-fat yogurt consumption affects 
chronic inflammation and endotoxemia in apparently healthy, obese women. 
Design: Apparently healthy premenopausal women with BMI of 18.5 to 27 (lean) and 30 to 40 
kg/m2 (obese) participated in a 9-week randomized, controlled study. Participants in each BMI 
group were randomly assigned to either a low-fat yogurt-supplemented group (Y, yogurt lean; 
YO, yogurt obese) or a soy pudding-supplemented control group (C, control lean; CO, control 
obese) with n = 30/group. Participants were advised to consume 12 oz. of yogurt or the control 
food daily for 9 weeks while maintaining their usual caloric intake. Participants provided fasting 
blood samples at wk 0, 3, 6, and 9 for determination of inflammation and endotoxemia. The 
mRNA expressions of genes related to inflammation were further determined in peripheral blood 
mononuclear cells (PBMC) of obese participants at wk 0 and 9. 
Results: At baseline, obese participants had increased plasma biomarkers of chronic 
inflammation and endotoxemia compared to lean individuals. After 9 weeks, YO biomarkers of 
chronic inflammation decreased from baseline: interleukin-6 (IL-6) by 17%, high-sensitivity C-
reactive protein (hsCRP) by 9%, tumor necrosis factor alpha (TNF-α) by 7%, TNF-α/soluble 
tumor necrosis factor receptor II (sTNF-RII) by 7%. After 9 weeks, YO had 5% increased 
plasma immunoglobulin M endotoxin-core antibody (IgM EndoCAb), as well as 54% increased 
nuclear factor kappa B inhibitor alpha (IκB-α) and 20% increased transforming growth factor 
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beta 1 (TGFβ1) mRNA expression in PBMC. Y also had decreased TNF-α, TNF-α/sTNF-RII 
and increased IgM EndoCAb from baseline. Biomarkers of inflammation were unchanged in C 
and CO at 9 weeks. CO had moderate decrease in soluble CD14 (sCD14) and increase in 
lipopolysaccharide-binding protein (LBP)/sCD14 ratio. 
Conclusion: Consuming low-fat yogurt for 9 weeks reduces biomarkers of chronic inflammation 
and endotoxemia in apparently healthy premenopausal women compared to a non-dairy control 
food. This trial was registered at clinicaltrials.gov as NCT01686204. 
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5.2 Introduction 
Chronic inflammation resulting from obesity has been well characterized. Obesity 
increases adipose excretion or plasma accumulation of proinflammatory cytokines tumor 
necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte 
chemoattractant protein-1 (MCP-1), and C-reactive protein (CRP) (Kern, Ranganathan et al. 
2001, Kim, Park et al. 2006). In diet-induced obese animal models, mRNA expression and 
protein secretion of proinflammatory markers are up-regulated in adipose tissue, pancreatic islets, 
and the hypothalamus (De Souza, Araujo et al. 2005, Brake, Smith et al. 2006, Ehses, Perren et 
al. 2007). Increased chronic inflammation is proposed to contribute to comorbidity of chronic 
disease with obesity (Lumeng and Saltiel 2011).  
Unresolved low-grade obesity-associated inflammation originates from the interplay 
between immune cells and metabolic tissues such as adipose, liver, muscle, pancreas, and brain 
in response to excessive nutrient intake, leading to increased proinflammatory cytokines release 
(Gregor and Hotamisligil 2011). Inflammation is exacerbated by chronic endotoxin exposure 
resulting from compromised intestinal barrier function in obese individuals (Cani, Bibiloni et al. 
2008, Sun, Yu et al. 2010). Endotoxin, especially the Gram-negative-derived lipopolysaccharides 
(LPS) from gut microbiota, can effectively induce inflammation in humans (Kemna, Pickkers et 
al. 2005, Andreasen, Larsen et al. 2010). LPS inflammatory signaling is mediated by its 
translocation by lipopolysaccharide-binding protein (LBP) and membrane-bound or soluble 
CD14 (sCD14) to Toll-like receptor 4 (TLR4) and MD2 complex (Van Bossuyt, De Zanger et al. 
1988, Park, Song et al. 2009, Manco, Putignani et al. 2010). Furthermore, persistent postprandial 
inflammation and oxidative stress is exacerbated by obesity and contribute to chronic 
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inflammation (Burdge and Calder 2005, Esposito, Ciotola et al. 2007, Calder, Ahluwalia et al. 
2011). 
Yogurt consumption appears to be a promising strategy to improve obesity-associated 
intestinal barrier dysfunction and prevent chronic inflammation. Consuming yogurt containing 
lactobacillus reduces surrogate markers of endotoxemia and decreases intestinal permeability 
(Zeng, Li et al. 2008, Schiffrin, Parlesak et al. 2009). Consumption of yogurt containing L. 
acidophilus and B. lactis decreases fecal haptoglobin in elderly individuals (Matsumoto, Ohishi 
et al. 2001). Consumption of yogurt containing L. acidophilus and B. lactis decreases serum IL-6 
in children (Yang and Sheu 2012). Epidemiological studies show increased dairy consumption  is 
associated with decreased risk of chronic diseases such as cardiovascular diseases, type 2 
diabetes and hypertension (Warensjö, Jansson et al. 2010, Tong, Dong et al. 2011, Ralston, Lee 
et al. 2012, Sluijs, Forouhi et al. 2012). However, the effect of yogurt consumption on 
inflammation and endotoxemia in obese population is still largely unknown. We hypothesized 
that regular consumption of a commercial low-fat yogurt would reduce biomarkers of chronic 
inflammation and low-grade endotoxemia in healthy premenopausal women. We tested this 
hypothesis by conducting a randomized trial using a macronutrient- and texture-matched non-
dairy food as a control.    
5.3 Material and Methods 
5.3.1 Study participants 
Obese and lean women were recruited to participate in the study as described in Section 
3.3.1. 
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5.3.2 Experimental design 
A randomized, controlled study was used to determine the effects of yogurt consumption 
on chronic inflammation and intestinal barrier function relative to consumption of a non-dairy 
control snack (Figure 5.1). This study was powered to detect an 8.2% difference of sCD14, the 
primary outcome (Laugerette, Vors et al. 2011). The recruitment, initial prescreening, enrollment, 
compliance, and completion rate of 128 subjects were previously described in Section 3.3.3.  
Briefly, n = 30 participants from each group: YO, yogurt obese; CO, control obese; Y, yogurt 
lean; C, control lean completed all study visits.  
 
Figure 5.1 Experimental design of chronic study. 
After 2 weeks of washout, lean and obese subjects were randomly assigned to either consume 12 
oz. of yogurt or a non-dairy control food for 9 weeks. Starting at wk 0, participants visited the study 
center every 3 weeks till the end of wk 9 to provide a fasting blood sample. 
To avoid confounding by probiotic or dairy consumption, the participants restricted 
consumption of dietary supplements, fermented foods and limited their dairy consumption to ≤ 4 
servings/day for 2 weeks before the intervention (washout period, wk -2 to wk 0) and throughout 
the intervention. From the beginning of wk 0 to the end of wk 9 (intervention period), the 
subjects consumed 12 oz. of yogurt or the control food daily. The composition of the 
Visit 5 (wk 9)
Fasting blood
Visit 4 (wk 6)
Fasting blood
Visit 3 (wk 3)
Fasting blood
Intervention
Visit 2 (wk 0)
Fasting blood
Visit 1 (wk -2)
Screening
Washout
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intervention foods were described in Section 3.3.2. Participants visited the study center at wk 0, 
3, 6 and 9 to provide fasting blood samples. Fasting blood samples were collected from the 
antecubital vein into evacuated tubes containing ethylenediaminetetraacetic acid (EDTA) or 
sodium heparin (Becton, Dickinson and Company, Franklin Lakes, NJ). At wk 0 and 9, 
peripheral blood mononuclear cells (PBMC) were immediately isolated from 20 mL of sodium 
heparin-blood samples for later mRNA analysis as described in Section 5.3.6, below. For 
biomarker analysis, plasma was prepared from blood samples held on ice and centrifuged (4°C, 
15 min, 1500 × g) within 20 min of collection. Aliquots from the upper layer of plasma were 
snap-frozen in liquid nitrogen. All samples were stored at -80 °C until analysis. 
5.3.3 Inflammatory markers  
IL-6 and TNF-α in EDTA plasma were measured by human high-sensitive ELISA kits 
(IL-6, Cat # SS600B; TNF-α, Cat # SSTA00D; R&D System, Minneapolis, MN). Soluble TNF-
Receptor II (sTNF-RII) was measured by a human ELISA kit (Cat# SRT200; R&D System, 
Minneapolis, MN). High-sensitivity C-reactive protein (hsCRP) was measured by a human 
ELISA kit (Cat # BC-1119; BioCheck Inc., Foster City, CA). All the measurements were 
performed on a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA), 
following the manufacturers’ instruction. 
5.3.4 Endotoxemia markers 
LBP and immunoglobulin M Endotoxin-core antibody (IgM EndoCAb) in EDTA plasma 
were measured by human ELISA kits (LBP, Cat # HK315; IgM EndoCAb, Cat # HK504-IGM; 
Hycult Biotech, Uden, Netherlands). Sodium heparin plasma sCD14 was measured by a human 
ELISA kit (Cat # DC140; R&D System, Minneapolis, MN). All the measurements were 
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performed on a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA), 
following the manufacturers’ instruction. The ratio between LBP and sCD14 was calculated as a 
marker for endotoxemia. 
5.3.5 PBMC isolation and mRNA analysis 
PBMC were isolated from sodium heparin blood by gradient centrifugation using 
Histopaque®-1077 (Sigma-Aldrich, St. Louis, MO), following the manufacturer’s instruction 
with minor modifications. Briefly, 20 mL blood was diluted with 15 mL isotonic, sterile, 
pyrogen-free phosphate buffered saline (PBS) (MP Biomedicals, Santa Ana, CA) and then 
carefully loaded onto 15 mL Histopaque®-1077 in a clear, 50 mL centrifuge tube. After 
centrifugation at 400 × g for 30 min at room temperature, the interface layer containing 
mononuclear cells was collected and washed twice with PBS. Cell number was then determined 
on a TC10™ automated cell counter (Bio-Rad, Hercules, CA) and around 1 × 106 cells were 
transferred to a new centrifuge tube and pelleted at 250 × g for 10 min at room temperature. The 
pellet was suspended in 1 mL RNAlater (Life Technologies, Carlsbad, CA), mixed well by 
vortexing, and stored at 4 °C overnight. The next day, the cells were pelleted at 8000 × g for 5 
min at 4 °C and stored at -80 °C until RNA extraction. 
 RNA was extracted by TRIzol reagent (Life Technologies, Carlsbad, CA) following the 
manufacturer’s recommended protocol. Briefly, cells were homogenized by pipetting up and 
down in TRIzol reagent. Chloroform (Fisher Scientific, Pittsburgh, PA) was added for phase 
separation, and aqueous phase was removed and mixed with isopropanol (Fisher Scientific, 
Pittsburgh, PA) to precipitate RNA. RNA was pelleted by centrifugation, washed with 75% 
ethanol (Fisher Scientific, Pittsburgh, PA), and dissolved in RNase-free water (Dot Scientific, 
 147 
 
Burton, MI). The extracted RNA was further purified using an RNeasy mini kit (Qiagen, 
Valencia, CA). Briefly, the RNA solution was mixed with the supplied lysis buffer and ethanol, 
and then loaded onto a column, digested with an RNase-free DNase (Qiagen, Valencia, CA) and 
RNA was eluted with RNase-free water. RNA concentration was then determined by 
fluorometric quantitation on a Qubit (Life Technologies, Carlsbad, CA). Then, cDNA was 
synthesized from 1 μg RNA using an iScript™ cDNA synthesis kit (Bio-Rad, Hercules, CA) on 
a Veriti® thermal cycler (Life Technologies, Carlsbad, CA), resulting in a 20 μL reaction 
volume. Then, 5 μL of the newly synthesized cDNA product was pooled for preparation of a 
standard curve. 
 Reverse transcription quantitative PCR (RT-qPCR) was performed using the iTaq™ 
Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA), on a Bio-Rad CFX96 system 
(Bio-Rad, Hercules, CA), following the manufacture’s protocol. To prevent amplification of 
genomic DNA, specific primers were designed by the NCBI primer design tool to span an intron-
exon boundary of genes (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome) (Altschul, Gish et al. 1990). Primers were 
manufactured by Integrated DNA Technologies (Coralville, IA) at 25 nmol scale. The genes and 
primer sequences determined by RT-qPCR are listed in Table 5.1. The controls consisted of 
RNA18S5 and RPRL0 genes that are stably expressed in PBMC (Bas, Forsberg et al. 2004, 
Dheda, Huggett et al. 2004). The RT-qPCR reaction volume was 10 μL, consisting of 4 μL of 
20-times diluted cDNA and 6 μL of master mix (5 μL of SYBR® Green Supermix; 0.5 μL of 
each 2.5 μM primer). Each RT-qPCR run included no cDNA and no reverse transcriptase as 
negative controls. A 6-point standard curve was prepared using the 4-fold serial dilution of the 
samples cDNA pool and the unknown samples were quantified by the relative standard curve 
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method using Bio-Rad CFX manager 2.1 software (Bio-Rad, Hercules, CA) (Grala, Roche et al. 
2014). 
5.3.6 Statistical analysis 
All results were expressed as mean ± standard error. Statistical analysis was conducted on 
SAS 9.4 software (Cary, NC). The significance level was set at α = 0.05 for all tests. At baseline, 
the differences of Y vs. C, and YO vs. CO were analyzed by independent T-test. Pearson 
correlation coefficients of paired markers were analyzed by linear regression modeling. Time-
dependent changes of IL-6 and sCD14 in each group were determined by repeated-measures 
ANOVA with Dunnett's test for multiple comparisons. At wk 9, the difference of biomarkers 
between yogurt and control treatment groups was analyzed by analysis of covariance (ANCOVA) 
with baseline as the covariate. The difference between wk 0 and wk 9 in each group was 
analyzed by paired T-test.  
5.4 Results 
At baseline, obese participants had levels of biomarkers indicative of chronic 
inflammation and endotoxemia. Relative to lean participants, obese had increased fasting plasma 
IL-6 (111%), hsCRP (135%), TNF-α (23%), LBP (28%), LBP/sCD14 ratio (27%), but 31% less 
plasma IgM EndoCAb than the lean participants (Table 5.2). However, the baseline biomarkers 
within lean or obese groups were not different. Baseline plasma biomarkers of chronic 
inflammation, IL-6, hsCRP, TNF-α, and sTNF-RII were correlated in all study participants 
(Table 5.3). Among the markers for endotoxemia, LBP and IgM EndoCAb were negatively 
correlated (r = - 0.3431, P = 0.0002). No other correlation between endotoxemia markers were 
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identified. Furthermore, fasting plasma LBP was more strongly correlated to proinflammatory 
biomarkers markers than sCD14 and IgM EndoCAb. 
The average concentrations of IL-6 and sCD14 at wk 0, 3, 6, and 9 in each group are 
presented in Appendix A.3 Supplementary Table 5.1. The average concentrations of hsCRP, 
TNF-α, sTNF-RII, TNF-α/sTNF-RII ratio, LBP, LBP/sCD14 ratio, and IgM EndoCAb at wk 0 
and 9 in each group are presented in Appendix A.3 Supplementary Table 5.2. 
5.4.1 Fasting plasma inflammation markers 
YO plasma IL-6 decreased by 17% from baseline after 3 weeks, which was further 
maintained at wk 6 and 9. However, at wk 3, 6 and 9, YO and CO IL-6 were not significantly 
different, given the lower baseline CO IL-6 (Figure 5.2). Y, C, and CO IL-6 was unchanged 
from baseline during 9 weeks. Similar to IL-6, YO plasma hsCRP decreased by 9% from 
baseline at wk 9 (Figure 5.3). After adjusting for baseline, YO tended to have lower hsCRP than 
CO (2.42 ± 0.32 vs. 2.98 ± 0.32 mg/L, P = 0.1088). In contrast, Y, C, and CO hsCRP were 
unchanged at wk 9. YO and Y plasma TNF-α decreased by 7% and 9%, respectively at wk 9 
(Figure 5.4). In addition, Y had 13% lower TNF-α than C at wk 9. YO plasma sTNF-RII 
increased by 4%. Because of these changes, YO and Y TNF-α/sTNF-RII ratio decreased by 7% 
each. 
5.4.2 Fasting plasma endotoxemia biomarkers 
Plasma LBP was unchanged in all groups at wk 9 (Figure 5.5 A and B). At wk 3, 6, and 
9, CO fasting plasma sCD14 decreased by 6%, 10%, and 8%, respectively from baseline. C 
fasting plasma sCD14 decreased by 7% temporarily at wk 3 and returned to baseline at wk 6 and 
9. In contrast, YO and Y sCD14 was unchanged by the intervention (Figure 5.5 C and D). The 
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LBP/sCD14 ratio, a marker of endotoxemia, increased by 17% in C, and by 11% in CO but did 
not change in Y and YO (Figure 5.5 E and F). The LBP/sCD14 ratio was 9% higher in CO than 
in YO. Y and YO plasma IgM EndoCAb increased by 6% and 5%, respectively (Figure 5.6). Y 
also had 10% higher IgM EndoCAb than C at wk 9.  
5.4.3 Expression of mRNA in PBMC 
We determined the change in PBMC mRNA expression of several key factors and 
downstream target genes involved in the TLR4/NF-κB pathway including TLR4 (encoding Toll-
like receptor 4), RELA (encoding p65 subunit of nuclear factor kappa B), NFKBIA (encoding 
nuclear factor kappa B inhibitor alpha), PTGS2 (encoding cyclooxygenase-2), NCF1 (encoding 
the p47 subunit of nicotinamide adenine dinucleotide phosphate-oxidase, or NADPH oxidase), 
TNF (encoding tumor necrosis factors), and IFNG (interferon-γ) and the mRNA expression of 
TGFB1 (encoding transforming growth factor beta 1, or TGFβ1), a key factor in the resolution of 
inflammation. The analysis focused on obese individuals, given the greater magnitude of changes 
in biomarkers of endotoxemia and chronic inflammation. At baseline, YO and CO gene 
expression did not differ (Figure 5.7). After 9 weeks, YO NFKBIA and TGFB1 increased by 54% 
and 20% from baseline, respectively (Figure 5.8). In addition, YO had 36% more increase in 
TGFB1 than CO. In contrast, CO mRNA expression of the genes in the present study was 
unchanged at wk 9 from baseline. 
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Table 5.1 Primer sequences of target and reference PBMC genes. 
Name 
GenBank accession 
number Forward  (primer sequence 5′–3′) Reverse  (primer sequence 5′–3′) 
RNA18S5 NR_003286.2  CTG AGA AAC GGC TAC CAC ATC GCC TCG AAA GAG TCC TGT ATT G 
RPLP0 NM_001002.3 CTC GTG GAA GTG ACA TCG TCT GCT TGG AGC CCA CAT TGT CT 
TLR4 NM_003266.3 GTC CCT GAA CCC TAT GAA CTT T AAC CAG CCA GAC CTT GAA TAC 
RELA NM_001145138.1 CCA GAC CAA CAA CAA CCC CT GGG GGC ACG ATT GTC AAA GA 
NFKBIA NM_020529.2 GAG CTC CGA GAC TTT CGA GG TGT AGA CAC GTG TGG CCA TT 
PTGS2 NM_000963.3 AAC TGC TCA ACA CCG GAA T CCC TTG AAG TGG GTA AGT ATG TAG 
NCF1 NM_000265.5 CTG AGC CCA ACT ATG CAG GT TGA CGT CGT CTT TCC TGA TG 
TNF NM_000594.3 CCT CTC TCT AAT CAG CCC TCT AGG GTT TGC TAC AAC ATG GG 
IFNG NM_000619.2 GGC TTT TCA GCT CTG CAT CG TCT GTC ACT CTC CTC TTT CCA 
TGFB1 NM_000660.5 CGA CTC GCC AGA GTG GTT AT CGG TAG TGA ACC CGT TGA TGT 
RNA18S5, encoding 18s rRNA; RPLP0, encoding ribosomal protein large P0; TLR4, encoding Toll-like receptor 4; RELA, encoding p65 subunit of 
nuclear factor kappa B; NFKBIA, encoding nuclear factor kappa B inhibitor alpha; PTGS2, encoding cyclooxygenase-2, or COX-2; NCF1, 
encoding the p47 subunit of nicotinamide adenine dinucleotide phosphate-oxidase, or NADPH oxidase; TNF, encoding tumor necrosis factors, or 
TNF; IFNG, encoding interferon-γ; TGFB1, encoding transforming growth factor beta 1, or TGFβ1. 
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Table 5.2 Fasting baseline characteristics enrolled participants (mean ± standard error, n = 30/group). 
Characteristic (unit) 
Group Significance (P)1 
C CO Y YO P VS. C 
CO VS. 
YO 
Obese VS. 
Lean 
Age (year) 25.3 ± 1.1 31.9 ± 1.6 24.8 ± 0.8 36.7 ± 2.0 0.7603 0.0609 <.0001 
Height (m) 1.66 ± 0.01 1.65 ± 0.01 1.67 ± 0.01 1.65 ± 0.01 0.7534 0.6489 0.2883 
Weight (kg) 62.3 ± 1.6 93.5 ± 2.2 64.7 ± 1.5 94.1 ± 1.9 0.2788 0.8336 <.0001 
BMI (kg/m2) 22.5 ± 0.4 34.3 ± 0.5 23.3 ± 0.5 34.4 ± 0.7 0.2603 0.9670 <.0001 
IL-6 (pg/mL) 0.74 ± 0.08 1.56 ± 0.13 0.88 ± 0.13 1.86 ± 0.22 0.3941 0.2487 <.0001 
LBP (μg/mL) 9.9 ± 0.9 12.4 ± 0.7 9.3 ± 0.6 12.3 ± 0.9 0.6044 0.9302 0.0010 
sCD14(ng/mL) 1421 ± 50 1481 ± 45 1402 ± 59 1388 ± 45 0.7993 0.1539 0.6579 
LBP/sCD14 7.14 ± 0.69 8.62 ± 0.58 6.89 ± 0.44 9.13 ± 0.73 0.7584 0.5881 0.0032 
hsCRP (mg/L) 1.24 ± 0.26 2.97 ± 0.31 1.15 ± 0.21 2.63 ± 0.37 0.7872 0.4840 <.0001 
TNF-α (pg/mL) 1.10 ± 0.07 1.25 ± 0.1 1.14 ± 0.09 1.52 ± 0.12 0.7755 0.0815 0.0104 
sTNF-RII (pg/mL) 2125 ± 72 2452 ± 94 2028 ± 69 2550 ± 101 0.3362 0.4827 <.0001 
IgM EndoCAb (MMU/mL) 99.6 ± 10.6 70.7 ± 4.2 101.4 ± 10.1 68.7 ± 7.1 0.9078 0.8091 0.0004 
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Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; BMI, body mass index; IL-6, interleukin 6; LBP, 
lipopolysaccharide-binding protein; sCD14, soluble CD14; hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor alpha; sTNF-
RII, soluble tumor necrosis factor receptor II; IgM EndoCAb, immunoglobulin M endotoxin-core antibody. 
1 Differences between yogurt and pudding treatment groups in non-obese [P (C vs. Y)] and obese individuals [P (CO vs. YO)], and the differences 
between obese and lean subjects [P (Obese vs. Lean)] were determined by independent T-test (PROC TTEST).  
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Table 5.3 Pearson correlation coefficients between paired markers of all participants at baseline. 
    IL-6 hsCRP TNF-α sTNF-RII LBP sCD14 
hsCRP 
r1 0.3788           
P2 <.0001           
TNF-α 
r1 0.2880 0.1965 
    P2 0.0017 0.0337 
    
sTNF-RII 
r1 0.3140 0.3017 0.3891       
P2 0.0005 0.0008 <.0001       
LBP 
r1 0.3634 0.5411 0.0663 0.2392 
  P2 <.0001 <.0001 0.4754 0.0088 
  
sCD14 
r1 0.1590 0.1819 -0.0864 0.2855 0.0979   
P2 0.0854 0.0467 0.3523 0.0016 0.2874   
IgM 
EndoCAb 
r1 -0.1426 -0.1336 -0.0671 -0.2500 -0.3431 -0.0908 
P2 0.1234 0.1473 0.4701 0.0061 0.0002 0.3281 
Abbreviations: IL-6, interleukin 6; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14; 
hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor alpha; sTNF-RII, soluble tumor 
necrosis factor receptor II; IgM EndoCAb, immunoglobulin M endotoxin-core antibody. 
1 Pearson correlation coefficient. 
2 P value. 
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Figure 5.2 Fasting plasma interleukin 6 (IL-6) of (A) obese and (B) lean participants at baseline 
and after consuming 12 oz. of yogurt or a non-dairy control food daily for 9 weeks. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese (n = 30/group). Group differences at 
wk 9 were tested for significance by ANCOVA using baseline level as a covariate. Within-group 
differences between wk 0 and wk 9 means were tested by paired T-test. # Significantly different from YO 
baseline, P < 0.05.  
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Figure 5.3 Fasting plasma high-sensitivity C-reactive protein (hsCRP) in (A) obese and (B) lean 
participants at baseline and after consuming 12 oz. of yogurt or a non-dairy control food daily for 
9 weeks. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese (n = 30/group). Between-group 
differences in wk 9 means were assessed by ANCOVA with baseline as a covariate. Within-group 
differences between wk 0 and wk 9 means were compared by paired T-test. # Significantly different from 
YO baseline, P < 0.05.  
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 Figure 5.4 Fasting plasma tumor necrosis factor alpha (TNF-α) of (A) obese and (B) lean, 
soluble tumor necrosis factor receptor II (sTNF-RII) of (C) obese and (D) lean, and TNF-
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α/sTNF-RII ratio of (E) obese and (F) lean participants at baseline and after consuming 12 oz. of 
yogurt or a non-dairy control food daily for 9 weeks. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese (n = 30/group). Between-group 
difference of wk 9 means were compared by ANCOVA with baseline as a covariate. Within-group 
differences between wk 0 and wk 9 means were compared by paired T-test. # Significantly different from 
YO or Y baseline, P < 0.05. $ Significantly different between the YO and CO, or Y and C, P < 0.05. 
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Figure 5.5 Fasting plasma lipopolysaccharide-binding protein (LBP) of (A) obese and (B) lean, 
soluble CD14 (sCD14) of (C) obese and (D) lean, and LBP/sCD14 ratio of (E) obese and (F) 
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lean participants at baseline and after consuming 12 oz. of yogurt or a non-dairy control food 
daily for 9 weeks. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. Between-group differences of wk 9 
means were compared by ANCOVA with baseline as a covariate. Within-group differences between wk 0 
and wk 9 means were compared by paired T-test. * Significantly different from C or CO baseline, P < 
0.05. $ Significantly different between CO and YO, P < 0.05. 
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Figure 5.6 Fasting plasma immunoglobulin M endotoxin-core antibody (Ig M EndoCAb) in (A) 
obese and (B) lean participants, after consuming 12 oz. of yogurt or a control food daily for 9 
weeks. 
C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese (n = 30/group). Group differences at 
wk 9 were compared by ANCOVA with baseline as the covariate. The means of wk 0 and wk 9 within 
each group were compared by paired T-test. P < 0.05. # Significantly different from YO or Y baseline, P 
< 0.05. $ Significantly different between Y and C, P < 0.05. 
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Figure 5.7 Baseline fasting PBMC relative gene expression, normalized to 18s rRNA and 
RPLP0.  
CO, control obese; YO, yogurt obese (n = 30/group). The relative expression of target genes between 
groups was compared by independent T-test. No significant differences between YO or CO gene 
expression was detected. TLR4, encoding Toll-like receptor 4; RELA, encoding p65 subunit of nuclear 
factor kappa B; NFKBIA, encoding nuclear factor kappa B inhibitor alpha; PTGS2, encoding 
cyclooxygenase-2, or COX-2; NCF1, encoding the p47 subunit of nicotinamide adenine dinucleotide 
phosphate-oxidase, or NADPH oxidase; TNF, encoding tumor necrosis factors, or TNF; IFNG, encoding 
interferon-γ; TGFB1, encoding transforming growth factor beta 1, or TGFβ1. 
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Figure 5.8 Fold-change of fasting PBMC gene expression between wk 0 to wk 9, during which 
obese participants consumed 12 oz. of yogurt or control food daily. 
CO, control obese; YO, yogurt obese (n = 30/group). The fold-change from baseline of target genes 
between groups was compared by independent T-test. The difference between wk 0 and wk 9 in each 
group was compared by paired T-test.  # Significantly different from YO baseline, P < 0.05. 
$ Significantly different between YO and CO, P < 0.05. TLR4, encoding Toll-like receptor 4; RELA, 
encoding p65 subunit of nuclear factor kappa B; NFKBIA, encoding nuclear factor kappa B inhibitor 
alpha; PTGS2, encoding cyclooxygenase-2, or COX-2; NCF1, encoding the p47 subunit of nicotinamide 
adenine dinucleotide phosphate-oxidase, or NADPH oxidase; TNF, encoding tumor necrosis factors, or 
TNF; IFNG, encoding interferon-γ; TGFB1, encoding transforming growth factor beta 1, or TGFβ1. 
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5.5 Discussion 
 Daily consumption of 12 oz. of low-fat yogurt for 9 weeks reduced biomarkers for 
inflammation and low-grade endotoxemia in both lean and obese women relative to those 
consuming a non-dairy control snack. Yogurt consumption reduced plasma TNF-α and TNF-
α/sTNF-RII ratio but increased IgM EndoCAb in both lean and obese individuals, and further 
reduced IL-6 and hsCRP in obese individuals. Yogurt consumption also upregulated IκB-α and 
TGFβ1 mRNA expression in PBMC in obese participants. These improvements occurred despite 
~ 0.9 kg weight gain in YO and CO, and were concurrent with reduced postprandial metabolic 
dysregulation in YO (Chapters 3 and 4). 
5.5.1 Chronic inflammation 
Inflammation has a pivotal role in linking obesity to various metabolic diseases (Lumeng 
and Saltiel 2011). Increased IL-6, hsCRP, and TNF-α have been associated with obesity in both 
adults and children (Panagiotakos, Pitsavos et al. 2005, Mauras, DelGiorno et al. 2010). This is 
corroborated by higher baseline plasma IL-6, hsCRP, and TNF-α in obese compared to lean 
participants in the present study. The reported levels of IL-6, hsCRP and TNF-α in obese non-
diabetic population ranges from 2.00 to 4.30 pg/mL, 0.59 to 5.98 mg/L, and 1.42 to 2.69 pg/mL, 
respectively (Bastard, Jardel et al. 2000, Esposito, Pontillo et al. 2003, Rexrode, Pradhan et al. 
2003, Maachi, Piéroni et al. 2004, Park, Park et al. 2005). The variation might be partly 
attributed to the different ELISA kits. Fasting concentrations of these biomarkers were reduced 
in individuals consuming low-fat yogurt for 9 weeks. Absolute TNF-α levels may not correspond 
to pro-inflammatory status, as sTNF-RII and other circulating TNF receptors can bind to TNF 
and inhibit its activity (Van Meijl and Mensink 2010). Thus, it is notable that low-fat yogurt 
consumption also increased plasma sTNF-RII in obese participants, and decreased the TNF-
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α/sTNF-RII ratio in both obese and lean participants. Similarly, 8-week consumption of 500 mL 
low-fat milk and 150 g low-fat yogurt increased the sTNF-RII and decreased the TNF-α/sTNF-
RII ratio in overweight and obese individuals (Van Meijl and Mensink 2010). Weight loss by 
restricted diet and exercise also led to decreased TNF-α and increased sTNF-RII (Zahorska-
Markiewicz, Olszanecka-Glinianowicz et al. 2008). The recombined form of sTNF-RII namely 
etanercept is used to improve inflammatory conditions in patients with metabolic syndrome 
(Bernstein, Berry et al. 2006). The function and regulation of sTNF-RII is not yet fully 
understood. sTNF-RII is shed from the membrane-bound forms in response to inflammatory 
stimuli which also induce TNF-α secretion (Porteu and Nathan 1990).  The shedding results in 
decreased membrane-bound TNF receptor, thus inhibiting TNF-α activity (Van Zee, Kohno et al. 
1992).  Given the reproducible effect of dairy products to modulate sTNF-RII, it may be 
worthwhile to elucidate the mechanism by which this occurs. 
Intervention studies on the immune-modulating and anti-inflammatory effects of yogurt 
consumption are limited. In elderly individuals, consumption of 100 g/day yogurt containing L. 
acidophilus and B. lactis for 2 weeks decreased fecal haptoglobin, but plasma inflammatory 
biomarkers were not determined (Matsumoto, Ohishi et al. 2001). In children with H. pylori, 400 
mL/day yogurt containing L. acidophilus and B. lactis for 4 weeks decreased serum IL-6 (Yang 
and Sheu 2012). In inflammatory bowel disease (IBD) patients, consumption of 125 g of yogurt 
containing L. rhamnosus and L. reuteri for 30 days led to increase in regulatory CD4+ CD25high 
T cells and decreases the percentage of TNF-α- or IL-12-producing monocytes and dendritic 
cells (Lorea Baroja, Kirjavainen et al. 2007). Although yogurt composition, dosage, intervention 
period, and participant population have varied in these studies, it appears these data support the 
intestinal and systemic anti-inflammatory activity of yogurt. The yogurt in the present study is a 
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commercially available product that contains conventional yogurt starter cultures (Section 3.3.2) 
and is more representative of typical yogurt products in the U.S. Thus, the present data suggest 
that probiotic fortification is not necessary in yogurt to modulate chronic inflammatory 
biomarkers in apparently healthy women. It is worth of noting that although yogurt consumption 
decreased the levels of inflammatory biomarkers in obese participants, the resulting levels were 
still higher than that in the lean participants. Thus, dietary intervention might be assisted by other 
strategies such as losing weight, exercise and pharmaceutical approaches to manage obesity-
associated inflammation. 
5.5.2 Chronic endotoxemia 
Obesity is associated with subclinical endotoxemia, which increases chronic 
inflammation (Cani, Amar et al. 2007, Andreasen, Larsen et al. 2010). Direct quantitation of LPS 
is challenging, due to its short half-life, low blood concentrations and the difficulty of removing 
interference from the blood matrix (Novitsky 1998, Munford 2005). In addition, determination of 
LPS alone neglects other proinflammatory bacterial compounds such as glycolipids and 
lipoproteins derived from pathogenic Gram-positive bacteria (Schroder and Schumann 2005). 
LBP and sCD14 have been proposed as surrogate markers of endotoxemia because of their roles 
in sequestering and translocating LPS and other bacterial compounds to inflammatory signaling 
pathways (Schroder and Schumann 2005). LBP also accelerates LPS-lipoprotein binding in vitro, 
especially to chylomicrons, which reduces LPS toxicity of LPS and PBMC proinflammatory 
cytokines increase (Vreugdenhil, Rousseau et al. 2003). Moreover, LBP promotes the 
detoxification of lipoteichoic acid, a cell wall component of Gram-positive bacteria, by 
chylomicrons (Vreugdenhil, Rousseau et al. 2003). Subclinically low LBP is considered to 
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enhance the LPS signaling while high LBP inhibits LPS-induced toxicity (Kitchens and 
Thompson 2005).  
LBP is higher in overweight/obese individuals than in normal-weight individuals, 
indicating low-grade chronic endotoxemia (Sun, Yu et al. 2010). Serum LBP is also associated 
with increased abdominal obesity, proinflammatory cytokine IL-6 and IL-8, but low 
concentrations of HDL-cholesterol (Gonzalez-Quintela, Alonso et al. 2013). Indeed, baseline 
plasma LBP of obese participants was 28% higher than lean participants, and was positively 
associated with IL-6 and hsCRP in the present study. On the other hand, fasting plasma sCD14 
was similar between the obese and lean in the present study. Similarly, sCD14 is not associated 
with obesity in another study population (n = 420, 55% females, age 18-92 year) (Gonzalez-
Quintela, Alonso et al. 2013). The increased endotoxemia in obese women is partly attributed to 
increased intestinal permeability. In healthy women, visceral adiposity is positively associated 
with intestinal permeability assessed by the ratio of urinary excretion of orally ingested sucralose 
to mannitol (Gummesson, Carlsson et al. 2011). Increased intestinal permeability assessed by 
similar sugar absorption test is associated with increased blood insulin, the homeostasis model 
assessment of insulin resistance (HOMA-IR) index, and decreased HDL concentration in obese 
women (Teixeira, Souza et al. 2012). 
Healthy men have postprandial plasma LBP/sCD14 ratios that are correlated with plasma 
endotoxin (Laugerette, Furet et al. 2012, Laugerette, Alligier et al. 2014). We observed that 
obese participants had 27% higher plasma LBP/sCD14 ratio than the lean participants at baseline, 
which suggested increased endotoxin exposure. Moderate increases in LBP/sCD14 ratio were 
found in CO and C, but not the yogurt-consuming groups, suggesting protective effects of yogurt 
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against chronic endotoxemia. The increase of LBP/sCD14 ratio in the control groups was not 
consistent with the lack of changes in IgM EndoCAb and the inflammatory markers. Reliable 
measurement of LPS might help to clarify whether LBP/sCD14 ratio is a good measure of 
changes in fasting endotoxin level.  
Fasting plasma sCD14 decreased from baseline in CO but not YO at 9 wk. Plasma sCD14 
is found to be correlated with central adiposity (de Courten, Moreno-Navarrete et al. 2015), but 
not in the present study participants and others (Gonzalez-Quintela, Alonso et al. 2013). Thus, it 
is difficult to interpret the association of this change with chronic endotoxemia. Plasma sCD14 in 
healthy adults is ~ 1000-fold molar more than the LPS level in fatal septic shock patients so the 
magnitude of change in the present study bears consideration (Wright 1991, Bas, Gauthier et al. 
2004). Also, sCD14 improves insulin sensitivity in obese individuals (de Courten, Moreno-
Navarrete et al. 2015), which is consistent with reduced postprandial glucose levels in YO 
relative to CO (Chapter 4).  
The inner core of endotoxin is considered as the only molecular pattern that is conserved 
across various gram-negative bacteria. IgM EndoCAb can bind to this molecular pattern, thus 
protecting against endotoxin. (Poxton 1995). Decreased EndoCAb has been proposed as a 
marker of endotoxin exposure (Barclay 1995). In a cross-sectional study involving 93 age-
matched middle-aged women, IgM EndoCAb is lower in the obese (55% of lean women) and 
obese diabetic women (30% of lean women) (Hawkesworth, Moore et al. 2013). Similarly, IgM 
EndoCAb level in obese participants was 69% of the level in lean participants in the present 
study. Yogurt consumption increased the IgM EndoCAb level in both obese and lean participants, 
suggesting lower level of endotoxin exposure resulting from the yogurt intervention. 
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Other dietary interventions have improved intestinal barrier function in various 
populations. For example, consumption of 300 g/day yogurt containing L. johnsonii for 4 weeks 
decreased plasma LBP, sCD14 and surrogate markers of LPS permeability in elderly adults with 
intestinal bacterial overgrowth (Schiffrin, Parlesak et al. 2009). In 30 diarrhea-predominant 
irritable bowel syndrome patients, consumption of 400 g/day fermented milk containing L. 
acidophilus and B. longum for 4 weeks decreased small bowel permeability assessed by sugar 
absorption test (Zeng, Li et al. 2008). In 93 healthy overweight volunteers, a gut microbiota-
targeted dietary intervention for 9 weeks (BMI ≥ 28 kg/m2) decreased gut permeability, 
concurrent with reduced LBP, TNF-α and IL-6 (Xiao, Fei et al. 2014). 
5.5.3 Gene expression in PBMC 
PBMC gene expression can be used as a biomarker of immune function and chronic 
inflammation (de Bont, Netea et al. 1998, O'Rourke, Kay et al. 2006, Holven, Retterstol et al. 
2013). To better understand the effect of low-fat yogurt consumption on chronic inflammation, 
we examined the expression of genes involved in TLR4-activitated cytokine expression in 
PBMC from obese participants. TLR4 is located on the surface of various immune cells such as 
monocytes, macrophages, Kupffer cells, and preadipocytes, and plays an essential role in sensing 
endotoxin and activating the inmate immunity (Beutler 2000, Manco, Putignani et al. 2010). 
TLR4 mRNA expression is increased in the monocytes of patients with metabolic syndromes, 
and its level is upregulated by increased exposure to LPS (Muzio, Bosisio et al. 2000, Jialal, 
Huet et al. 2012, Parajuli, Sonobe et al. 2012). Although our results suggested YO had reduced 
endotoxemia, the PBMC TLR4 was unchanged from baseline at wk 9. 
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Upon TLR4 endotoxin stimulation, a downstream signaling cascade is triggered that 
leads to activation of the NF-κB pathway (Manco, Putignani et al. 2010). Nuclear factor kappa B 
inhibitor alpha (IκBα, encoded by NFKBIA) inhibits the NF-κB pathway by trapping the 
heterodimeric complex containing p50 and p65 (encoded by RELA) in the cytosol (Scherer, 
Brockman et al. 1995). YO NFKBIA increased by 54% from baseline at wk 9 of the intervention. 
However, genes downstream of NF-κB including PTGS2 (encoding cyclooxygenase-2, or COX-
2), NCF1 (encoding the p47 subunit of nicotinamide adenine dinucleotide phosphate-oxidase, or 
NADPH oxidase), TNF (encoding tumor necrosis factors, or TNF), and IFNG (encoding 
interferon-γ) were not affected by the intervention. Given the reduction in YO plasma TNF-α, 
non PBMC sources of TNF such as the intestine, adipose tissue, or skeletal muscle may have 
contributed to this change. TGF-β1 is an anti-inflammatory and reparative cytokine that 
suppresses proinflammatory signaling from Toll-like receptors (Serhan and Savill 2005). YO 
TGFB1 (encoding TGF-β1) expression increased by 20% by the intervention. Whether PBMC is 
a major source of circulating proinflammatory cytokine and whether TGF-β1 excretion by 
PBMC reduces plasma IL-6 and hsCRP need further examination. 
5.5.4 Study limitation 
The mechanism by which yogurt improves intestinal barrier function and prevents 
chronic inflammation requires further investigation. Yogurt components, dairy proteins, calcium, 
microbes, and vitamin D are associated with decreased chronic inflammation (Lorea Baroja, 
Kirjavainen et al. 2007, Zemel and Sun 2008, Pal and Ellis 2010, Shab-Bidar, Neyestani et al. 
2012). Constant postprandial stress may increase chronic inflammation and atherosclerosis 
(Burdge and Calder 2005). Pre-meal yogurt consumption reduced postprandial hyperglycemia 
and inflammation in obese participants (Chapter 4). This effect might contribute to suppression 
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of chronic inflammation. However, we did not specify how participants should consume yogurt 
or the control food. A further analysis of three-day food records indicated that Y and YO 
consumed yogurt with 69% and 66% of meals (Appendix A.3 Supplementary Table 5.3), 
respectively. This may still not capture the yogurt-eating pattern of participants. Therefore, the 
extent the postprandial response and timing of yogurt consumption contributes to long-term anti-
inflammatory effect of yogurt consumption needs further investigation.  
5.6 Conclusion 
In summary, our work demonstrated that consuming 12 oz. of yogurt daily reduced 
chronic inflammation and endotoxemia in apparently healthy premenopausal women, which was 
in accordance with our hypothesis. Yogurt consumption decreased the plasma TNF-α and TNF-
α/sTNF-RII ratio in both obese and lean participants. Furthermore, plasma IL-6 and hsCRP 
decreased in obese participants, suggesting a further benefit of yogurt consumption on the obese 
participants. Plasma IgM EndoCAb increased in both obese and lean participants, suggesting 
decreased endotoxin exposure. Lastly, yogurt intervention upregulated NFKBIA and TGFB1 
expression in PBMC, although it did not affect the NF-κB downstream pro-inflammatory genes. 
These improvements occurred despite ~0.9 kg weight gain in YO and CO during intervention, 
and were concurrent with reduced postprandial metabolic dysregulation in YO (Chapters 3 and 
4). 
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Chapter 6: Conclusions and Future Directions 
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6.1 Conclusions 
In the present study, we tested the hypothesis that low-fat yogurt consumption would 
reduce postprandial and chronic inflammation associated with obesity by decreasing 
endotoxemia. This hypothesis was tested by a randomized, controlled, isocaloric study design in 
apparently healthy premenopausal women. In addition, the effects of yogurt consumption on 
body weight, blood pressure were examined. We found that obese participants had increased 
baseline plasma biomarkers of chronic inflammation and endotoxemia compared to lean 
individuals, indicative of metabolic dysfunction. Compared to lean individuals, obese 
participants had exacerbated postprandial inflammation, accompanied by hyperglycemia and 
increased endotoxemia after a high-fat, high-carbohydrate challenge meal. Such increases in 
inflammation, glucose and endotoxemia were suppressed concurrently by pre-meal consumption 
of yogurt in the obese. In addition, yogurt consumption reduced postprandial hypoglycemia in 
lean individuals, possibly by preventing insulin over-secretion. After 9-week daily consumption 
of 12 oz. of yogurt, obese individuals had decreased plasma biomarkers of chronic inflammation 
and endotoxemia, despite ~ 0.9 kg weight gain during intervention. Obese individuals 
experienced a temporary decrease in diastolic blood pressure after 3 weeks, but such decrease 
did not maintain at the end of intervention. These results support that low-fat yogurt 
consumption reduces postprandial and chronic inflammation, possibly by decreasing 
endotoxemia in obese individuals. This is in accordance with epidemiological studies associating 
increased dairy consumption with decreased risk of chronic diseases such as cardiovascular 
diseases, type 2 diabetes and hypertension (Warensjö, Jansson et al. 2010, Tong, Dong et al. 
2011, Ralston, Lee et al. 2012, Sluijs, Forouhi et al. 2012). In addition, the present study 
included a non-dairy dietary control food and non-obese individuals in a relatively large number 
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of participants with an isocaloric design. Our study outcomes provide increasing evidence of the 
anti-inflammatory effect of yogurt reported in prior intervention studies (Matsumoto, Ohishi et al. 
2001, Yang and Sheu 2012).  More importantly, we contribute novel evidence on the beneficial 
effects of low-fat yogurt consumption on postprandial metabolism in both obese and lean 
apparently healthy premenopausal women. Because inflammation links obesity to metabolic 
diseases, our findings on the anti-inflammatory effect of a commercially available yogurt is a 
feasible dietary recommendation for management of obesity-associated chronic inflammation. 
Diet plays a pivotal role in prevention and treatment of the metabolic consequences of obesity. 
For example, various low-carbohydrate or energy restricted diets have been developed to 
promote health in obese populations. Although some of these diets were effective during short-
term interventions, such benefits might not be sustainable due to poor adherence (Bonow and 
Eckel 2003). The good adherence to the present study intervention suggests it might be feasible 
to incorporate low-fat yogurt into habitual diet to achieve longer-term benefit.  
High-fat, high-carbohydrate foods contribute to modern diets and a “constant feeding” 
has become common due to increased food availability. Therefore, postprandial stress might 
occur regularly and pose a risk for health, especially in obese individuals who experience 
exacerbated postprandial dysmetabolism. We demonstrated that one serving of a commercially 
available yogurt before a meal could effectively reduce postprandial hyperglycemia and 
inflammation in obese individuals. After 9-week yogurt consumption, obese individuals had 
decreased levels of biomarkers for chronic inflammation, but those levels were still higher than 
that in lean participants. Therefore, other strategies such as losing weight, exercise, or 
pharmaceutical approaches should also be considered to reduce obesity-associated chronic 
inflammation. It is worth noting the lower postprandial IL-6 increases in the second challenge 
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meal test than in the first one, suggesting extra benefits on postprandial metabolism from regular 
yogurt consumption. A large cohort prospective study finds long-term yogurt consumption is 
associated with decreased body weight (Mozaffarian, Hao et al. 2011). Therefore, habitual 
yogurt consumption might deliver extra health benefits for obese individuals. Interestingly, 
yogurt consumption also protects lean individuals from hypoglycemia after a high-fat, high-
carbohydrate meal, possibly by preventing insulin over-secretion. 
Increased added sugar consumption has been linked to weight gain during short-term 
interventions (Morenga, Mallard et al. 2012). We also observed ~ 0.9 kg weight gain in obese 
participants, providing that the interventions supplied 54 g of added sugar. Although we did not 
observe negative metabolic outcomes related to the weight gain, long-term weight gain may be 
problematic. Yoplait has recently reformulated the yogurt by reducing added sugar by 25%. 
Whether such change conveys extra benefits needs further examination.  
This study was powered on soluble CD14 (sCD14), originally proposed as the primary 
biomarkers of chronic endotoxemia (Laugerette, Vors et al. 2011). However, we did not find an 
association between sCD14 and obesity at baseline. Therefore, it might not be a sensitive 
biomarker for chronic endotoxemia in this study population. Reliable direct measurement of 
endotoxin might help to determine whether sCD14 reflects chronic endotoxemia. Nevertheless, 
the increase in immunoglobulin M endotoxin-core antibody at the end of intervention supports 
the anti-endotoxemia effect of low-fat yogurt. Our results suggest that lower endotoxemia by 
yogurt consumption is accompanied by decreased inflammation both postprandially and 
chronically. To the best of our knowledge, this is the first report that consuming a low-fat 
conventional yogurt could reduce the risk of metabolic endotoxemia in apparently healthy 
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premenopausal women. Dietary intervention aimed at improving intestinal barrier function 
appears to be a promising target for reducing endotoxemia and thus inflammation. It needs to be 
pointed out that the obesity-associated endotoxemia is characterized by a two- to three times 
threshold increase in circulating endotoxin, due to impaired intestinal barrier function (Cani, 
Amar et al. 2007). The protective effects of low-fat yogurt against metabolic endotoxemia might 
not apply to clinical endotoxemia that is associated with to septic shock. 
6.2 Future directions 
We demonstrated that low-fat yogurt consumption could reduce postprandial and chronic 
inflammation, possibly by decreasing endotoxemia in obese individuals. However, the 
mechanism by which yogurt improves acute postprandial and chronic intestinal barrier function 
is still unclear. Animal or in vitro models might be better tools to examine the effects of low-fat 
yogurt consumption on change in intestinal barrier function. For example, whether the beneficial 
effect is mediated by modulating gut microbiota or the tight junction integrity might be study of 
interest. In addition, direct assessment of gut permeability such as sugars (lactulose and mannitol) 
absorption test might be incorporated in future studies. Furthermore, we found that pre-meal 
consumption reduced postprandial hyperglycemia in obese individuals without affecting insulin 
secretion. Prior studies suggest such insulin-independent effect might be related to stomach 
emptying rate. But such hypothesis needs to be tested. It is also worth of exploring other 
underlying mechanisms by which low-fat yogurt modulates postprandial glycemia. For example, 
in vitro model could be used to test whether yogurt components regulate glucose transporter, 
which has been proposed as potential mechanism by which polyphenols improve glucose 
response (Kobayashi, Suzuki et al. 2000, Manzano and Williamson 2010). Lastly, we observed ~ 
0.9 kg weight gain in obese participants and increased added sugar intakes in all participants 
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after 9-week intervention. Although no negative metabolic effects associated with the weight 
gain was observed, how to avoid the weight and dietary changes in similar isocaloric study 
design needs to be considered in future studies.  
In the present study, low-fat yogurt consumption also affected the biomarker levels of 
inflammation and metabolic endotoxemia in lean participants who are considered relatively 
healthy compared to the obese individuals. The implication of such modulating effects of low-fat 
yogurt on cytokines and immune function in otherwise healthy population needs further 
investigation. 
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A.1 Appendix Materials for Chapter 3 
A.1.1 Analysis of isoflavones in soy pudding by HPLC 
Chemicals 
Hydrogen chloride (HCl) (37%) was from Acros Organics (Morris Plains, NJ). Daidzein, 
glycitein, genistein, and butylated hydroxytoluene (BHT) were from Sigma-Aldrich (St. Louis, 
MO). Ethanol, acetic acid, and acetonitrile were from Fisher Scientific (Fairlawn, NJ). Soy 
puddings of chocolate, vanilla, chocolate/vanilla swirl flavor were from ZenSoy (South 
Hackensack, NJ). 
Isoflavones extraction 
 Isoflavones were extracted according to Franke et al. with modifications (Franke, Custer 
et al. 1994). Briefly, 1 g soy pudding was added to 6.25 mL of 37% HCl and 30 mL of 96% 
ethanol (containing 0.05% BHT as antioxidant). This slurry was vortexed for 10 s followed by 
10 min of sonication at room temperature (FS140H, Fisher Scientific, Pittsburg, PA). After 
refluxing the mixture for 2 h at 90 °C, the mixture was cooled to room temperature and the 
ethanol lost during refluxing was replaced. Then, 1.2 mL of the above mixture was removed and 
centrifuged at 12,000 × g for 10 min. 
HPLC analysis 
 Isoflavones were analyzed by HPLC as previously described, with minor modifications 
(Franke, Custer et al. 1994). A Shimadzu LC-20XR system was equipped with an SPD-20AV 
detector set to 260 nm. A 10 μL injection was eluted through a 250 mm × 4.6 mm i.d., 5 μm 
Waters Xterra MS C18 column (Waters Corporation, Milford, MA, USA) via a binary gradient of 
acetic acid/water (10/90 V/V) (A) and acetonitrile (B). The proportion of B increased from 23 to 
70% over 8 min, then decreased to 23% until 9 min, and held at 23% until 21 min. Isoflavones 
were detected using authentic internal standards. 
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Results 
Table A.3.1 Isoflavones contents in soy pudding determined HPLC (mg/100g) 
Flavor Daidzein Glycitein Genistein 
Chocolate 2.00 ± 0.09 1.64 ± 0.01 5.34 ± 0.16 
Vanilla 1.84 ± 0.24 1.29 ± 0.16 4.38 ± 0.61 
Isoflavones were quantified by reverse phase resolution at 260 nm. Data are expressed as mean ± standard 
deviation of triplicate determination. 
Reference 
Franke, A. A., L. J. Custer, C. M. Cerna and K. K. Narala (1994). "Quantitation of 
Phytoestrogens in Legumes by Hplc." Journal of Agricultural and Food Chemistry 42(9): 1905-
1913. 
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A.1.2 NDSR nutrient content of the alternative substitute 
Nutrient Values 
Primary Energy Sources 
 Energy (kilocalories) 347 kcal 
Energy (kilojoules) 1452 kj 
Total Fat 3.674 g 
Total Carbohydrate 64.807 g 
Available Carbohydrate 63.786 g 
Total Protein 14.866 g 
Animal Protein 14.866 g 
Vegetable Protein 0.000 g 
Alcohol 0.000 g 
% Calories from Fat 9.31% 
% Calories from Carbohydrate 72.28% 
% Calories from Protein 18.29% 
% Calories from Alcohol 0.00% 
Fat and Cholesterol 
 Cholesterol 14 mg 
Total Saturated Fatty Acids (SFA) 2.371 g 
Total Monounsaturated Fatty Acids (MUFA) 1.010 g 
Total Polyunsaturated Fatty Acids (PUFA) 0.105 g 
Total Trans-Fatty Acids (TRANS) 0.102 g 
Total Conjugated Linoleic Acid (CLA 18:2) 0.017 g 
Omega-3 Fatty Acids 0.031 g 
% Calories from SFA 6.01% 
% Calories from MUFA 2.56% 
% Calories from PUFA 0.27% 
Polyunsaturated to Saturated Fat Ratio 0.044 
Cholesterol to Saturated Fatty Acid Index 3.075 
Carbohydrates 
 Total Sugars 55.826 g 
Fructose 7.518 g 
Galactose 3.062 g 
Glucose 8.641 g 
Lactose 12.145 g 
Maltose 1.021 g 
Sucrose 23.439 g 
Starch 0.000 g 
Added Sugars (by Total Sugars) 14.118 g 
Added Sugars (by Available Carbohydrate) 42.728 g 
Fiber 
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Total Dietary Fiber 1.021 g 
Soluble Dietary Fiber 0.269 g 
Insoluble Dietary Fiber 0.735 g 
Pectins 0.000 g 
Vitamins 
 Total Vitamin A Activity (Retinol Equivalents) 448 mcg 
Total Vitamin A Activity (International Units) 1500 IU 
Total Vitamin A Activity (Retinol Activity Equivalents) 448 mcg 
Beta-Carotene Equivalents (derived from provitamin A carotenoids) 7 mcg 
Retinol 447 mcg 
Vitamin D (calciferol) 9.999 mcg 
Vitamin D2 (ergocalciferol) 0.000 mcg 
Vitamin D3 (cholecalciferol) 9.999 mcg 
Vitamin E (International Units) 0 IU 
Vitamin E (Total Alpha-Tocopherol) 0.068 mg 
Natural Alpha-Tocopherol (RRR-alpha-tocopherol or d-alpha-tocopherol) 0.068 mg 
Synthetic Alpha-Tocopherol (all rac-alpha-tocopherol or dl-alpha-tocopherol) 0.000 mg 
Total Alpha-Tocopherol Equivalents 0.068 mg 
Beta-Tocopherol 0.000 mg 
Gamma-Tocopherol 0.000 mg 
Delta-Tocopherol 0.000 mg 
Vitamin K (phylloquinone) 0.340 mcg 
Vitamin C (ascorbic acid) 2.381 mg 
Thiamin (vitamin B1) 0.126 mg 
Riboflavin (vitamin B2) 0.606 mg 
Niacin (vitamin B3) 0.323 mg 
Niacin Equivalents 1.741 mg 
Pantothenic Acid 1.664 mg 
Vitamin B-6 (pyridoxine, pyridoxyl, & pyridoxamine) 0.136 mg 
Total Folate 31 mcg 
Dietary Folate Equivalents 31 mcg 
Natural Folate (food folate) 31 mcg 
Synthetic Folate (folic acid) 0 mcg 
Vitamin B-12 (cobalamin) 1.599 mcg 
Carotenoids 
 Beta-Carotene (provitamin A carotenoid) 7 mcg 
Alpha-Carotene (provitamin A carotenoid) 0 mcg 
Beta-Cryptoxanthin (provitamin A carotenoid) 0 mcg 
Lutein + Zeaxanthin 0 mcg 
Lycopene 0 mcg 
Minerals 
 Calcium 1000 mg 
Phosphorus 300 mg 
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Magnesium 51 mg 
Iron 0.238 mg 
Zinc 2.517 mg 
Copper 0.272 mg 
Manganese 0.221 mg 
Selenium 10.546 mcg 
Sodium 197 mg 
Potassium 460 mg 
Fatty Acids 
 SFA 4:0 (butyric acid) 0.109 g 
SFA 6:0 (caproic acid) 0.075 g 
SFA 8:0 (caprylic acid) 0.048 g 
SFA 10:0 (capric acid) 0.105 g 
SFA 12:0 (lauric acid) 0.126 g 
SFA 14:0 (myristic acid) 0.388 g 
SFA 16:0 (palmitic acid) 1.000 g 
SFA 17:0 (margaric acid) 0.000 g 
SFA 18:0 (stearic acid) 0.357 g 
SFA 20:0 (arachidic acid) 0.000 g 
SFA 22:0 (behenic acid) 0.000 g 
MUFA 14:1 (myristoleic acid) 0.000 g 
MUFA 16:1 (palmitoleic acid) 0.082 g 
MUFA 18:1 (oleic acid) 0.840 g 
MUFA 20:1 (gadoleic acid) 0.000 g 
MUFA 22:1 (erucic acid) 0.000 g 
PUFA 18:2 (linoleic acid) 0.075 g 
PUFA 18:3 (linolenic acid) 0.031 g 
PUFA 18:4 (parinaric acid) 0.000 g 
PUFA 20:4 (arachidonic acid) 0.000 g 
PUFA 20:5 (eicosapentaenoic acid [EPA]) 0.000 g 
PUFA 22:5 (docosapentaenoic acid [DPA]) 0.000 g 
PUFA 22:6 (docosahexaenoic acid [DHA]) 0.000 g 
TRANS 16:1 (trans-hexadecenoic acid) 0.000 g 
TRANS 18:1 (trans-octadecenoic acid [elaidic acid]) 0.068 g 
TRANS 18:2 (trans-octadecadienoic acid [linolelaidic acid]; incl. c-t, t-c, t-t) 0.000 g 
CLA cis-9, trans-11 0.014 g 
CLA trans-10, cis-12 0.003 g 
Amino Acids 
 Tryptophan 0.085 g 
Threonine 0.609 g 
Isoleucine 0.810 g 
Leucine 1.497 g 
Lysine 1.334 g 
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Methionine 0.439 g 
Cystine 0.136 g 
Phenylalanine 0.810 g 
Tyrosine 0.752 g 
Valine 1.232 g 
Arginine 0.449 g 
Histidine 0.367 g 
Alanine 0.636 g 
Aspartic Acid 1.180 g 
Glutamic Acid 2.912 g 
Glycine 0.357 g 
Proline 1.762 g 
Serine 0.922 g 
Isoflavones and Similar 
 Daidzein 0.000 mg 
Genistein 0.000 mg 
Glycitein 0.000 mg 
Coumestrol 0.000 mg 
Biochanin A 0.000 mg 
Formononetin 0.000 mg 
Sugar Alcohols (polyols) 
 Erythritol 0.000 g 
Inositol 0.024 g 
Isomalt 0.000 g 
Lactitol 0.000 g 
Maltitol 0.000 g 
Mannitol 0.000 g 
Pinitol 0.000 g 
Sorbitol 0.058 g 
Xylitol 0.007 g 
Other 
 Acesulfame Potassium 0.000 mg 
Aspartame 0.000 mg 
Saccharin 0.000 mg 
Sucralose 0.000 mg 
Tagatose 9.866 mg 
Caffeine 0 mg 
Phytic Acid 2.279 mg 
Oxalic Acid 1.783 mg 
3-Methylhistidine 0.000 mg 
Sucrose Polyester 0.000 g 
Choline 47.627 mg 
Betaine 2.722 mg 
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Glycemic Index (glucose reference) 33 
Glycemic Index (bread reference) 47 
Glycemic Load (glucose reference) 21 
Glycemic Load (bread reference) 30 
Nitrogen 2.347 g 
Ash 3.470 g 
Water 253.377 g 
Grams 340.194 g 
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A.2 Appendix Materials for Chapter 4 
Supplementary Table 4.1 Postprandial plasma glucose (mg/dL) changes in two separate challenge meal tests (mean ± standard error, n = 
30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 1 
(wk 0) 
Lean 
C 86.1 ± 2.2 70.1 ± 3.1 * 68.2 ± 2.5 *$ 79.2 ± 2.8 77.9 ± 2.2 $ 
0.0793 <.0001 0.0207 
Y 84.2 ± 1.1 73.3 ± 2.7 # 77.8 ± 2.5 $ 81.3 ± 3.7 85.9 ± 2.0 $ 
Obese 
CO 89.4 ± 1.6 102.5 ± 5.1 *$ 94.7 ± 4.4 89.3 ± 2.1 86.7 ± 1.4 
0.0204 0.0007 0.0050 
YO 89.4 ± 1.4 88.1 ± 2.9 $ 88.6 ± 2.6 83.2 ± 2.0 84.5 ± 1.5 
Test 2 
(wk 9) 
Lean 
C 82.6 ± 1.4 71.3 ± 3.4 * 74.9 ± 2.6 * 76.1 ± 2.7 78.9 ± 1.8 
0.0432 <.0001 0.5848 
Y 83.4 ± 1.1 77.0 ± 2.2 # 78.6 ± 2.4 81.7 ± 1.9 83.4 ± 1.7 
Obese 
CO 93.0 ± 2.4 109.1 ± 7.2 *$ 102.1 ± 6.4 $ 90.1 ± 4.1 87.0 ± 2.9 
0.0241 <.0001 0.0015 
YO 91.2 ± 1.6 90.4 ± 3.8 $ 86.7 ± 3.9 $ 84.8 ± 2.2 83.7 ± 1.2 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in pudding treatment group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with 
time as independent variable. # Significantly different from baseline in yogurt treatment groups, P < 0.05, determined by repeated-measures 
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ANOVA (PROC MIXED) with time as independent variable. $ Significantly different between control and yogurt treatment at different time 
points, determined by ANOVA with baseline as covariate (PROC GLM). 
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Supplementary Table 4.2 Postprandial plasma TG changes (mg/dL) after challenge meals (mean ± standard error, n = 30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 1 
(wk 0) 
Lean 
C 66.9 ± 5.1 87.1 ± 5.2 * 115.3 ± 10.7 * 104.6 ± 7.3 * 99.1 ± 10.8 * 
0.8804 <.0001 0.4650 
Y 72.0 ± 7.1 93.2 ± 9.1 # 107.5 ± 10.4 # 106.5 ± 9.6 # 101.2 ± 8.5 #  
Obese 
CO 94.9 ± 7.4 120.8 ± 8.9 * 137.7 ± 10.2 * 149.2 ± 12.3 * 147.4 ± 12.1 * 
0.8506 <.0001 0.1052 
YO 89.1 ± 7.7 114.4 ± 9.3 # 146.1 ± 12.8 # 157.3 ± 14 # 156.6 ± 13.3 # 
Test 2 
(wk 9) 
Lean 
C 65.3 ± 3.1 88.6 ± 5.0 * 110.4 ± 7.6 * 108.6 ± 7.3 * 101.0 ± 7.9 * 
0.7417 <.0001 0.4763 
Y 65.7 ± 5.8 86.3 ± 8.1 # 101.3 ± 9.0 # 104.4 ± 8.4 # 102.0 ± 7.9 # 
Obese 
CO 97.5 ± 7.4 128.6 ± 8.9 * 139.1 ± 9.6 * 147.8 ± 10.8 * 148.5 ± 12.0 * 
0.7489 <.0001 0.0348 
YO 91.1 ± 8.3 120.5 ± 10.9 # 150.3 ± 14.6 # 162.8 ± 16.4 # 162.3 ± 17.2 # 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in control treatment group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with time 
as independent variable. # Significantly different from baseline in yogurt treatment groups, P < 0.05, determined by repeated-measures ANOVA 
(PROC MIXED) with time as independent variable. 
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Supplementary Table 4.3 Relative postprandial plasma insulin changes (Δ μIU/mL) from baseline at second challenge meal (mean ± standard 
error, n = 30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 2 
(wk 9) 
Lean 
C 0.0 ± 0.0 43.7 ± 7.4 * 35.8 ± 7.2 * 18.9 ± 2.4 *$ 5.2 ± 1.1 
0.0357 <.0001 0.1792 
Y 0.0 ± 0.0 34.0 ± 2.8 # 22.9 ± 2.0 # 10.4 ± 1.4 #$ 4.8 ± 1.1 
Obese 
CO 0.0 ± 0.0 89.9 ± 12.8 * 80.7 ± 13.7 * 34.3 ± 9.6 * 14.4 ± 6.3 
0.7605 <.0001 0.9716 
YO 0 ± 0 89.3 ± 16.5 # 73.7 ± 17.0 # 33.5 ± 8.6 8.1 ± 2.5 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in pudding treatment group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with 
time as independent variable. # Significantly different from baseline in yogurt treatment groups, P < 0.05, determined by repeated-measures 
ANOVA (PROC MIXED) with time as independent variable. $ Significantly different between pudding and yogurt treatment at different time 
points, determined by independent T-test (PROC TTEST). 
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Supplementary Table 4.4 Relative postprandial plasma IL-6 changes (Δ pg/mL) from baseline after challenge meals (mean ± standard error, n = 
30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 1 
(wk 0) 
Lean 
C 0.0 ± 0.0 0.04 ± 0.06 0.23 ± 0.13 0.20 ± 0.10 0.62 ± 0.15 * 
0.9236 <.0001 0.5026 
Y 0.0 ± 0.0 -0.02 ± 0.07 0.07 ± 0.12 0.31 ± 0.14 0.68 ± 0.13 # 
Obese 
CO 0.0 ± 0.0 -0.01 ± 0.08 0.28 ± 0.15 0.77 ± 0.27 * 1.35 ± 0.27 *$ 
0.0879 <.0001 0.0374 
YO 0.0 ± 0.0 -0.21 ± 0.08 0.03 ± 0.14 0.50 ± 0.14 # 0.57 ± 0.19 #$ 
Test 2 
(wk 9) 
Lean 
C 0.0 ± 0.0 -0.07 ± 0.04 0.04 ± 0.07 0.28 ± 0.16 * 0.54 ± 0.18 * 
0.8424 <.0001 0.4887 
Y 0.0 ± 0.0 -0.02 ± 0.08 0.01 ± 0.08 0.30 ± 0.12 # 0.38 ± 0.14 # 
Obese 
CO 0.0 ± 0.0 0.07 ± 0.11 0.35 ± 0.15 0.65 ± 0.13 * 1.13 ± 0.21 *$ 
0.0209 <.0001 0.2459 
YO 0.0 ± 0.0 -0.15 ± 0.06 0.09 ± 0.10 0.29 ± 0.15 0.60 ± 0.12 #$ 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; IL-6, interleukin 6 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in control treatment group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with time 
as independent variable. # Significantly different from baseline in yogurt treatment groups, P < 0.05, determined by repeated-measures ANOVA 
(PROC MIXED) with time as independent variable. $ Significantly different between control and yogurt treatment at different time points, 
determined by independent T-test (PROC TTEST). 
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Supplementary Table 4.5 Relative postprandial plasma LBP changes (Δ μg/mL) from baseline after challenge meals (mean ± standard error, n = 
30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 1 
(wk 0) 
Lean 
C 0.00 ± 0.00 0.19 ± 0.17 -0.09 ± 0.17 -0.31 ± 0.20 -0.10 ± 0.14 
0.3051 0.0270 0.0731 
Y 0.00 ± 0.00 0.06 ± 0.20 -0.42 ± 0.25 -0.24 ± 0.34 -0.69 ± 0.27 
Obese 
CO 0.00 ± 0.00 0.10 ± 0.16 0.00 ± 0.22 -0.06 ± 0.17 -0.14 ± 0.15 
0.1442 0.4394 0.3936 
YO 0.00 ± 0.00 -0.34 ± 0.33 -0.62 ± 0.34 -0.58 ± 0.40 -0.45 ± 0.31 
Test 2 
(wk 9) 
Lean 
C 0.00 ± 0.00 0.17 ± 0.14 $ 0.52 ± 0.27 $ -0.18 ± 0.20 $ 0.19 ± 0.25 $ 
0.0002 0.0004 0.1149 
Y 0.00 ± 0.00 -0.44 ± 0.15 #$ -0.31 ± 0.18 $ -0.86 ± 0.16 #$ -0.54 ± 0.16 #$ 
Obese 
CO 0.00 ± 0.00 0.08 ± 0.27 -0.04 ± 0.24 -0.37 ± 0.27 -0.26 ± 0.18 
0.1456 0.0258 0.5378 
YO 0.00 ± 0.00 -0.30 ± 0.11 -0.40 ± 0.14 # -0.71 ± 0.18 # -0.28 ± 0.18 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; LBP, lipopolysaccharide-binding protein. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in control group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with time as 
independent variable. # Significantly different from baseline in yogurt groups, P < 0.05, determined by repeated-measures ANOVA (PROC 
MIXED) with time as independent variable. $ Significantly different between control and yogurt at different time points, determined by 
independent T-test (PROC TTEST). 
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Supplementary Table 4.6 Relative postprandial plasma sCD14 changes (Δ ng/mL) from baseline after challenge meals (mean ± standard error, n 
= 30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 1 
(wk 0) 
Lean 
C 0.0 ± 0.0 -52.7 ± 29.7 -62.4 ± 27.2 -75.9 ± 30.1 -12.2 ± 37.4 
0.3608 0.0016 0.4851 
Y 0.0 ± 0.0 -89.3 ± 25.8 # -76.2 ± 26.9 # -76.3 ± 23.2 -69.7 ± 28.8 
Obese 
CO 0.0 ± 0.0 -106 ± 24.7 *$ -137.5 ± 29.4 *$ -89.8 ± 28.7 * -33.4 ± 23.0 
0.0063 <.0001 0.2037 
YO 0.0 ± 0.0 -31.8 ± 27.0 $ -50 ± 27.2 $ -17.6 ± 24.7 5.2 ± 19.3 
Test 2 
(wk 9) 
Lean 
C 0.0 ± 0.0 4.9 ± 23.7 -14.0 ± 16.1 7.0 ± 23.7 13.9 ± 28.6 
0.1877 0.1137 0.3027 
Y 0.0 ± 0.0 -52.0 ± 22.2 # -49.4 ± 21.9 -25.3 ± 23.5 4.5 ± 24.6 
Obese 
CO 0.0 ± 0.0 -72.8 ± 27.4*$ -75.8 ± 29.2 *$ -65.6 ± 24.3 -21.4 ± 24.5 
0.0025 0.0168 0.1988 
YO 0.0 ± 0.0 -4.9 ± 19.6$ 11.3 ± 16.3 $ -7.7 ± 20.0 36.4 ± 22.9 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; sCD14, soluble CD14. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in control group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with time as 
independent variable. # Significantly different from baseline in yogurt groups, P < 0.05, determined by repeated-measures ANOVA (PROC 
MIXED) with time as independent variable. $ Significantly different between control and yogurt at different time points, determined by 
independent T-test (PROC TTEST). 
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Supplementary Table 4.7 Postprandial plasma LBP/sCD14 ratio changes after challenge meals (mean ± standard error, n = 30/group). 
      Time (h) Significance (P)1 
      0 1 2 3 4 Treatment Time 
Treatment 
× Time 
Test 1 
(wk 0) 
Lean 
C 1.00 ± 0.00 1.05 ± 0.03 1.02 ± 0.03 1.03 ± 0.03 1.01 ± 0.02 
0.8039 0.0050 0.6760 
Y 1.00 ± 0.00 1.08 ± 0.03 # 1.03 ± 0.03 1.04 ± 0.04 0.98 ± 0.04 
Obese 
CO 1.00 ± 0.00 1.10 ± 0.03 *$ 1.12 ± 0.03 *$ 1.06 ± 0.03 $ 1.01 ± 0.02 
0.0090 <.0001 0.1308 
YO 1.00 ± 0.00 1.02 ± 0.03 $ 1.02 ± 0.03 $ 0.98 ± 0.03 $ 0.97 ± 0.02 
Test 2 
(wk 9) 
Lean 
C 1.00 ± 0.00 1.00 ± 0.02 1.05 ± 0.03 1.01 ± 0.03 $ 1.00 ± 0.03 
0.0628 0.0557 0.4688 
Y 1.00 ± 0.00 0.99 ± 0.02 1.00 ± 0.02 0.93 ± 0.02 #$ 0.94 ± 0.03 
Obese 
CO 1.00 ± 0.00 1.07 ± 0.03 * 1.06 ± 0.03 $ 1.04 ± 0.03 $ 1.02 ± 0.03$ 
0.0004 0.1496 0.0868 
YO 1.00 ± 0.00 0.99 ± 0.02 0.96 ± 0.01 $ 0.94 ± 0.02 $ 0.95 ± 0.02$ 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; LBP, lipopolysaccharide-binding protein; sCD14, soluble 
CD14. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in control group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with time as 
independent variable. # Significantly different from baseline in yogurt groups, P < 0.05, determined by repeated-measures ANOVA (PROC 
MIXED) with time as independent variable. $ Significantly different between control and yogurt at different time points, determined by 
independent T-test (PROC TTEST). 
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A.3 Appendix Materials for Chapter 5 
Supplementary Table 5.1 Fasting plasma concentration of IL-6 and sCD14 measured at wk 0, 3, 6, and 9 (mean ± standard error, n = 30/group). 
 Biomarkers 
(unit) 
Group 
Time (wk) Significance (P)1 
0 3 6 9 Time Treatment 
Treatment × 
Time 
IL-6 (pg/mL) 
C 0.74 ± 0.08 0.69 ± 0.05 0.73 ± 0.08 0.89 ± 0.11 
0.1432 0.3846 0.7722 
Y 0.88 ± 0.13 0.80 ± 0.19 0.91 ± 0.23 0.87 ± 0.10 
CO 1.56 ± 0.13 1.49 ± 0.12 1.50 ± 0.12 1.47 ± 0.11 
0.0040 0.4018 0.0726 
YO 1.86 ± 0.22 1.53 ± 0.19 # 1.44 ± 0.18 # 1.59 ± 0.19 # 
sCD14 
(ng/mL) 
C 1421 ± 50 1316 ± 46 * 1340 ± 44 1323 ± 48 
0.0003 0.8631 0.6751 
Y 1402 ± 59 1378 ± 54 1330 ± 52 1287 ± 55 
CO 1481 ± 45 1391 ± 46 * 1337 ± 51 * 1365 ± 44 * 
0.0182 0.6642 0.0182 
YO 1388 ± 45 1326 ± 44 1324 ± 42 1388 ± 49 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; IL-6, interleukin 6; sCD14, soluble CD14. 
1 The effects of treatment, time and treatment × time were determined by repeated-measures ANOVA (PROC MIXED) with treatment, time and 
treatment × time as independent variables.  
* Significantly different from baseline in control group, P < 0.05, determined by repeated-measures ANOVA (PROC MIXED) with time as 
independent variable. # Significantly different from baseline in yogurt groups, P < 0.05, determined by repeated-measures ANOVA (PROC 
MIXED) with time as independent variable. 
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Supplementary Table 5.2 Fasting plasma concentration of biomarkers measured at wk 0 and wk 9 (mean 
± standard error, n = 30/group). 
Biomarkers (unit) Group 
Time (wk) Significance (P) 
0 9 Time1 Treatment2 
hsCRP (mg/L) 
C 1.24 ± 0.26 1.33 ± 0.23 0.6434 
0.8471 
Y 1.15 ± 0.21 1.22 ± 0.22 0.6428 
CO 2.97 ± 0.31 2.98 ± 0.32 0.9173 
0.1088 
YO 2.63 ± 0.37 2.42 ± 0.32 0.0057 
TNF-α (pg/mL) 
C 1.10 ± 0.07 1.21 ± 0.09 0.1404 
0.0149 
Y 1.14 ± 0.09 1.05 ± 0.09 0.0201 
CO 1.25 ± 0.10 1.23 ± 0.08 0.7099 
0.6922 
YO 1.52 ± 0.12 1.42 ± 0.10 0.0128 
sTNFRII (pg/mL) 
C 2125 ± 72 2211 ± 92 0.2683 
0.1941 
Y 2028 ± 69 2022 ± 69 0.8940 
CO 2452 ± 94 2385 ± 95 0.1857 
0.0100 
YO 2550 ± 101 2644 ± 103 0.0296 
TNF-α/ sTNFRII 
(pg/mL) 
C 
0.00052 ± 
0.00003 
0.00053 ± 
0.00003 
0.3239 
0.0338 
Y 
0.00057 ± 
0.00005 
0.00053 ± 
0.00004 
0.0275 
CO 
0.00051 ± 
0.00004 
0.00053 ± 
0.00004 
0.2404 
0.0173 
YO 
0.00059 ± 
0.00004 
0.00055 ± 
0.00004 
0.0049 
LBP (μg/mL) 
C 9.9 ± 0.9 10.5 ± 1.0 0.2746 
0.2869 
Y 9.3 ± 0.6 9.4 ± 0.6 0.7795 
CO 12.4 ± 0.7 12.9 ± 0.9 0.6000 
0.1586 
YO 12.3 ± 0.9 11.7 ± 0.8 0.1828 
LBP/sCD14 ratio 
C 7.14 ± 0.69 8.32 ± 0.85 0.0109 
0.5985 
Y 6.89 ± 0.44 7.72 ± 0.64 0.0679 
CO 8.62 ± 0.58 9.60 ± 0.68 0.0116 
0.0360 
YO 9.13 ± 0.73 8.71 ± 0.68 0.3701 
EndoCab IgM 
(MMU/mL) 
C 99.6 ± 10.6 97.9 ± 9.6 0.5571 
0.0286 
Y 101.4 ± 10.1 107.3 ± 10.6 0.0059 
CO 70.7 ± 4.2 70 ± 4 0.6528 
0.0622 
YO 68.7 ± 7.1 72.2 ± 8 0.0455 
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Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese; hsCRP, high-
sensitivity C-reactive protein; TNF-α, tumor necrosis factor alpha; sTNF-RII, soluble tumor necrosis 
factor receptor II; LBP, lipopolysaccharide-binding protein; IgM EndoCAb, immunoglobulin M 
endotoxin-core antibody. 
1 The difference between wk 0 and wk 9 was compared by paired T-test (PROC TTEST). 
2 The group difference at wk 9 was compared by ANCOVA with baseline (wk 0) as covariate (PROC 
GLM).  
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Supplementary Table 5.3 Self-reported yogurt or soy pudding time of consumption, determined by 
analysis of 3-day food records. 
Group 
Consumption time 
With meal without meal 
C (n = 29) 58% 42% 
Y (n = 30) 69% 31% 
CO (n = 30) 46% 54% 
YO (n = 30) 66% 34% 
Abbreviations: C, control lean; CO, control obese; Y, yogurt lean; YO, yogurt obese. 
